



City Research Online

City, University of London Institutional Repository

Citation: Zanelli, S., Agnoletti, D., Alastruey, J., Allen, J., Bianchini, E., Bikia, V., Boutouyrie, P., Bruno, R. M., Climie, R., Djamaledine, D., et al (2024). Developing technologies to assess vascular ageing: a roadmap from VascAgeNet. *Physiological Measurement*, 45(12), 121001. doi: 10.1088/1361-6579/ad548e

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/33269/>

Link to published version: <https://doi.org/10.1088/1361-6579/ad548e>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

ACCEPTED MANUSCRIPT • OPEN ACCESS

Developing technologies to assess vascular ageing: a roadmap from VascAgeNet

To cite this article before publication: Serena Zanelli *et al* 2024 *Physiol. Meas.* in press <https://doi.org/10.1088/1361-6579/ad548e>

Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2024 The Author(s). Published on behalf of Institute of Physics and Engineering in Medicine by IOP Publishing Ltd.



As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 4.0 licence, this Accepted Manuscript is available for reuse under a CC BY 4.0 licence immediately.

Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by/4.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is specifically stated in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

Developing technologies to assess vascular ageing: A roadmap from VascAgeNet

Serena Zanelli^{1,2} * [0000-0002-8020-8375], Davide Agnoletti^{36,37} * [0000-0001-8108-7133], Jordi Alastruey¹⁹ * [0000-0003-3742-5259], John Allen^{31,32} * [0000-0002-7263-0533], Elisabetta Bianchini⁵ * [0000-0002-1827-8866], Vasiliki Bikia^{42,43} * [0000-0002-4660-1560], Pierre Boutouyrie^{25,26} [0000-0002-4375-3569], Rosa Maria Bruno^{25,26} * [0000-0002-6107-3356], Rachel Climie⁴¹ * [0000-0002-7960-360X], Djammaledine Djeldjli¹⁵ [0000-0003-1343-0168], Eugenia Gkaliagkousi¹⁶ [0000-0002-6324-2475], Alessandro Giudici^{22,23} * [0000-0002-8288-3980], Kristina Gopcevic¹⁷ * [0000-0003-4045-6734], Andrea Grillo¹¹ * [0000-0002-4455-4991], Andrea Guala^{6,7} * [0000-0002-5006-8164], Bernhard Hametner²⁸ [0000-0003-2048-1019], Jayaraj Joseph³⁰ [0000-0002-7279-9099], Parmis Karimpour⁴, Vimarsha Kodithuwakku⁴¹ [0000-0002-0657-3251], Panicos A. Kyriacou⁴ * [0000-0002-2868-485X], Antonios Lazaridis¹⁶ [0000-0002-7205-4644], Mai Tone Lønnebakken⁴⁴ * [0000-0002-5600-8859], Maria Raffaella Martina⁵ * [0000-0003-2489-8639], Christopher Clemens Mayer²⁸ [0000-0002-5612-5481], P. M. Nabeel²⁹ * [0000-0001-7280-0048], Petras Navickas⁹ [0000-0002-0978-0571], János Nemcsik¹⁸ * [0000-0002-3573-0287], Stefan Orter²⁸, Chloe Park³³ * [0000-0001-8302-7484], Telmo Pereira¹⁰ [0000-0001-9119-7774], Giacomo Pucci^{34,35} [0000-0003-0180-859X], Ana Belen Amado Rey²⁰ * [0000-0002-2845-7104], Paolo Salvi¹² [0000-0001-8663-5426], Ana Carolina Gonçalves Seabra²⁰ [0000-0003-1481-0998], Ute Seeland⁴⁵ [0000-0002-1979-386X], Thomas van Sloten³⁹ [0000-0003-2870-482X], Bart Spronck^{22,24} [0000-0003-1076-1922], Gerard Stansby^{32,40} [0000-0001-5539-3049], Indra Steens³⁸ * [0000-0002-9025-2011], Thomas Stieglitz^{20,21} [0000-0002-7349-4254], Isabella Tan^{13,14} [0000-0003-3123-6190], Dave Veerasingham⁸ * [0000-0001-6142-8180], Siegfried Wassertheurer²⁸, Thomas Weber²⁷ * [0000-0003-0617-0417], Berend E. Westerhof^{46,47} * [0000-0003-4753-2461], and Peter H. Charlton^{3,4} * [0000-0003-3836-8655]

¹ Laboratoire Analyse, Géométrie et Applications, Université Sorbonne Paris Nord, Paris, France

² Axelife, Redon, France

³ Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK

⁴ Research Centre for Biomedical Engineering, City, University of London, London, EC1V 0HB, UK

⁵ Institute of Clinical Physiology, Italian National Research Council (CNR), Pisa, Italy

⁶ Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

⁷ CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain

⁸ University Hospital Galway, Cardiothoracic Surgery, Galway, Ireland

⁹ Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, Lithuania

¹⁰ Polytechnic University of Coimbra, Coimbra Health School, 3046-854 Coimbra, Portugal

¹¹ Department of Medical, Surgical and Health Sciences, University of Trieste, Italy

¹² Istituto Auxologico Italiano, IRCCS, Milan, Italy

¹³ Macquarie University, Sydney, Australia

¹⁴ The George Institute for Global Health, Sydney, Australia

¹⁵ LCOMS, Université de Lorraine, F-57000 Metz, France

¹⁶ Faculty of Medicine, Aristotle University of Thessaloniki, Greece

¹⁷ Faculty of Medicine, University of Belgrade, Serbia

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
- ¹⁸ Department of Family Medicine, Semmelweis University, Budapest, Hungary
¹⁹ Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EU, UK
²⁰ Laboratory for Biomedical Microtechnology, Department of Microsystems Engineering - IMTEK, IMBIT - NeuroProbes, BrainLinks-BrainTools Center, University of Freiburg, Freiburg, Germany
²¹ Bernstein Center Freiburg, University of Freiburg, Freiburg, Germany
²² Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University
²³ GROW School for Oncology and Reproduction, Maastricht University
²⁴ Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University
²⁵ Université Paris Cité, INSERM, PARCC, F-75015 Paris, France
²⁶ Pharmacology and Hypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015 Paris, France
²⁷ Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria
²⁸ Center for Health & Bioresources, Medical Signal Analysis, AIT Austrian Institute of Technology GmbH, Vienna, Austria
²⁹ Healthcare Technology Innovation Centre, IIT Madras, Chennai – 600 113, India
³⁰ Department of Electrical Engineering, Indian Institute of Technology Madras, Chennai – 600 036, India
³¹ Research Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5RW, UK
³² Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
³³ University College London
³⁴ Department of Medicine and Surgery, University of Perugia, Perugia, Italy
³⁵ Unit of Internal Medicine, "Santa Maria" Terni Hospital, Terni, Italy
³⁶ Department of Medical and Surgical Sciences, University of Bologna, Italy
³⁷ IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Bologna, Italy
³⁸ Dept of Internal Medicine, Maastricht University, Maastricht, the Netherlands
³⁹ Dept of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
⁴⁰ Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK
⁴¹ Menzies Institute for Medical Research, University of Tasmania
⁴² Stanford University
⁴³ Swiss Federal Institute of Technology of Lausanne
⁴⁴ Department of Heart Disease, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway
⁴⁵ Institute of Social Medicine, Epidemiology and Health Economics, Charité – Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
⁴⁶ Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
⁴⁷ Department of Neonatology, Radboud University Medical Center, Radboud Institute for Health Sciences, Amalia Children's Hospital, Nijmegen, the Netherlands

* Section leads

E-mail: pc657@cam.ac.uk

Keywords: arterial stiffness, arteriosclerosis, atherosclerosis, blood pressure, cardiovascular, prevention, pulse wave velocity, risk assessment

Abstract

Vascular ageing is the deterioration of arterial structure and function which occurs naturally with age, and which can be accelerated with disease. Measurements of vascular ageing are emerging as markers of cardiovascular risk, with potential applications in disease diagnosis and prognosis, and for guiding treatments. However, vascular ageing is not yet routinely assessed in clinical practice. A key step towards this is the development of technologies to assess vascular ageing. In this Roadmap, experts discuss several aspects of this process, including: measurement technologies; the development

1
2
3 pipeline; clinical applications; and future research directions. The Roadmap summarises the state of
4 the art, outlines the major challenges to overcome, and identifies potential future research directions
5 to address these challenges.
6
7
8

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

Contents

1	2. Introduction	5
2	MEASUREMENT TECHNOLOGIES	10
3	4. Ultrasound imaging	10
4	5. Computed tomography and magnetic resonance imaging	16
5	6. Oscillometry techniques	20
6	7. Applanation tonometry	25
7	8. Photoplethysmography techniques.....	29
8	9. Circulating biomarkers.....	36
9	10. Risk scores.....	41
10	DEVELOPMENT PIPELINE	45
11	11. Development using synthetic pulse wave data	45
12	12. In-vitro and ex-vivo models: Importance and challenges	50
13	13. Technical validation	55
14	14. Assessing clinical utility	59
15	15. From research to market: medical device regulation.....	63
16	16. Commercial translation of academic innovations.....	68
17	17. Influencing policy makers	74
18	CLINICAL APPLICATIONS	82
19	18. Cognitive decline and dementia.....	82
20	19. Heart failure.....	86
21	20. Peripheral arterial disease	90
22	21. Challenges in vascular ageing and atrial fibrillation	97
23	FUTURE RESEARCH DIRECTIONS.....	102
24	22. Young people	102
25	23. Using machine learning in vascular ageing assessment.....	112
26	24. Sex and gender-based differences in vascular ageing.....	116
27	25. Mathematical modelling for understanding of pulse wave analysis	121
28	26. Using multiple sensing modalities to assess vascular age.....	126
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1. Introduction

Author(s): Serena Zanelli¹; Peter H. Charlton²

Institution(s): ¹ Laboratoire Analyze, Geometrie et Applications, University Sorbonne Paris Nord, Paris, France; Axelife, Redon, France; ² Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Research Centre for Biomedical Engineering, City, University of London, London, UK.

ORCID(s): 0000-0002-8020-8375; 0000-0003-3836-8655

Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 17.9 million deaths per year [1]. Vascular ageing is a concept capturing the changes to the vascular structure and function which occur naturally with age [5] and can be accelerated in disease [3]. Specific aspects of vascular ageing can be measured, such as changes in arterial elasticity or vessel lumen area. It may be helpful to assess vascular ageing in clinical practice, as measurements of vascular ageing have been found to be predictive of cardiovascular events and all-cause mortality, independently of classical cardiovascular risk factors [2,6]. However, vascular ageing is not yet widely assessed in routine practice [3]. A key step towards incorporating vascular ageing assessment in routine practice is the development of technologies to assess vascular ageing [4].

Overview

In this Roadmap, experts provide their perspectives on the development of technologies to assess vascular ageing. Its purpose is to guide future research and development in the field, focusing on specific areas of opportunity for the research community. The Roadmap consists of short sections on topics ranging from specific measurement technologies to particular clinical applications. Each section stands alone, offering a summary of the state of the art, the major challenges to overcome, and the scientific and technological breakthroughs that could potentially address these challenges. The sections are categorised into four areas, as illustrated in Figure 1:

- 1. Measurement technologies:** A wide range of measurement technologies to assess vascular ageing are presented, including imaging techniques, technologies suitable for use in the clinic, and wearable technologies.
- 2. Development pipeline:** The methods used to develop devices and translate them into clinical practice are discussed. The methods span the development pipeline, from early-stage research to commercialisation.
- 3. Clinical applications:** Key clinical applications of vascular ageing technologies are presented, encompassing diseases affecting the heart, brain, and blood vessels.
- 4. Future research directions:** Key areas for future research and innovation are discussed.

The sections are each self-contained, allowing readers to delve directly into specific sections of interest, without the need to read the entire Roadmap from beginning to end.




Figure 1. The four areas of the Roadmap.

Source: Servier Medical Art, <https://smart.servier.com/> (CC BY 4.0)

Themes

Some common themes emerge throughout the Roadmap:

- The ideal measurement technology:** The authors of the Roadmap are clear in their view that there are several measurement technologies available for assessing vascular age with differing capabilities and advantages and disadvantages. Yet, none of these technologies are seen as the ideal solution. Across the Roadmap, the ideal technology emerges as one which is: low cost; safe (*i.e.* non-invasive and without the need for ionising radiation); operator-independent; easy to use (with minimal training or expertise required); portable; well tolerated by patients; and quick to take measurements.
- Requirements for clinical use:** The case for adopting a technology into clinical practice is much strengthened by: validation (evidence that its measurements are reliable, including their repeatability and reproducibility); evidence for its clinical utility (showing added value in comparison to standard care); evidence for its acceptability (that the device is acceptable to patients); and evidence for its cost-effectiveness.
- Identifying potential use cases:** Several potential use cases for vascular ageing technologies emerge through the Roadmap, including: prognosis and risk stratification; diagnosis (including early diagnosis of diseases potentially through screening, distinguishing between different diseases, and prompting treatment); targeting therapies according to vascular ageing measurements; and phenotyping patients.

- **Communicating with stakeholders in the development process:** Several sections of the Roadmap refer to communicating with stakeholders in the development process, highlighting the need to: facilitate communication between different stakeholders; promote awareness of the importance of vascular ageing; gaining trust from patients and device users; engage policy makers; and effectively communicate with patients about the risks associated with vascular ageing. There is opportunity to develop the academic research culture to increase the level of public and patient involvement in the development process.
- **Opportunities for innovative device design:** Some authors present a vision of innovative devices which measure multiple vascular ageing parameters simultaneously, or even investigate multiple diseases at the same time. Such devices could use multiple sensing modalities to achieve this.
- **The benefits of modelling:** Several sections highlight the potential benefits of using cardiovascular models in the development process, such as to aid the development of pulse wave analysis algorithms or to help better understand the physiological origins of pulse waves.

Challenges and solutions

Several key challenges and potential solutions emerge from the Roadmap:

- **Conducting clinical studies:** Clinical studies will underpin the translation of vascular ageing technologies into clinical practice. Validation studies are required to assess agreement between vascular ageing measurements and reference parameters. Studies assessing the effectiveness and cost-effectiveness of interventions based on vascular ageing measurements will be essential. Such studies should include a diversity of subjects to understand the clinical utility of technologies across different groups (*e.g.* across the sexes, across ages, across different body types, and across different pathologies such as atrial fibrillation). Pragmatic study designs may help facilitate large-scale studies whilst minimising study costs.
- **Ensuring measurements are accurate:** There are several challenges to ensuring measurements of vascular ageing are accurate. First, signals are susceptible to artifacts which can obscure the phenomena of interest. Automated quality assessment algorithms can identify artifact-free measurements suitable for analysis. Second, physiological variability leads to beat-by-beat variability in signals and the phenomena of interest, which should be accounted for in analyses. Third, measurements can be operator-dependent, and (semi-) automation of data acquisition and/or analysis may help reduce inter-operator variability (and have the added benefit of reducing the level of training required).
- **Obtaining measurements in daily life:** Assessments of vascular ageing have traditionally been largely confined to clinical settings. Wearable and non-contact devices may provide opportunity to perform assessments unobtrusively and longitudinally in daily life, providing clinicians with a more holistic view of the vascular status of the monitored subject. These technologies could enable measurements across large numbers of subjects, and facilitate large-scale clinical studies.
- **Creating datasets:** Datasets facilitate the development of vascular ageing technologies, whether during device design (*e.g.* development of signal processing algorithms), clinical translation (*e.g.* development of reference values), or the assessment of clinical utility and cost-effectiveness. The field would benefit from more freely available datasets, which should include a diversity of subjects, and may include raw physiological signals for algorithm

development. In addition, generative models could be used to generate data starting from a smaller dataset. Synthetic data could then be used to refine vascular ageing assessment techniques or to investigate fields where the real-world data are unbalanced (*e.g.* imbalances in sex and gender).

- **Establishing reference values:** There is a need for reference values for vascular structure and function assessments, which should be age- and sex-specific, and be created not just for adults but also young people.
- **Developing standards and definitions:** The field would benefit from further development of standards and definitions, such as: reference standard(s) for vascular ageing assessments; device validation protocols; measurement protocols; and definitions of key concepts such as early vascular ageing. The development of scientific consensus documents would greatly aid this process.
- **Developing medical devices:** Several Roadmap sections discuss the challenges of developing technologies to assess vascular ageing, which are largely common to all medical device development. These include: the difficulties of commercialising academic research; the need to meet regulatory requirements; and the cost of developing devices. These challenges can be addressed through education about the development pipeline, including an awareness of what is required at each stage and when translational activities should be incorporated.
- **Furthering our understanding of underlying theories:** It is beneficial to further our understanding of the theories behind measurement technologies, such as the physiological mechanisms underpinning measurements, and the assumptions on which measurements are based (*e.g.* the assumptions behind single-point and two-point measurements, and the dependency of measurements on age and blood pressure). A more detailed understanding could help translate technologies into pressing clinical needs, such as establishing the basis for links between arterial stiffness and dementia. Physiological modelling may provide valuable insights to advance our understanding.

Outlook

Technologies to assess vascular ageing have potential to be valuable tools to aid diagnosis and prognosis, and to help guide treatments. Whilst much progress has been made in the development of such technologies, several challenges remain to translate vascular ageing assessments in routine clinical practice. The research directions outlined in this Roadmap will help to address these challenges. Ultimately, the successful development of vascular ageing technologies will be a multi-disciplinary effort, requiring the input of academic and commercial researchers, clinicians, and patients alike.

Vascular ageing research is particularly timely given its potential role in tackling various age-related diseases, in the light of ageing populations. Industry collaboration is essential for translating vascular ageing research into tangible products and services that benefit patients, clinicians, and society as a whole. By leveraging the expertise and resources of industry partners, researchers can accelerate the translation of scientific discoveries into clinical practice and address unmet needs in the field of vascular ageing.

Conflicts of Interest

S. Zanelli collaborates with Axelle, a company that designs and develops devices for assessing vascular ageing.

Acknowledgments

This work was supported by COST Action CA18216 VascAgeNet, supported by COST (European Cooperation in Science and Technology, www.cost.eu). PHC acknowledges funding from the British Heart Foundation (FS/20/20/34626).

References

- [1] G. A. Roth *et al.*, 'Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015', *J. Am. Coll. Cardiol.*, vol. 70, no. 1, pp. 1–25, 2017, doi: 10.1016/j.jacc.2017.04.052.
- [2] C. Vlachopoulos, K. Aznaouridis, and C. Stefanadis, 'Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis', *J. Am. Coll. Cardiol.*, vol. 55, no. 13, pp. 1318–27, 2010, doi: 10.1016/j.jacc.2009.10.061.
- [3] R. E. Climie *et al.*, 'Vascular ageing: moving from bench towards bedside', *Eur. J. Prev. Cardiol.*, vol. [in press], p. zwad028, Feb. 2023, doi: 10.1093/eurjpc/zwad028.
- [4] R. E. Climie, C. C. Mayer, R. M. Bruno, and B. Hametner, 'Addressing the Unmet Needs of Measuring Vascular Ageing in Clinical Practice - European COoperation in Science and Technology Action VascAgeNet', *Artery Res.*, vol. 26, no. 2, pp. 71–75, 2020, doi: 10.2991/artres.k.200328.001.
- [5] P. Nilsson, 'Early Vascular Ageing – A Concept in Development', *European Endocrinology*, vol. 11, no.1, pp.26–31, 2015, doi: 10.17925/EE.2015.11.01.26.
- [6] Ben-Shlomo, Y., Spears, M., Boustred, C., May, M., Anderson, S. G., Benjamin, E. J., Boutouyrie, P., Cameron, J., Chen, C. H., Cruickshank, J. K., Hwang, S. J., Lakatta, E. G., Laurent, S., Maldonado, J., Mitchell, G. F., Najjar, S. S., Newman, A. B., Ohishi, M., Pannier, B., ... Wilkinson, I. B, 'Aortic pulse wave velocity improves cardiovascular event prediction: An individual participant meta-analysis of prospective observational data from 17,635 subjects', *Journal of the American College of Cardiology*, vol. 63, no.7, pp.636–646, 2014, doi: 10.1016/j.jacc.2013.09.063.

MEASUREMENT TECHNOLOGIES

2. Ultrasound imaging

Author(s): Maria Raffaella Martina¹; Elisabetta Bianchini¹

Institution(s):¹ Institute of Clinical Physiology, Italian National Research Council (CNR), Pisa, Italy

ORCID(s): 0000-0003-2489-8639; 0000-0002-1827-8866

Status

Non-invasive Ultrasound (US) imaging is an affordable and safe technique, adopted since the mid 20th century in clinical and research settings, exploiting acoustic energy at not audible frequencies (higher than 20 kHz). This approach uses piezoelectric components to generate ultrasound waves, which hit biological structures, and then return where they are collected through the same transducer. Interaction with tissues induces reflection, refraction and scattering of the original signal that can be processed to obtain information (e.g., an image sequence) of a region of interest in real-time.

Standard US equipment includes signal generation and processing units, a monitor, and a hand-held probe in contact with the subject's body through a water-based gel which allows US waves' passage. Transducers, which can differ in shape, number of elements, and central frequency, are adopted depending on application and site, considering that lower frequencies provide lower spatial resolution but have greater penetration depth. Non-invasive solutions suitable for imaging of various vascular sites are available, including for example curved array for abdominal applications or phased array for cardiac and cerebral analysis. In addition, linear arrays are commonly used for vascular imaging with a frequency range of around 7-18 MHz. Interestingly, contrast agents consisting of encapsulated microbubbles containing gases can be used for contrast enhancement e.g., in atherosclerotic plaque analysis. In addition, when exploiting a working principle called Doppler Effect, that relies on the frequency content of ultrasound waves, velocities of vessels' blood can be also quantified. Within this section we are focusing on non-invasive assessment, but is worth noting that, also IntraVascular UltraSound (IVUS) approaches are available, working with a frequency range of around 20-60 MHz, and based on a dedicated catheter producing cross-sectional images for the investigation of e.g., coronary and pulmonary arteries. For a detailed overview of ultrasound principles and vascular applications, we refer the reader to the following sources: (*Hoskins et al, 2019*) and (*Bianchini et al, 2023*).

Non-invasive US can be used to obtain information in key superficial arteries associated with vascular disorders, such as arteriosclerosis related to the reduced arterial elasticity or the building of atherosclerotic plaque which modifies the morphology of a vessel. For example, the carotid artery is a large and central vessel, easily accessed by US, whose alterations can play a role in prevention, diagnosis and monitoring of relevant diseases (*Engelen et al., 2013*). Femoral, brachial and some aortic segments can be imaged as well, providing vascular information at these sites (*Bossuyt et al., 2015*). In fact, US techniques can provide a local structural and functional assessment: for example, diameter, intima-media thickness (IMT) and, assuming the cross-section of the artery to be circular, elastic parameters, such as the distensibility coefficient, (*Laurent et al., 2006*) can be assessed simultaneously

by processing longitudinal B-mode scans (see **Figure 2**) (Bianchini *et al.*, 2023). In addition, vascular deformation patterns can be obtained on short-axis imaging by two-dimensional speckle-tracking strain that quantifies wall circumferential deformation within the cardiac cycle.

Due to its intrinsic peculiarities, non-invasive US is able to provide a multi-site safe assessment along the arterial tree to obtain a heuristic evaluation of vascular ageing. However, this approach is currently underused, in part because of its usability and operator-dependency. Technological advances are increasing the utility of US in clinical and research settings, thanks for instance to portable probes (i.e. compact hand-held probes that can be directly connected with a computer or a mobile platform via USB or wireless) and reliable advanced processing algorithms whose combination can provide innovative architecture solutions.




Figure 2. (a) Standard longitudinal B-mode US image of a common carotid artery processed by software based on a contour tracking algorithm measuring diameter and Intima Media Thickness (IMT). (b) Measurements of instantaneous diameter. (c) Applanation tonometry for carotid blood pressure estimation, calibrated through brachial pressure assessment, that, combined with the US derived analysis, provides elastic parameters.

Current and Future Challenges

Challenges in the field are related to increasing the potential of non-invasive US in applications for vascular ageing assessment. In particular, key challenges are focused on the needs to decrease the inherent operator-dependency, spread the adoption of technological advances in practice, improve the image quality and resolution, and develop shared standardisation protocols.

Great advances have been achieved in the last years to address the above mentioned technological and operative challenges. In particular, semi-automatic image processing systems based on robust algorithms (Bianchini *et al.*, 2023) were introduced to improve the reliability of the final measurement by reducing e.g. the impact of the operator-variability on the final results. Moreover, three-dimensional imaging has been introduced, a promising tool for vessel morphology assessment overcoming limitations of two-dimensional imaging related to the selection of a single section (Bredahl K *et al.*, 2013, Ghulam QM *et al.*, 2020; Alzahrani *et al.*, 2023).

Other key aspects to take into consideration are the usability and accessibility of technology. Currently, hardware and software solutions are often fragmented, physically and commercially, particularly for more innovative applications. Conversely, integrated devices might provide the two-fold benefit of more easily available and usable approaches suiting healthcare systems' needs e.g., for analysis related to screening campaigns for vascular assessment or even for wearable applications,

1
2
3 based on pioneering ultrasound tools for continuous imaging of internal organs. Advances in this
4 direction have been done by the new generation of low-cost portable ultrasound scanners available
5 on the market, and the development of innovative US based patches (Wang *et al.*, 2022), but further
6 technological steps are needed for the effective hardware-software integration required in dedicated
7 cardiovascular applications.
8
9

10 Some specific further challenges are related to the development of advanced US based technologies
11 able to provide functional and structural insights in smaller time and space scales. Indeed, increased
12 temporal or spatial resolution might allow to detect and analyze structures not visible with standard
13 architectures or to record events of short duration. This kind of approach introduces further
14 requirements in terms of e.g., data acquisition, processing efficiency, equipment architecture.
15

16 Finally, standardised US acquisition protocols and guidelines by scientific expert committees are
17 crucial requirements for any clinical application and, especially for the more innovative methods, a
18 shared approach is lacking. The usefulness of standardisation should be taken into account starting
19 from the validation process in order to provide clear and comparable criteria for performance
20 assessment.
21
22
23
24

25 **Advances in Science and Technology to Meet Challenges**

26 Innovation in terms of technological development in hardware and software solutions, as well in their
27 integration, can address some of the above mentioned challenges, as schematized in **Figure 3**.
28

29 Advanced US architectures able to provide higher spatial (Ultra-High Frequency, UHF) or temporal
30 (Ultrafast) resolution compared to standard ultrasound equipments have been introduced.
31

32 Specifically, UHF US technique exploits transducer with operating frequencies up to 70 MHz providing
33 non-invasive high image quality of superficial vascular sites (Izzetti *et al.*, 2021). This approach can
34 open windows on structures and sites that have not been investigated so far, such as digital arteries,
35 relevant in particular diseases and to exploring systemic-peripheral vascular behaviour interaction
36 (Poli *et al.*, 2022).
37
38

39 On the other hand, ultrafast US is able to record data with high sampling frequency (frame-rates up
40 to ten thousand frames per second), thus allowing the analysis of rapid changes in a vascular site, such
41 as the study of shear wave propagation, an estimation of local arterial stiffness (Marais *et al.*, 2019)
42 and pulse wave imaging (Li *et al.*, 2019).
43
44

45 In order to be translated to the practice, advances in equipment architecture must be flanked by
46 improvements in reliability and usability. For example, effective implementation of a mobile tool for
47 vascular assessment requires the development of combined hardware-software solutions able to
48 integrate portable commercial probes with precise US data processing algorithms (Francesconi *et al.*,
49 2021).
50

51 Robust algorithmic approaches in general might be able to provide solid data for determination of
52 reference values where missing, a crucial step for translation from research to practice (Engelen *et al.*,
53 2013) (Bossuyt *et al.*, 2015). Novel applications exploiting digital signal processing can also introduce
54 advanced vascular analysis: for example, emerging method about peripheral arterial hemodynamic
55 states can contribute to face challenges related to the need for better quantification of complex
56 arterial hemodynamic patterns, such as ultrasound vector flow imaging (VFI). (Baun, 2021)
57
58
59
60

It is an imperative to mention also the potential impact of Artificial Intelligence (AI). On one hand, US features' quantification and the adoption of machine learning classifiers might help the investigation of clinically relevant parameters (Avanzo *et al.*, 2020), a challenging task due to the need of standardised big data; and, the combination of AI based approaches with multi-parameter information obtainable by US may provide, in one single imaging modality, tools able to improve clinical diagnosis. On the other hand, AI-based approaches might improve usability, by augmenting repeatability and time efficiency and providing the possibility to automate such methods.




Figure 3. Main limitations and possible solutions to meet challenges related to the application of US techniques in clinical practice for vascular ageing assessment.

Concluding Remarks

Non-invasive US imaging is a safe and relatively low-cost approach capable of providing multi-parameter data for an integrated assessment of vascular structure and function. Reliable and usable technologies based on the integration of standard and innovative architectures with (semi-) automatic processing approaches can expand the potentiality of US vascular ageing assessment in practice.

In this context, dialogue and collaboration among clinicians, researchers and industry in the field is necessary in order to harmonize methods and procedures and thus lead to a personalized description of a subject's vascular ageing.

Acknowledgements

This paper is based upon work from the COST Action CA18216 "Network for Research in Vascular Ageing" supported by COST (European Cooperation in Science and Technology, www.cost.eu).

Competing interests

Elisabetta Bianchini is co-founder of QUIPU s.r.l., Pisa, Italy a spin-off company of the Italian National Research Council and the University of Pisa developing software medical devices.

References

- Alzahrani A, Sultan SR, Aslam M. Reliability of tomographic 3D ultrasound in measuring internal carotid artery plaque volume. *Acta Radiol.* 2023 Nov;64(11):2931-2937. Doi: 10.1177/02841851231199222.
- Avanzo, M., Wei, L., Stancanello, J., Vallières, M., Rao, A., Morin, O., Mattonen, S.A. and El Naqa, I. (2020) 'Machine and deep learning methods for radiomics', *Medical Physics*, 47(5), pp. e185–e202. Available at: <https://doi.org/10.1002/mp.13678>.
- Baun, J. (2021) 'Emerging Technology: Ultrasound Vector Flow Imaging—A Novel Approach to Arterial Hemodynamic Quantification', *Journal of Diagnostic Medical Sonography*, 37(6), pp. 599–606. Available at: <https://doi.org/10.1177/87564793211036013>.
- Bianchini E, Guala A, Golemati S, Alastruey J, Climie RE, Dalakleidi K, Francesconi M, Fuchs D, Hartman Y, Malik AEF, Makūnaitė M, Nikita KS, Park C, Pugh CJA, Šatrauskienė A, Terentes-Printizios D, Teynor A, Thijssen D, Schmidt-Trucksäss A, Zupkauskienė J, Boutouyrie P, Bruno RM, Reesink KD. The Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action. *J Ultrasound Med.* 2023 Oct;42(10):2183-2213. doi: 10.1002/jum.16243.
- Bossuyt, J., Engelen, L., Ferreira, I., Stehouwer, C.D., Boutouyrie, P., Laurent, S., Segers, P., Reesink, K. and Van Bortel, L.M. (2015) 'Reference values for local arterial stiffness. Part B: femoral artery.', *Journal of hypertension*, 33(10), pp. 1997–2009. Available at: <https://doi.org/10.1097/HJH.0000000000000655>.
- Bredahl K, Taudorf M, Long A, Lönn L, Rouet L, Ardon R, Sillesen H, Eiberg JP. Three-dimensional ultrasound improves the accuracy of diameter measurement of the residual sac in EVAR patients. *Eur J Vasc Endovasc Surg.* 2013 Nov;46(5):525-32. doi: 10.1016/j.ejvs.2013.09.012. Epub 2013 Sep 19. PMID: 24091092.
- Engelen, L., Ferreira, I., Stehouwer, C.D., Boutouyrie, P. and Laurent, S. (2013) 'Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors.', *European heart journal*, 34(30), pp. 2368–2380. Available at: <https://doi.org/10.1093/eurheartj/ehs380>.
- Francesconi, M., Martina, M.R., Armenia, S., Buzzelli, A., Di Franco, G., Gemignani, V., Bianchini, E. and Bruno, R.M. (2021) 'Technical Validation and Usability of a Portable Ultrasound-Based System for Carotid Assessment of Vascular Ageing: A Pilot Study', *Heart, Lung and Circulation*, 30(11), pp. 1734–1743. <https://doi.org/https://doi.org/10.1016/j.hlc.2021.06.530>.
- Ghulam QM, Kilaru S, Ou SS, Sillesen H. Clinical validation of three-dimensional ultrasound for abdominal aortic aneurysm. *J Vasc Surg.* 2020 Jan;71(1):180-188. doi: 10.1016/j.jvs.2019.03.066.
- Hoskins, P., Martin, K., & Thrush, A. (Eds.). (2019). *Diagnostic Ultrasound, Third Edition: Physics and Equipment* (3rd ed.). CRC Press. <https://doi.org/10.1201/9781138893603>.
- Izzetti, R., Vitali, S., Aringhieri, G., Nisi, M., Oranges, T., Dini, V., Ferro, F., Baldini, C., Romanelli, M., Caramella, D. and Gabriele, M. (2021) 'Ultra-High Frequency Ultrasound, A Promising Diagnostic Technique: Review of the Literature and Single-Center Experience', *Canadian Association of Radiologists Journal*, 72(3), pp. 418–431. Available at: <https://doi.org/10.1177/0846537120940684>.
- Laurent, S., Cockcroft, J., Bortel, L. Van, Boutouyrie, P., Giannattasio, C., Hayoz, D., Pannier, B., Vlachopoulos, C., Wilkinson, I., Struijker-Boudier, H. and for Non-invasive Investigation of Large Arteries, E.N. (2006) 'Expert consensus document on arterial stiffness: methodological issues and clinical applications.', *European heart journal*, 27(21), pp. 2588–2605. Available at: <https://doi.org/10.1093/eurheartj/ehl254>.
- R.X. Li et al. 'Pulse Wave Imaging in Carotid Artery Stenosis Human Patients in Vivo', *Ultrasound Med Biol.* 2019 Feb;45(2):353-366. DOI: 10.1016/j.ultrasmedbio.2018.07.013.
- Marais, L., Pernot, M., Khettab, H., Tanter, M., Messas, E., Zidi, M., Laurent, S. and Boutouyrie, P. (2019) 'Arterial Stiffness Assessment by Shear Wave Elastography and Ultrafast Pulse Wave Imaging: Comparison with Reference Techniques in Normotensives and Hypertensives', *Ultrasound in Medicine and Biology*, 45(3), pp. 758–772. Available at: <https://doi.org/10.1016/j.ultrasmedbio.2018.10.032>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Poli, F., Fortier, C., Khettab, H., Faita, F., Vitali, S., Aringhieri, G., Ghiadoni, L., Taddei, S., Amar, L., Lorthoir, A. and others (2022) 'Validation and Feasibility of an Automated System for the Assessment of Vascular Structure and Mechanical Properties in the Digital Arteries: An Ultrahigh-Frequency Ultrasound Study', *Ultrasound in Medicine & Biology*, 48(4), pp. 711–716.

Wang C, Chen X, Wang L, Makihata M, Liu HC, Zhou T, Zhao X. Bioadhesive ultrasound for long-term continuous imaging of diverse organs. *Science*. 2022 Jul 29;377(6605):517-523. doi: 10.1126/science.abo2542.

Accepted Manuscript

3. Computed tomography and magnetic resonance imaging

Author(s): Andrea Guala

Institution(s): Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain and CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain

ORCID(s): 0000-0002-5006-8164

Status

Computed tomography (CT) and cardiovascular magnetic resonance (CMR) are advanced, relatively-recent medical imaging modalities offering a broad range of possibilities for research and clinical practice in vascular ageing. Indeed, they can provide high-resolution, time-resolved images of virtually all regions of the circulation, with excellent reproducibility (0). These modalities are thus considered standards for the 3D evaluation of vascular geometrical characteristics, such as diameter, volume, length, and tortuosity, among others, and are often key for the assessment of the impact of vascular characteristics on target organs, such as the heart, brain, and kidneys. CMR also offers high-quality assessment of blood velocity, while CT is the reference technique for the evaluation of calcium deposit (8).

CMR exploits the heterogeneity of the magnetic properties of tissues to form images. In particular, it creates images by applying (i) a strong, static magnetic field, which orients nuclei along a main axis, and (ii) lower-intensity, transversal magnetic field components, which dynamically perturb the static magnetic field. The temporal evolution of these perturbations is read by a receiving coil and used to form images and to assess blood velocity. Conversely, CT exploits the heterogeneity in the attenuation of X-rays in tissues. A CT scanner sends X-rays through the body and quantifies how much is retained by specific tissues.

Nonetheless, clinical guidelines as well as current clinical practice exploit only a limited part of what could be achieved by these imaging modalities, while an in-depth analysis of acquired images for opportunistic screening is rarely followed. In particular, regarding potential biomarkers for vascular ageing assessment by these modalities, only arterial diameter and coronary calcium score are effectively included in clinical guidelines. There are several reasons explaining the relatively-limited clinical impact of these imaging techniques for vascular ageing. Firstly, they are substantially more expensive than ultrasound (i.e. echocardiography, the most used imaging modality), while image interpretation requires specific training and, often, considerable post-processing, which is frequently non-standardised. This results in substantial heterogeneity in their availability, with low and lower-middle income countries, but also remote areas of wealthy countries, having very limited access (1). Differences in acquisition and post-processing often result in limited reproducibility across clinical centres. Moreover, CT exposes patients to ionizing radiations, while both CT and CMR often require the administration of external contrast agent, whose use has to be evaluated in light of the potential clinical benefit. Given these characteristics and problems, further work is needed to bring the possibilities offered by CT and CMR for the assessment of vascular ageing in clinical practice.

Current and Future Challenges

Ongoing work can be separated in two main aims: from one side to provide stronger clinical evidence of the advantages of acquiring images with these imaging techniques, and on the other side, optimising their use for greater benefit to patients.

Regarding clinical evidence, substantial prognostic value has been reported for several descriptors of arterial ageing acquired by CMR and CT. These descriptors can be grouped into three classes: arterial size, arterial stiffness and calcium deposits. Regarding arterial size, the strongest prognostic value has been reported for aortic diameter, specifically for adverse cardiovascular events and all-cause mortality(2–4). Notably, this prognostic value was demonstrated for a range of physiological diameters, likely showing the pre-clinical impact of ageing on this vessel. With respect to arterial stiffness, aortic pulse wave velocity (PWV) and distensibility by CMR have been shown to be significant predictors of adverse cardiovascular (5,6), cardiac (7) and extra-cardiac (7) events and all-cause mortality (5) in patients free from overt CV disease. Finally, coronary calcium score (CAC) by CT has been shown to have a strong predictive value for atherosclerotic cardiovascular disease and death in the general population, being thus suggested for risk-stratification in primary prevention (8).

Despite all these biomarkers having been shown to be useful for risk-stratification in large, prospective general-population studies, their use is hampered by technical, economic and practical challenges. Several advances are required to meet these challenges, as detailed below.

Advances in Science and Technology to Meet Challenges

A number of advances are required to meet the technical, economical and practical challenges hampering the use of vascular ageing biomarkers obtained by CT and CMR in clinical practice.

Firstly, expanding the availability of these imaging modalities. Currently, the modalities are not available in many parts of the world. As introduced, a key issue is cost: according to Catalan public healthcare provider, the cost of CT and CMR studies is 3.5 and 5 times that of an ultrasound study. This is one of the key reasons limiting the use of these imaging modalities. To reduce cost, the research community is working on reducing acquisition time and reducing the need for the administration of contrast agents. Another key aspect related to the use of these imaging modalities is the optimization of their use, meaning improving the identification of patients who are likely to benefit most from these tests.

Another set of key challenges arise in image acquisition and analysis. Differences in scanner, sequence and image modality have been shown to impact the absolute value of certain characteristics, such as arterial diameter, while most of these biomarkers are extracted via substantial post-processing. For diameter post-processing means applying multi-planar reconstruction to 3D images to visualise a plane perpendicular to the vessel's main axis. Despite being simple, this process requires time and impacts reproducibility (9). Fully-automatic segmentation of vessel boundary by machine learning algorithms is expected to provide a possible solution for inter-observer variability (10). For PWV and distensibility post-processing aims to track the propagation of velocity waves and arterial boundaries, respectively. Although several methods have been (and still are being) developed, none can be considered absolutely true, and there is no consensus for a method to be adopted by the whole community. Moreover, there is limited availability of commercial software to assess these biomarkers. Conversely, there is consensus on the parameter for the acquisition of images to compute CAC. Despite there being several possible ways to compute an overall coronary calcium score, the Agatston score is by far the most used, and considered a reference. In general, freely-available, open datasets

1
2
3 may be helpful for benchmarking post-processing, and thus assessing the impact of these image
4 analysis techniques on absolute values.
5

6 Finally, the community is moving fast in the proposition of alternatives to the administration of
7 contrast agents as well as in the reduction of ionizing radiation exposure. The former is pursued by
8 enhancing the regions of blood flow either by using velocity encoding or artificially via machine
9 learning algorithms.
10
11
12
13

14 **Concluding Remarks**

15 CMR and CT offer great opportunities for research and clinical practice for the assessment of arterial
16 ageing. Still, the relatively low availability, high cost and required expertise are key factors hampering
17 its widespread use. The clinical and technical research community is working on reducing cost,
18 radiation and contrast agent exposure, and time and variability in the analysis, likely solving many of
19 the current problems.
20
21
22
23

24 **Acknowledgements**

25 Guala A. has received funding from "la Caixa" Foundation (LCF/BQ/PR22/11920008).
26
27
28
29

30 **References**

- 31 0. Bianchini E, Lønnebakken MT, Wohlfahrt P, Piskin S, Terentes-Printzios D, Alastruey J, Guala A.
32 Magnetic Resonance Imaging and Computed Tomography for the Noninvasive Assessment of Arterial Aging : A
33 Review by the VascAgeNet COST Action. *Journal of the American Heart Association*. 2023;12:1–15.
34
- 35 1. Ogbole GI., Adeyomoye AO., Badu-Peprah A., Mensah Y., Nzeh DA. Survey of magnetic resonance
36 imaging availability in West Africa. *Pan Afr Med J* 2018;30:1–9. Doi: 10.11604/pamj.2018.30.240.14000.
37
- 38 2. Qazi S., Massaro JM., Chuang ML., D'Agostino RB., Hoffmann U., O'Donnell CJ. Increased Aortic
39 Diameters on Multidetector Computed Tomographic Scan Are Independent Predictors of Incident Adverse
40 Cardiovascular Events: The Framingham Heart Study. *Circ Cardiovasc Imaging* 2017;10(12):1–8. Doi:
41 10.1161/CIRCIMAGING.117.006776.
- 42 3. Norman P., Le M., Pearce C., Jamrozik K. Infrarenal aortic diameter predicts all-cause mortality.
43 *Arterioscler Thromb Vasc Biol* 2004;24(7):1278–82. Doi: 10.1161/01.ATV.0000131261.12051.7f.
44
- 45 4. Duncan JL., Harrild KA., Iversen L., Lee AJ., Godden DJ. Long term outcomes in men screened for
46 abdominal aortic aneurysm: Prospective cohort study. *BMJ* 2012;344(7857):1–9. Doi: 10.1136/bmj.e2958.
47
- 48 5. Redheuil A., Wu CO., Kachenoura N., et al. Proximal Aortic Distensibility is an Independent Predictor
49 of All- cause Mortality and Incident Cardiovascular Events in the Multi- Ethnic Study of Atherosclerosis. *J Am*
50 *Coll Cardiol* 2014;64(24):2619–29. Doi: 10.3851/IMP2701.Changes.
- 51 6. Ohyama Y., Ambale-Venkatesh B., Noda C., et al. Aortic Arch Pulse Wave Velocity Assessed by
52 Magnetic Resonance Imaging as a Predictor of Incident Cardiovascular Events: The MESA (Multi-Ethnic Study of
53 Atherosclerosis). *Hypertension* 2017;70(3):524–30. Doi: 10.1161/HYPERTENSIONAHA.116.08749.
- 54 7. Maroules CD., Khera A., Ayers C., et al. Cardiovascular outcome associations among cardiovascular
55 magnetic resonance measures of arterial stiffness : the Dallas heart study. *J Cardiovasc Magn Reson*
56 2014;16(3):1–9.
57
- 58 8. Arnett DK., Blumenthal RS., Albert MA., et al. 2019 ACC/AHA Guideline on the Primary Prevention of
59 Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force
60 on Clinical Practice Guidelines. *Circulation* 2019; 40(11): e596-e646.

1
2
3 9. Dux-Santoy L., Rodríguez-Palomares JF., Teixido-Tura G., et al. Registration-based semi-automatic
4 assessment of aortic diameter growth rate from contrast-enhanced computed tomography outperforms
5 manual quantification. *Eur Radiol* 2022;32(3):1997–2009. Doi: 10.1007/s00330-021-08273-2.
6

7 10. Garrido-oliver J., Aviles J., Córdova MM., et al. Machine learning for the automatic assessment of
8 aortic rotational flow and wall shear stress from 4D flow cardiac magnetic resonance imaging. *Eur Radiol* 2022.
9 Doi: 10.1007/s00330-022-09068-9.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

4. Oscillometry techniques

Author(s): Dave Veerasingam¹, Petras Navickas² and Telmo Pereira³

Institution(s):¹ University Hospital Galway, Cardiothoracic Surgery, Galway, Ireland; ² Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, Lithuania; ³ Polytechnic University of Coimbra, Coimbra Health School, Rua 5 de Outubro – S. Martinho do Bispo, Apartado 7006, 3046-854 Coimbra, Portugal.

ORCID(s): 0000-0001-6142-8180; 0000-0002-0978-0571; 0000-0001-9119-7774

Status

Vascular ageing (VA) due to structural changes in the arteries leads to reduced vascular compliance and increased arterial stiffness, which can be assessed using surrogate parameters of pulse wave analysis (PWA) by many noninvasive methods: tonometry, oscillometry (either single or two sites) (**Figure 4** and **Figure 5**), imaging techniques (magnetic resonance imaging, echocardiography), photoplethysmography as well as the use of estimated values of pulse wave velocity (PWV). Although tonometric carotid-femoral PWV (cfPWV) has generally been considered a reference standard of non-invasive VA assessment, validated devices, which combine cuff oscillometry and pulse wave analysis to estimate PWV on a single oscillometric blood pressure (BP) measurement, are lately gaining traction since they are non-invasive, easy-to-use, cost-effective, portable, operator-independent and, therefore, especially suitable for use in everyday clinical practice. Nonetheless, the epidemiologic data regarding the use of these methods remains significantly lower compared to tonometric methods.

Oscillometric pulse wave velocity is a non-invasive cuff-based measurement of blood flow velocity in the arteries, based on the principle that changes in blood pressure propagate through the arterial system as pressure waves, which are recorded as oscillations of the pressure in the cuff. There are two types of devices to estimate aortic PWV: two-point measurement devices that determine the difference in travel time of pulse waves between two different sensor positions (**Figure 4**) and single-point measurement devices that determine the time difference between the forward and backward wave considering the wave reflection model on one site (**Figure 5**), based on pulse wave analysis (PWA) and wave separation analysis algorithms (Laurent et al., 2016). Single-site oscillometric arterial stiffness assessment methods have major advantages since brachial and central BP can be measured at the same time, in addition, estimation of arterial stiffness only requires modest increase in measurement time. Therefore, 24-hour monitoring of central BP and arterial stiffness, which could provide additional information, is possible. Their limits have nevertheless to be taken into account since the theory behind estimation of arterial stiffness from single brachial measurement is based on a mathematical model combining several parameters from pulse wave analysis and wave separation analysis together with age and BP.

Overall increased PWV has been shown to predict cardiovascular, and in some cases all-cause, mortality in individuals with hypertension, end-stage kidney disease, diabetes mellitus, and in the general population (Vlachopoulos et al., 2010). What is more, it has been demonstrated that arterial stiffness, as a biomarker of cardiovascular risk prediction, is independently associated with outcomes, and improves discrimination, calibration as well as net reclassification.




Figure 4. Two-site oscillometric arterial stiffness assessment by calculating the brachial-ankle pulse wave velocity (baPWV) through the measurement of the transit time between the brachial artery and tibial artery through the oscillometric amplitude.

Definitions: BP - blood pressure; baPWV - brachial-ankle pulse wave velocity.




Figure 5. Single-site oscillometric arterial stiffness assessment method by the combination of cuff oscillometry, pulse wave analysis and validated algorithms including covariates such as age and systolic blood pressure.

Definitions: oPWA - oscillometric pulse wave analysis; oPWV - oscillometric pulse wave velocity; SBP - brachial systolic blood pressure

Current and Future Challenges

Oscillometric devices (ODs) are currently used to measure blood pressure in routine clinical practice. ODs that can also measure parameters of VA would be of added benefit in cardiovascular (CVS) risk detection and management. The routine clinical practice of CVS risk prediction and events are based on risk scores pertaining to age and traditional risk factors. VA assessment in terms of arterial stiffness, namely cfPWV parameter, has been shown to further improve on existing CVS risk scores and is well documented and accepted (Boutouyrie and Bruno, 2018). The Clinical practice guidelines of 2018 European Society of Hypertension/European Society of Cardiology guidelines allowed for PWV utility to detect hypertensive mediated organ damage (HMOD) (Williams et al., 2018). CVS risk increases with the presence of HMOD, some reversed by antihypertensive treatment, when used early, but may become irreversible despite improved BP control when hypertension is long standing with age (Kjeldsen et al., 2018). There are scant published clinical outcome trials above existing studies associated with weight reduction and increased exercise. ODs can measure PWV with a combination of PWA and the oscillometric property of the artery studied at diastolic and suprasystolic pressures by using transducers in inflatable cuffs. Cuffs placed peripherally on the limbs where the artery is palpable over a bone makes it comfortable for the patient without the requirement of groin exposure. Moreover, detection of the femoral pulse is challenging in an obese body habitus. Easy use and reproducibility of ODs not requiring expert personnel makes it one of the most used devices to measure PWV currently. ODs simultaneously measure peripheral blood and pulse pressure; estimated cfPWV; estimated central pulse pressure and augmentation index making utility of these added parameters attractive for the use of ODs in outcome studies related to VA. ODs that have a cuff with separate PPG sensors in the upper and lower extremities can measure ankle-brachial index (ABI) and brachial-ankle PWV (baPWV) which is also being used in longitudinal studies (Boutouyrie and Bruno, 2018). ODs utilise large artery regional PWV measurements and combined large and peripheral arteries (multi-regional PWV measurements) as well as static (single point) pulse wave measurements making the harmonisation of the various PWV parameters challenging. The length and path of the arterial tree traversed is estimated by surface anatomy which furthers compounds acceptability. A recent study involving 1162 subjects to define the agreement between a particular OD measuring PWV and the reference standard tonometric cfPWV measurement in the general population concluded that both values of PWV closely correlated highlighting applicability in the general population (Del Giorno et al., 2021). VA outcome trials using ODs to detect, monitor and guide therapy related to HMOD as well as further evidence for the validation of commercial ODs according to ARTERY Society guidelines will help overcome the challenge of routine acceptability (Wilkinson et al., 2010). The challenge in obtaining the new Medical Device Regulations (MDR) as a Class III medical device (software as a medical device - SAMD) for the indicated use will be a major step forward in the confident use of ODs in routine clinical practice for VA assessment.

Advances in Science and Technology to Meet Challenges

The concept of VA is currently envisioned as a key programmatic axis in cardiovascular research, but albeit the cumbersome evidence yielding some of VA biomarkers as major predictive factors (Boutouyrie and Bruno, 2018, Vlachopoulos et al., 2010), their translation into clinical practice has been relatively disappointing. Several reasons could be pinpointed for this, including technical and time-consuming features of the gold-standard two-point measurement approach, absence of a single,

1
2
3 simple and intuitive measure of VA, and lack of therapeutic approaches specifically aimed at restoring
4 VA trajectories. Future efforts in science should therefore be directed to tackle these challenges,
5 congenial with the consolidation of VA as a clinical cornerstone in CVS medicine. With this in mind,
6 measures of VA derived from ODs are a promising approach, mostly for its simplicity, readiness and
7 speed of measure. Notwithstanding, some challenges are yet to be met in order to preserve the
8 strength of more validated approaches in ODs. One major issue equates from the highly dependence
9 of current single-point ODs on proprietary algorithms that are heavily determined by features such as
10 age and BP, therefore making the extrapolated measures of arterial stiffness highly dependent on
11 aspects rather than vascular function per se, invariably leading to a penalised prognostic information
12 above the two conventional risk factors. On the other hand, the proprietary algorithm idiosyncrasies
13 and their intertwining with BP measurement technology may introduce further variability in the
14 estimations, also compromising the comparability amongst technologies. The emergence of
15 algorithms that are able to extract VA parameters solely based on the waveform characteristics from
16 oscillometric BP measurement in single-point systems (Baulmann et al., 2022) is definitely a promising
17 step forward to accurately assess these parameters, simultaneously meeting the requirements for
18 everyday clinical practice. Achieving the widespread use of these technologies, and its incorporation
19 in sensors/wearables interconnected with portable smart devices would provide added opportunities
20 to explore the oscillometric arterial waveforms in a big data approach, incorporating machine and
21 deep learning algorithms for feature extraction and classification, conveying further opportunities of
22 sophisticated analysis of the waveform envelope towards the extraction of useful information that
23 would not, otherwise, be accessible (for a thorough review, read (Bikia et al., 2021)). This sophisticated
24 processing of the oscillometric arterial waveform in an integrative multimodal methodology including
25 clinical information and multiple individual risk factors, could well pave the way towards the
26 emergence of a single and robust estimate of VA, further contributing to a broader application of this
27 concept in clinical practice.

38 **Concluding Remarks**

39 VA in the form of arterial stiffness measures has the clinical utility of CVS risk prediction and is
40 independently associated with outcomes and improves discrimination, calibration as well as net
41 reclassification. Oscillometric arterial stiffness estimates show a good and satisfactory agreement
42 compared to the reference standard (tonometric) PWV assessment. Oscillometric arterial stiffness
43 analysis is a non-invasive, easy-to-use, cost-effective, portable, operator-independent and suitable for
44 use in everyday clinical practice. Notwithstanding the merits of ODs in the science of VA, further
45 technological developments are needed for the ODs to fully match the accuracy and predictive ability
46 of the gold-standard method, to be readily available for inclusion in daily-life portable smart devices
47 and to benefit from artificial intelligence capabilities in the form of a VA single classifier. Also, strict
48 validation requirements for OD-based VA measurement must be set and compulsory. Therefore, using
49 pooled studies and registries of large numbers of subjects from multidisciplinary research will further
50 advance our understanding and use of VA assessment into daily clinical practice.
51
52
53
54
55
56
57
58
59
60

Acknowledgements

This article is based upon work from the European COST ACTION CA18216 “Network for Research in Vascular Ageing”, supported by COST (European Cooperation in Science and Technology, www.cost.eu).

References

- BAULMANN, J., DÖRR, M., GENZEL, E., STÄUBER, A., RICHTER, S., OHLOW, M.-A. & ECKERT, S. 2022. Feasibility of Calculating Aortic Pulse Wave Velocity from Oscillometric Upper Arm Pulse Waves Using the Antares Algorithm. *Artery Research*, 28, 1-8. <https://doi.org/10.1007/s44200-021-00009-3>
- BIKIA, V., FONG, T., CLIMIE, R. E., BRUNO, R.-M., HAMETNER, B., MAYER, C., TARENTES-PRINTZIOS, D. & CHARLTON, P. H. 2021. Leveraging the potential of machine learning for assessing vascular ageing: state-of-the-art and future research. *European Heart Journal - Digital Health*, 2, 676-690. DOI: [10.1093/ehjdh/ztab089](https://doi.org/10.1093/ehjdh/ztab089)
- BOUTOUYRIE, P. & BRUNO, R.-M. 2018. The Clinical Significance and Application of Vascular Stiffness Measurements. *American Journal of Hypertension*, 32, 4-11. DOI: [10.1093/ajh/hpy145](https://doi.org/10.1093/ajh/hpy145)
- DEL GIORNO, R., TROIANI, C., GABUTTI, S., STEFANELLI, K. & GABUTTI, L. 2021. Comparing oscillometric and tonometric methods to assess pulse wave velocity: a population-based study. *Annals of Medicine*, 53, 1-16. DOI: [10.1080/07853890.2020.1794538](https://doi.org/10.1080/07853890.2020.1794538)
- KJELDSSEN, S. E., NARKIEWICZ, K., BURNIER, M. & OPARIL, S. 2018. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Taylor & Francis. DOI: [10.1080/08037051.2018.1530564](https://doi.org/10.1080/08037051.2018.1530564)
- LAURENT, S., MARAIS, L. & BOUTOUYRIE, P. 2016. The noninvasive assessment of vascular aging. *Canadian Journal of Cardiology*, 32, 669-679. DOI: [10.1016/j.cjca.2016.01.039](https://doi.org/10.1016/j.cjca.2016.01.039)
- VLACHOPOULOS, C., AZNAOURIDIS, K. & STEFANADIS, C. 2010. Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness. *Journal of the American College of Cardiology*, 55, 1318-1327. DOI: [10.1016/j.jacc.2009.10.061](https://doi.org/10.1016/j.jacc.2009.10.061)
- WILKINSON, I., MCNIERY, C., SCHILLACI, G., BOUTOUYRIE, P., SEGERS, P., DONALD, A. & PHILIP, J. C. On behalf of the ARTERY Society (2010) ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: Part 1, arterial pulse wave velocity. *Artery Res*, 4, 34-40. <https://doi.org/10.1016/j.artres.2010.03.001>
- WILLIAMS, B., MANCIA, G., SPIERING, W., AGABITI ROSEI, E., AZIZI, M., BURNIER, M., CLEMENT, D. L., COCA, A., DE SIMONE, G., DOMINICZAK, A., KAHAN, T., MAHFOUD, F., REDON, J., RUILOPE, L., ZANCHETTI, A., KERINS, M., KJELDSSEN, S. E., KREUTZ, R., LAURENT, S., LIP, G. Y. H., MCMANUS, R., NARKIEWICZ, K., RUSCHITZKA, F., SCHMIEDER, R. E., SHLYAKHTO, E., TSIQOUFIS, C., ABOYANS, V., DESORMAIS, I. & GROUP, E. S. D. 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European Heart Journal*, 39, 3021-3104. DOI: [10.1097/HJH.0000000000001940](https://doi.org/10.1097/HJH.0000000000001940)

5. Applanation tonometry

Author(s): Andrea Grillo¹, Paolo Salvi², Isabella Tan^{3,4}

Institution(s): ¹ Department of Medical, Surgical and Health Sciences, University of Trieste, Italy; ² Istituto Auxologico Italiano, IRCCS, Milan, Italy; ³ Macquarie University, Sydney, Australia; ⁴ The George Institute for Global Health, Sydney, Australia

ORCID(s): 0000-0002-4455-4991; 0000-0001-8663-5426; 0000-0003-3123-6190

Status

Arterial tonometry has historically been one of the most widely used technologies for assessment of vascular ageing. Deriving from experiments with sphygmography in the late nineteenth century for measuring blood pressure, arterial tonometry received a new interest in the last decades of the twentieth century with the availability of transcutaneous high-fidelity tonometry sensors.

Tonometry enables the assessment of vascular districts in which an artery runs superficially and may be compressed against underlying supporting structures, such as bones or fibrous fasciae. It is based on the principle of applanation (flattening) and derived from ocular tonometry (Imbert-Fick law), which states that the pressure within a thin-walled sphere is equal to the force required to flatten the sphere's surface divided by the area of applanation. When an arterial segment is deformed along its vertical axis near the centre line, assuming there is a uniform deformation of the artery along its length, the tonometer is thus able to measure the internal arterial pressure. **Figure 6** illustrates the system operation in which an arterial wall, represented by an ideal membrane, is flattened by a force that only depends on the blood pressure and the applanation area, as tensile forces are perpendicular to the pressure vectors. Piezoresistive strain-gages determine the force exerted on the sensor element, which is directly proportional to intra-arterial pressure. This allows for the recording of the dynamic arterial pressure waveforms, which have been shown to be superimposable over those recorded invasively with an intra-arterial catheter when some conditions are satisfied (Eckerle, 2006). Unlike ocular tonometry, which measures intraocular pressure directly, arterial tonometry cannot measure intra-arterial pressure but rather only relative changes in pressure. In order to obtain absolute blood pressure values, arterial tonometry requires calibration with auscultatory or oscillometric blood pressure values.

Miniaturization and development of multiple-element sensors allowed the manufacture of very accurate and small-dimension tonometers that are currently marketed as manual pen probes. A proper operator technique for correct positioning of the probe and the avoidance of motion artifacts are required to obtain a good quality measurement. Averaging of multiple cardiac cycles (from 3 to 10) reduces effects of beat-to-beat variability and removal of small artifacts in the waveform. When optimal measurement conditions are present, arterial applanation tonometry is usually a well-tolerated, reproducible and non-invasive test that can be performed in several arterial segments (carotid, brachial, radial, femoral, posterior tibial and dorsalis pedis arteries) and allow for haemodynamic measurements through arterial pulse wave analysis.

One leading application of arterial tonometry is in the determination of large artery stiffness. Pioneering studies documented the increase of pulse wave velocity (PWV) with age as the hallmark of stiffening of the aorta (Kelly et al., 1989). The measurement of carotid to femoral pulse wave velocity (cfPWV) has early on become the reference method for measuring arterial stiffness, which can be easily obtained by tonometry of the carotid artery and the femoral artery. cfPWV can then be

determined by dividing the arterial path length (external distance measurement) by transit time between the foot of the carotid and femoral pressure waveforms (Laurent et al., 2006). In addition, the analysis of aortic waveform features, such as central blood pressure and wave reflection-related parameters, derived from either carotid artery or radial artery tonometry, is also useful to obtain information about the process of ageing of the vascular tree.




Figure 6. Applanation tonometry. Left panel: transcutaneous arterial tonometry in radial artery. Right panel: Applanation tonometry principle: a circular structure with a given pressure inside (artery) is flattened; in this way circumferential pressures are equalized and the sensor records the intra-arterial pressure (P). Tensile forces (T) are perpendicular to pressure vectors. Lower panel: raw recording of a radial applanation tonometry sampled at 1 kHz.

Current and Future Challenges

Despite advances in technology of commercially available tonometers and their clinical validation for cardiovascular prevention, the adoption of this method in a wide audience is still limited outside of medical research centres. Some reasons can be attributed to the need of dedicated time and of trained operators, along with the direct and indirect costs of the examination. At this point of its technical development, arterial tonometry has reached a consolidated amount of research that may justify its applicability, and a main challenge will be to promote its use and to include it in clinical guidelines. To

1
2
3 achieve this goal, there is still the need to obtain evidence from clinical studies that treatment of
4 patients based on information from tonometry is more effective than current standard care.

5
6 There are a large number of tools available to measure vascular ageing, based either on tonometry or
7 on other methodologies, yet there is currently no consensus on how to apply vascular ageing
8 measures. Current evidence based on comparative studies of different methodologies is oriented
9 toward the support of arterial tonometry compared to other measures, in part due to its better
10 replicability and reliability (Grillo et al., 2018). A methodological consensus is urgently required to
11 guide research in the field of vascular ageing.
12
13

14 A further methodological issue is the way the central aortic pulse wave is defined from arterial
15 tonometry (Salvi et al., 2015). Two methods are currently available to record the central aortic
16 pressure wave: 1) The “direct” method, in which arterial tonometry from the common carotid artery
17 with proper calibration is used as a surrogate for aortic pressure due to the close proximity of the
18 vessels; 2) The “indirect” method, where central waveform is synthesized from a peripheral arterial
19 waveform (such as brachial or radial waveform obtained from tonometry) with a generalised transfer
20 function. Calibration of the central or peripheral pressure waveforms with an external blood pressure
21 measurement (commonly with cuff-based oscillometric brachial blood pressure) is required for both
22 methods, and how this is done may affect the estimate of central aortic pressures (Sharman et al.,
23 2017). Again, a consensus is advisable to provide a clear message to a large audience, stating if both
24 the direct or indirect methods are equally valid and interchangeable for clinical application or not, and
25 which method of calibrating the arterial waveform, be it carotid or peripheral, is the most
26 appropriate.
27
28
29
30
31
32

33 **Advances in Science and Technology to Meet Challenges**

34
35 With the adoption in a clinical setting being the biggest challenge for arterial tonometry, several
36 advances have been realised to make this technique more suitable for its everyday use. Although it is
37 a relatively simple method to learn, obtaining a good quality pulse signal from tonometry requires
38 operator training and dedicated time.
39

40 For the measurement of cfPWV, the need to perform applanation tonometry on both carotid and
41 femoral arteries simultaneously, which is not easy to perform for a single operator, was overcome
42 by the use of an ECG-gated technique, or, more recently, by using mechanical holders for positioning the
43 tonometric probe, or by replacing femoral tonometry with a cuff-based acquisition (Butlin and Qasem,
44 2016). This cuff-based evaluation of the peripheral femoral pulse seems to be more suitable for some
45 cultures, where direct examination of the groin area may be considered inappropriate. The use of cuff-
46 based or plethysmography-based methods to evaluate the pulse waveform from peripheral arteries,
47 although more appealing for its ease of use, presents some limitations because of the dampening of
48 measured pulse waves with loss of high-frequency information. Thus, tonometry remains the
49 reference method for the applications where analysis of the components of the waveform is of
50 interest.
51
52

53
54 Currently, the use of tonometry is advancing on parameters that may be clinically useful in special
55 populations or settings. From the central aortic pressure wave, information can be extracted about
56 the balance between the oxygen supply and demand of the myocardium, namely the subendocardial
57 viability ratio (SEVR). Originally determined by invasive heart catheterization, this index has recently
58 been improved in its non-invasive formulation by arterial tonometry (Salvi et al., 2021), and may be
59
60

1
2
3 particularly relevant in the aged population, where a high risk of myocardial ischemia exist and
4 relevant alterations in the central waveform, such as pressure amplification, have already
5 demonstrated predictive power (Benetos et al., 2012).
6
7
8
9

10 **Concluding Remarks**

11 Despite the constant increase in original research on applanation tonometry in the last 20 years, its
12 use for the evaluation and treatment of vascular ageing will become more common if supported by
13 strong clinical evidence. Further studies are necessary to evaluate the best use of arterial tonometry
14 in the clinical setting for quantifying vascular age, with the aim to detect early vascular ageing and
15 thus assist in early intervention.
16
17
18
19

20 **Acknowledgements**

21 This review was partially supported by the Italian Ministry of Health.
22
23
24
25

26 **References**

- 27 Benetos, A., Gautier, S., Labat, C., Salvi, P., Valbusa, F., Marino, F., Toulza, O., Agnoletti, D., Zamboni, M.,
28 Dubail, D., 2012. Mortality and cardiovascular events are best predicted by low central/peripheral pulse
29 pressure amplification but not by high blood pressure levels in elderly nursing home subjects: the PARTAGE
30 (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study.
31 *Journal of the American College of Cardiology* 60, 1503–1511.
32
33 Butlin, M., Qasem, A., 2016. Large artery stiffness assessment using SphygmoCor technology. *Pulse* 4, 180–192.
34
35 Eckerle, J.S., 2006. Tonometry, Arterial, in: *Encyclopedia of Medical Devices and Instrumentation*. John Wiley &
36 Sons, Ltd. <https://doi.org/10.1002/0471732877.emd250>
37
38 Grillo, A., Parati, G., Rovina, M., Moretti, F., Salvi, L., Gao, L., Baldi, C., Sorropago, G., Faini, A., Millasseau, S.C.,
39 2018. Short-term repeatability of noninvasive aortic pulse wave velocity assessment: comparison between
40 methods and devices. *American Journal of Hypertension* 31, 80–88.
41
42 Kelly, R., Hayward, C., Avolio, A., O’rourke, M., 1989. Noninvasive determination of age-related changes in the
43 human arterial pulse. *Circulation* 80, 1652–1659.
44
45 Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., Pannier, B., Vlachopoulos,
46 C., Wilkinson, I., Struijker-Boudier, H., 2006. Expert consensus document on arterial stiffness: methodological
47 issues and clinical applications. *European heart journal* 27, 2588–2605.
48
49 Salvi, P., Baldi, C., Scalise, F., Grillo, A., Salvi, L., Tan, I., De Censi, L., Sorropago, A., Moretti, F., Sorropago, G.,
50 2021. Comparison between invasive and noninvasive methods to estimate subendocardial oxygen supply and
51 demand imbalance. *Journal of the American Heart Association* 10, e021207.
52
53 Salvi, P., Grillo, A., Parati, G., 2015. Noninvasive estimation of central blood pressure and analysis of pulse
54 waves by applanation tonometry. *Hypertension Research* 38, 646–648.
55
56 Sharman, J.E., Avolio, A.P., Baulmann, J., Benetos, A., Blacher, J., Blizzard, C.L., Boutouyrie, P., Chen, C.-H.,
57 Chowienzyk, P., Cockcroft, J.R., 2017. Validation of non-invasive central blood pressure devices: ARTERY
58 Society task force consensus statement on protocol standardization. *European Heart Journal* 38, 2805–2812.
59
60

6. Photoplethysmography techniques

Author(s): Peter H. Charlton¹; Djammaledine Djeldji²; Serena Zanelli^{3,4}

Institution(s): ¹ Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; ² LCOMS, Université de Lorraine, F-57000 Metz, France; ³ Laboratoire Analyse, Géométrie et Applications, Université Sorbonne Paris Nord, Paris, France

⁴Axelife, Redon, France

ORCID(s): 0000-0003-3836-8655; 0000-0003-1343-0168; 0000-0002-8020-8375


Status

Photoplethysmography is an optical measurement technique in which an arterial pulse wave signal known as the photoplethysmogram (PPG) is acquired by shining light on the skin, and measuring the amount of light either transmitted through, or reflected from, the tissue. Photoplethysmography is widely used in clinical and consumer devices, such as fingertip pulse oximeters and smartwatches, for oxygen saturation and heart rate monitoring. The shape and timing of PPG pulse waves change with age (**Figure 7 (a)**), providing an opportunity to assess vascular age from the PPG [Charlton et al., 2022].


A range of techniques have been proposed to assess vascular age from the PPG, which broadly fall into three categories **Figure 7 (b)** [Charlton et al., 2022]. Firstly, a single PPG signal can be used to obtain a parameter indicative of vascular age from the pulse wave shape. The PPG signal can be measured by devices such as smartwatches, pulse oximeters, and non-contact cameras (using imaging photoplethysmography – iPPG). Secondly, two PPG signals can be used, such as finger and toe signals, to obtain pulse transit time (the time taken for the pulse wave to travel between two sites). Thirdly, pulse arrival time (the time delay between heart contraction and the arrival of a pulse wave) can be obtained from a PPG signal and another signal which provides information on the time of heart contraction (such as the electrocardiogram, ECG). Once a parameter has been obtained, it can be transformed into either a clinically relevant parameter (such as pulse wave velocity, PWV) or a diagnostic category (see **Figure 7 (c)**). Research to date provides evidence on [Charlton et al., 2022]: (i) the level of agreement between PPG-derived parameters and reference indicators of vascular age; (ii) the repeatability and reproducibility of PPG parameters; and (iii) their potential clinical utility in peripheral arterial disease, diabetes, and cardiovascular risk assessment.

Future advances in photoplethysmography-based technologies could enable unobtrusive vascular ageing assessments across a wide section of society, utilising either contact PPG measurements from everyday devices such as smartwatches, or non-contact measurements from smartphones and tablets.

(a) The shape and timing of PPG pulse waves changes with age:



(b) The three categories of techniques for obtaining a parameter indicative of vascular age:



(c) Approaches for transforming a PPG-derived parameter into a clinically relevant parameter or diagnostic category:




Figure 7. Assessing vascular ageing from contact photoplethysmography.

Definitions: PPG - photoplethysmogram; PTT - pulse transit time; PAT - pulse arrival time; ECG - electrocardiogram.

Adapted from: [Charlton et al., 2022] and [Charlton et al., 2022b] under the [CC BY 4.0 licence](https://creativecommons.org/licenses/by/4.0/).

Current and Future Challenges

There are several challenges to using photoplethysmography-based technologies for vascular ageing assessment, which are now described.

A key challenge is in obtaining accurate physiological information from PPG signals given that the PPG is influenced not only by vascular ageing but also a range of other factors. For instance, PPG pulse wave shape is also influenced by heart rate, stroke volume, blood pressure, and peripheral vascular compliance [Charlton 2019]. Similarly, the timing of PPG pulse waves is influenced by blood pressure. Therefore, it is a challenge to ensure photoplethysmography-based assessments of vascular ageing are not overly influenced by other cardiovascular properties. Pulse wave shape is also influenced by measurement factors such as [Charlton 2022b]: anatomical site, contact vs. non-contact photoplethysmography, wavelength of light, transmission vs. reflectance photoplethysmography, contact pressure, temperature, and skin color. The PPG signal also exhibits beat-to-beat variations, partly due to physiological variations [Elgendi2012]. All these influences should be accounted for when developing PPG-based techniques.

The challenge of obtaining accurate physiological information is all the greater for in the case of iPPG. iPPG consists of extracting a PPG signal from a video of the skin (usually the face) by analysing the pulsatile changes in light intensity (**Figure 8**). Consequently, even involuntary movements such as the small movements associated with breathing and the heart beating can cause changes in facial position and orientation, causing changes in the region of interest (ROI) and its illumination [Djeldjli2021]. Once a stable signal is obtained, pulse wave parameters can be derived (**Figure 8**) and transformed into clinically relevant outputs using the same approach as for contact PPG signals (**Figure 7 (c)**). Similarly to contact PPG signals, features can be extracted from iPPG signals which are related to blood pressure (BP), arterial stiffness, and vascular ageing assessment [Djeldjli2021]. Consequently, there is the same challenge of separating information on vascular ageing from other factors influencing the iPPG signal. iPPG is an attractive alternative to contact photoplethysmography in cases of trauma, burns, and contagious diseases [Djeldjli2021]. In addition, it could be used with tablets and smartphones to conduct unobtrusive hemodynamic assessments. This provides great incentive for overcoming the additional challenges associated with iPPG.

A second challenge is presented by PPG signal quality, as the PPG signal is highly susceptible to noise. Low quality signals can be caused by movement artefacts, poor sensor contact, low light intensity (which can be related to skin tone), reduced perfusion, and the use of iPPG as opposed to contact PPG. Potential options for handling low signal quality include: rejecting periods of low signal quality; using mathematical techniques to remove motion artifact from low-quality signals; and using simultaneous accelerometry signals for motion artefact removal.

A third challenge is in establishing reference values for PPG-derived parameters. Whilst some work has been conducted on establishing reference values [Choi 2023], normal and pathological values of a wide range of parameters have not yet been comprehensively defined. Reference values could take into account physiological factors which are known to influence PPG pulse waves, such as blood pressure, heart rate, age, and arterial stiffness [Elgendi2012]. It is also important to consider the impact of measurement factors, and to investigate whether different ranges are required for different measurement configurations (such as different anatomical sites).

A fourth challenge is in translating PPG-based techniques into clinical practice. As described in detail in Section 11, techniques should be validated against reference measurements, the potential clinical utility of techniques should be investigated, and finally the cost-effectiveness of techniques should be

assessed. These examples demonstrate the feasibility of translating PPG-based technologies into practice.

A fifth challenge is ensuring that PPG-based techniques perform well across subjects of all ethnicities. There are known differences between ethnicities in the patterns of vascular ageing [Schutte2020] which should be taken into account in all vascular ageing assessments. In addition, since photoplethysmography involves interaction between light and the skin, PPG-based measurements can be affected by skin color. This phenomenon is well-documented for pulse oximetry which uses PPG signals of two wavelengths [Al-Halawani2023], and is now a key consideration for other PPG-based measurements such as wearable heart rate monitoring [Koerber2023].




Figure 8. Imaging photoplethysmography (iPPG) waveform extraction and analysis: facial images are captured by a colour camera. Then the forehead is selected as Region Of Interest (ROI). The raw iPPG signal is extracted from the ROI using spatial averaging. Before extracting the waveform, the signal is smoothed and filtered. Three waveform features can be computed: (a) temporal, (b) areas and (c) derivatives and amplitude features. These features are related to heart rate, blood pressure, vascular ageing and arterial stiffness.

Advances in Science and Technology to Meet Challenges

Novel publicly available datasets containing a range of PPG signals and reference physiological parameters would greatly aid work towards obtaining accurate physiological information from PPG signals. Currently, there are relatively few publicly available contact PPG datasets which are well-suited to vascular ageing research [Charlton2022], and similarly there are relatively few iPPG datasets (such as the BP4D+ dataset, a dataset designed for emotion recognition which contains movement [Zhang2014]). Novel datasets could include PPG signals measured from subjects with different characteristics (spanning ranges of age, blood pressure, and skin tone), using different measurement configurations (including anatomical site and contact vs non-contact measurements). Such datasets are of even greater value when they include reference vascular ageing parameters (such as pulse wave velocity, blood pressure, and age), and other physiological parameters (such as stroke volume). Advances in approaches for simulating PPG pulse waves recently led to the creation of a database of simulated PPG pulse waves containing reference measurements of a wide range of physiological parameters [Charlton2019]. Future work based on novel datasets could identify optimal measurement

1
2
3 configurations and analysis techniques for obtaining parameters of vascular ageing which are not
4 unduly influenced by other factors. The recent development of a technique to reconstruct a contact
5 PPG signal from an iPPG signal [Bousefsaf2021] provides opportunity to use the more plentiful contact
6 PPG datasets when developing iPPG technologies [Djeldjli2021].
7

8
9 A second research direction towards obtaining accurate physiological information is developing novel
10 PPG analysis techniques, leveraging advances in artificial intelligence techniques. Deep learning
11 models, such as Convolutional Neural Networks, are widely employed in PPG analysis thanks to their
12 capability of automatically extracting features from the signal avoiding the need for handcrafted
13 features [Charlton 2022]. When working with deep learning techniques, particular attention must be
14 paid to the amount of data required, the balance between classes inside the dataset (such as normal
15 and pathological subjects), and the validation process that is used to correctly test the proposed
16 model. An alternative approach is to combine our understanding of the physiology of the PPG pulse
17 wave with traditional signal processing techniques to obtain more refined measures of vascular
18 ageing, which can be achieved by decomposing pulse waves into forward and backward waves
19 [Lin2022], or harnessing the additional information provided by multi-wavelength
20 photoplethysmography which can be related to different depths of vasculature [Liu2019].
21
22

23
24 The development of PPG sensor hardware may also help improve the accuracy of PPG-derived
25 parameters. For instance, multi-wavelength photoplethysmography could provide insights into
26 hemodynamics at different depths of the vasculature, and be used to assess arteriolar pulse transit
27 time (the time taken for the pulse wave to travel through the arterioles) [Liu 2018]. This may provide
28 complementary assessments of vascular ageing to those typically conducted on large arteries (such as
29 PWV), and may also help separate the influences of macro- and micro-vasculature on PPG signals.
30
31

32
33 The challenge presented by PPG signal quality is encountered in many other PPG applications
34 [Charlton 2023], providing opportunity to translate work developed for other applications to vascular
35 ageing assessment techniques, although methods to discriminate between high quality PPG -
36 pathological or not, during physical activity or not - and low quality PPG, still need to be further
37 explored. Further development of PPG sensor hardware may improve signal quality: combinations of
38 different wavelengths could be more robust to movement and external noise; and potentially
39 different wavelengths could be used based on the level of noise in the corresponding signals. Another
40 approach is to develop strategies to obtain measurements during periods of high signal quality and
41 steady cardiovascular state, such as while motionless or asleep.
42
43

44
45 The widespread and growing use of PPG sensors may help tackle the challenges of establishing normal
46 ranges for PPG-derived parameters, and translating PPG-based vascular ageing assessments into
47 clinical practice. Large studies are now being conducted using PPG measurements obtained from
48 consumer devices, greatly aiding clinical translation [Perez2019]. Such studies typically use
49 parameters derived from the PPG signal by the device. Therefore, to use this approach in the field of
50 vascular ageing, consumer devices would either need to be equipped with an algorithm to assess
51 vascular age, or to provide the PPG signal for retrospective analysis. This would then enable the
52 development of reference ranges of parameters, and help assess clinical utility through linkage with
53 electronic health record data.
54
55

56
57 The need to ensure equitable performance of PPG-based vascular ageing assessments between
58 ethnicities means that studies of PPG-based devices techniques should include subjects with a
59 sufficiently wide range of skin colors (potentially using objective skin pigmentation assessment [Al-
60 Halawani2023]). Photoplethysmography device designers might consider the wavelength and

intensity of light, and source-detector separation distance used to ensure equitable performance. Whilst photoplethysmography is widely used in wearable devices, it may not be the optimal sensing technology for wearable pulse wave measurement, with several alternatives in development such as electrical bioimpedance [Kireev2022]. Alternatives to photoplethysmography are covered in another recent Roadmap [Charlton2023], and those which do not use light sensing may help ensure performance is not affected by skin pigmentation.

Concluding Remarks

Photoplethysmography is an attractive modality for vascular ageing assessment at scale, being non-invasive and widely incorporated into clinical and consumer devices. However, there are challenges in obtaining accurate physiological information from PPG signals, handling low-quality signals, establishing reference ranges of PPG-derived parameters, and translation into clinical practice. These challenges could be tackled through the development of publicly available PPG datasets, advanced PPG sensing hardware and analysis techniques, and harnessing the widespread use of PPG devices in daily life to conduct large-scale studies. The success of photoplethysmography-based techniques will be dependent on identifying clinical use cases which this technology is well suited to, as already demonstrated by the development of PPG-based technologies for detecting peripheral arterial disease.

Conflicts of Interest

S. Zanelli collaborates with Axelife, a company that designs and develops devices for assessing vascular ageing. P. Charlton has performed consultancy work for companies developing photoplethysmography sensors.

Acknowledgements

This work was supported by COST Action CA18216 VascAgeNet, supported by COST (European Cooperation in Science and Technology, www.cost.eu). PHC acknowledges funding from the British Heart Foundation (FS/20/20/34626).

References

- [Charlton2022] Charlton PH, Paliakaitė B, Pilt K, Bachler M, Zanelli S, Kulin D, Allen J, Hallab M, Bianchini E, Mayer CC, Terentes-Printzios D, Dittrich V, Hametner B, Veerasingam D, Žikić D, Marozas V. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular age: a review from VascAgeNet. *Am J Physiol Circ Physiol* 2022;322:H493–H522. <https://doi.org/10.1152/ajpheart.00392.2021>
- [Charlton2022b] Charlton PH, Kyriacou PA, Mant J, Marozas V, Chowienczyk P, Alastruey J. Wearable Photoplethysmography for Cardiovascular Monitoring. *Proceedings of the IEEE* 2022;110(3):355–81. <https://doi.org/10.1109/JPROC.2022.3149785>
- [Charlton2019] Charlton PH, Mariscal Harana J, Vennin S, Li Y, Chowienczyk P, Alastruey J. Modeling arterial pulse waves in healthy aging: a database for in silico evaluation of hemodynamics and pulse wave indexes. *American Journal of Physiology-Heart and Circulatory Physiology*. 2019;317(5):H1062–85. <https://doi.org/10.1152/ajpheart.00218.2019>

- [Djeldjli2021] Djeldjli D, Bousefsaf F, Maaoui C, Bereksi-Reguig F, Pruski A. Remote estimation of pulse wave features related to arterial stiffness and blood pressure using a camera. *Biomed Signal Process Control* 2021;64:102242. <https://doi.org/10.1016/j.bspc.2020.102242>
- [Zanelli2021] S. Zanelli, M. A. El Yacoubi, M. Hallab and M. Ammi, "Transfer learning of CNN-based signal quality assessment from clinical to non-clinical PPG signals," *2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*, 2021, pp. 902-905, doi: 10.1109/EMBC46164.2021.9629640.
- [Bousefsaf2021] Bousefsaf, F., Djeldjli, D., Ouzar, Y., Maaoui, C., & Pruski, A. (2021). iPPG 2 cPPG: Reconstructing contact from imaging photoplethysmographic signals using U-Net architectures. *Computers in Biology and Medicine*, 138, 104860.
- [Elgendi2012] Elgendi, M. (2012). On the analysis of fingertip photoplethysmogram signals. *Current cardiology reviews*, 8(1), 14-25.
- [Choi2023] Choi J, Park MG. Variations in the Second Derivative of a Photoplethysmogram with Age in Healthy Korean Adults. *International Journal of Environmental Research and Public Health*. 2023 Jan;20(1):236. <https://doi.org/10.3390/ijerph20010236>
- [Zhang2014] Zhang X, Yin L, Cohn JF, Canavan S, Reale M, Horowitz A, et al. BP4D-Spontaneous: a high-resolution spontaneous 3D dynamic facial expression database. *Image and Vision Computing*. 2014 Oct 1;32(10):692–706. <https://doi.org/10.1016/j.imavis.2014.06.002>
- [Liu 2018] Liu J, Yan BP, Zhang Y ting, Ding X rong, Su P, Zhao N. Multi-wavelength photoplethysmography enabling continuous blood pressure measurement with compact wearable electronics. *IEEE Transactions on Biomedical Engineering*. 2019;66(6):1514–25. <https://doi.org/10.1109/TBME.2018.2874957>
- [Perez 2019] Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. *New England Journal of Medicine*. 2019;381(20):1909–17. <https://doi.org/10.1056/NEJMoa1901183>
- [Schutte2020] Schutte, A. E., Kruger, R., Gafane-Matemane, L. F., Breet, Y., Strauss-Kruger, M., & Cruickshank, J. K. Ethnicity and Arterial Stiffness. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020;40(5), 1044–1054. <https://doi.org/10.1161/ATVBAHA.120.313133>
- [Koerber2023] Koerber, D., Khan, S., Shamsheri, T., Kirubarajan, A., & Mehta, S. Accuracy of Heart Rate Measurement with Wrist-Worn Wearable Devices in Various Skin Tones: A Systematic Review. *Journal of Racial and Ethnic Health Disparities*. 2023;10(6), 2676–2684. <https://doi.org/10.1007/s40615-022-01446-9>
- [Al-Halawani2023] Al-Halawani, R., Charlton, P. H., Qassem, M., & Kyriacou, P. A. A review of the effect of skin pigmentation on pulse oximeter accuracy. *Physiological Measurement*. 2023;44, 05TR01. <https://doi.org/10.1088/1361-6579/acd51a>
- [Charlton2023] Charlton, P. H., Allen, J., Bailón, R., Baker, S., Behar, J. A., Chen, F., Clifford, G. D., Clifton, D. A., Davies, H. J., Ding, C., Ding, X., Dunn, J., Elgendi, M., Ferdoushi, M., Franklin, D., Gil, E., Hassan, M. F., Hernesniemi, J., Hu, X., ... Zhu, T. The 2023 wearable photoplethysmography roadmap. *Physiological Measurement*. 2023; 44(11), 111001. <https://doi.org/10.1088/1361-6579/acead2>
- [Kireev2022] Kireev, D., Sel, K., Ibrahim, B., Kumar, N., Akbari, A., Jafari, R., & Akinwande, D. Continuous cuffless monitoring of arterial blood pressure via graphene bioimpedance tattoos. *Nature Nanotechnology*. 2022; 17(8), 864–870. <https://doi.org/10.1038/s41565-022-01145-w>
- [Lin2022] Lin, W.-H., Zheng, D., Li, G., Zhou, H., & Chen, F. Investigation on Pulse Wave Forward Peak Detection and Its Applications in Cardiovascular Health. *IEEE Transactions on Biomedical Engineering*. 2022; 69(2), 700–709. <https://doi.org/10.1109/TBME.2021.3103552>
- [Liu2019] Liu, J., Yan, B. P., Zhang, Y., Ding, X., Su, P., & Zhao, N. Multi-wavelength photoplethysmography enabling continuous blood pressure measurement with compact wearable electronics. *IEEE Transactions on Biomedical Engineering*. 2019; 66(6), 1514–1525. <https://doi.org/10.1109/TBME.2018.2874957>

7. Circulating biomarkers

Author(s): Kristina Gopcevic¹, Antonios Lazaridis², Eugenia Gkaliagkousi²

Institution(s): ¹Faculty of Medicine, University of Belgrade, Serbia; ²Faculty of Medicine, Aristotle University of Thessaloniki, Greece

ORCID(s): 0000-0003-4045-6734; 0000-0002-7205-4644; 0000-0002-6324-2475

Status

Over the past few decades, many circulating biomarker candidates identified in serum/plasma and tissue have shown potential in early detection and diagnosis of cardiovascular diseases and vascular ageing, as illustrated in **Figure 9**. However, only a few have been carefully evaluated in a large cohort of samples for further validation of their utility (Gopcevic *et al* 2021). The lack of a rapid, convenient and reliable format of testing for a promising biomarker in an appropriate specimen type presents an obvious bottleneck for successful translation of biomarker candidates in the clinic. The most promising are: superoxide-dismutase (SOD), matrix metalloproteinases (MMPs), high sensitivity C reactive protein (hsCRP), interleukin-6 (IL-6) and interleukin-1b (IL-1b), growth differentiation factor-15 (GDF-15), micro ribonucleic acids (miRNAs), DNA methylation, extracellular vesicles (EVs) (Femmino *et al.*, 2020, Gkaliagkousi *et al* 2021, Lazaridis *et al* 2022) and telomere shortening. Current measurement techniques for MMPs activity include: zymography using different substrates and immunoassays. Reactive oxygen and nitrogen species can be measured directly – concentration of reactive species produced or indirectly - targeting the molecules of the antioxidant system changed in response to increased redox stress, such as activity of SOD. The hsCRP, IL-6, IL-1b, and GDF-15 markers can all be measured with readily available quantitative immunoassays. Concerning profiling of miRNAs, the reverse transcription quantitative real-time polymerase chain reaction (PCR) is the most widely sensitive method. EVs are potent mediators of inflammation, coagulation, oxidative stress and immune system modulation, therefore holding a significant mechanistic role in the pathophysiology of cardiovascular disease. To determine the EVs origin, structure, and size, immunoblotting of specific proteins, flow cytometry, transmission electron microscopy, and nanoparticle tracking analysis are used. DNA methylation is predominantly measured in DNA extracted from various tissues, commonly whole blood. Bisulfite sequencing is considered to be the reference method for single-base resolution measurement of DNA methylation levels and PCR-based techniques are routinely used to study DNA methylation on a gene-specific basis, after bisulfite treatment. Currently also, genome-wide analyses such as massive parallel sequencing and microarray-based platforms have been developed for methylome profiling and identification of differentially methylated regions at a genome-wide scale. Finally, telomere shortening is measured in DNA extracted from peripheral blood leukocytes. There are three main methods for measuring telomere length: (a) Southern blot, (b) quantitative PCR, and (c) fluorescent in situ hybridization-based methods. Overall, Southern blot remains the most accurate method for precise measurement of telomere length while qPCR is the most employed method for large population-based studies.




Figure 9. Some circulating biomarkers with the highest potential for early detection and diagnosis of cardiovascular disease and vascular ageing. Adopted from Gopcevic et al, 2021.

Current and Future Challenges

The current knowledge of MMPs provides a perception of their multifunctional implication in, highlighting their relevance as potential therapeutic options. At least 27 MMPs can be determined by bioassays, zymography, western blotting, ELISA. All methods have many disadvantages: low specificity, limits of detection, broad spectrum of substrate specificity. It has been recently proposed use of different kind of biosensors (Kirchhain *et al* 2019) which allowed detection of MMPs using MALDI-TOF technique. Currently it is difficult to accurately measure and assess RONS levels, owing to their extremely short half-lives. The measurement of SOD is one of most accepted means of measuring RONS activity owing to their levels reflecting their activity catalyzing the dismutation of the strong superoxide radical (O_2^-) (Griendling *et al* 2016). Among many other methods, SOD activity is measured indirectly as a concentration of water-soluble formazan dye which can be detected by the increase in absorbance at 450 nm. IL-6 is considered one of the most representative biomarkers of vascular ageing, closely associated with its chronic inflammatory microenvironment. Understanding the biology of IL-6 receptor and its signalling axis remains a major challenge due to the significant anti-inflammatory potential observed with targeted anti-IL6 monoclonal antibodies. However, the existing therapeutic antibodies available are few due to various biological and economic limitations (Gopcevic *et al* 2021). At the same time, the role of interleukin-1b as a cytokine-based therapy for the secondary prevention of atherosclerotic events and the specific mechanisms driving its beneficial effect on cardiovascular events reduction, remain to be elucidated (Ridker P *et al*, 2017). hsCRP is an inflammatory biomarker strongly linked to vascular wall biology and the prediction of future CV events (Mozos *et al* 2019). However, being an acute phase reactant, elevated hsCRP levels currently lack specificity for CV disease. Therefore, it is still an unresolved issue whether a causal relationship between hsCRP and CV disease exists and whether hsCRP measurement could provide clinically meaningful incremental predictive value in risk prediction and reclassification (2). Highly elevated GDF-15 levels have been mostly linked to pathological conditions including inflammation, myocardial ischemia, and notably cancer. With age, only a moderate increase in GDF-15 blood levels is observed. Hence, there is a clear

1
2
3 need to better understand several GDF-15 mediated effects (including its physiological role in ageing).
4 Particular emphasis should be placed on its immunomodulatory potential (Brábek *et al* 2020). At
5 present, the biggest challenge concerning all miRNA profiling approaches is the lack of a consensus
6 normalization method. This is due to the individual nature and composition of miRNAs and the
7 resulting data distribution of profiling experiments. In addition, data derived by assays of circulating
8 miRNAs suffer from a lack of validated, universal, reference miRNAs which can firmly detected in the
9 blood (Vlachopoulos *et al* 2015). Current methods for isolation, identification and quantification of
10 EVs need further standardisation. Their application in (bio)medical sciences requires an accurate
11 assessment of their biochemical and physical properties. Several aspects should be considered when
12 translating DNA methylation markers into clinical practice. These include (i) identification of the best
13 genomic regions since methylation takes place over large and poorly defined regions, (ii) address of
14 the low-level methylation phenomenon in order to set a cut-off point between pathologically
15 significant and insignificant methylation, (iii) pre-analytical processing techniques, and finally (iv)
16 standardisation of data analysis to define which method has the highest diagnostic potential
17 (Wischhusen *et al* 2020; Marabita *et al* 2016). Finally, telomere length (TL) measurement suffers from
18 a substantial inter-individual variability of leukocyte TL across multiple populations and various tissue
19 types, and it is questionable whether findings in circulating leukocytes can be generalized to other
20 tissues. Importantly, most TL measurement techniques produce a measure of the average TL, which
21 is not representative of the mechanisms linking TL to ageing (Wagner 2022).
22
23
24
25
26
27
28
29

30 **Advances in Science and Technology to Meet Challenges**

31 A better understanding of which MMP is involved (and when) in a specific pathological process could
32 lead to the potential application of MMPs as biomarkers for early diagnostic approaches and for
33 estimating the prognosis of the disease. Over the last decade, the growing interest for MMPs has
34 pushed the development of a variety of devices based on different recognition methods and signal
35 transductions aimed at measuring MMP enzymatic activity. Modification of amino acid residues
36 allowed detection of some MMPs using biosensors and proteomic based techniques (Kirchhain *et al*
37 2019). Many methods have been devised to measure RONS with various levels of sensitivity and
38 accuracy. These include chemical assays for, H₂O₂, or •OH generation, direct chemiluminescent assays,
39 fluorescence detection, and either direct or spin trapping–based electron paramagnetic resonance
40 (EPR) spectroscopy. Only EPR enables the direct detection of free radicals, but other assays can be
41 informative if used with proper controls. Apart from the established role of hsCRP as a biomarker
42 surrogate for predicting the risk of vascular events in primary cardiovascular prevention, further
43 advances have provided direct evidence that reducing hsCRP can reduce rates of recurrent
44 cardiovascular events, therefore paving the way for the effective identification and management of
45 residual inflammatory risk with targeted anti-inflammatory drugs (Jain *et al* 2013). Substantial
46 advances have been made in translating the biology of IL-6 into the development of several effective
47 monoclonal agents that target the IL-6 signaling pathway, thus showing promising results (Vaiserman
48 and Krasnienkov 2021). Similarly, several effective inhibitors of IL-1b signaling have been clinically
49 approved, therefore expanding the IL-1 signal-targets for the treatment of a broad spectrum of
50 diseases beyond those with inflammatory substrate (Kaneko et al., 2019). GDF-15 has been widely
51 explored as a biomarker for disease prognosis. More importantly, the prognostic impact of GDF-15 in
52 healthy individuals has been recently clarified by providing continuous reference values for GDF-15 in
53 apparently healthy older adults and showing a significant association between reference values and
54
55
56
57
58
59
60

1
2
3 risk of all-cause mortality (Ridker *et al* 2017). Considering the special features of miRNAs such as small
4 size, low content, and high sequence similarity, a great effort has been put into the improvement and
5 development of many sensitive nucleic acids' amplification techniques along with the conventional
6 miRNA detection methods, allowing for an improved detection accuracy of miRNAs (Choy *et al* 2021,
7 Ouyang *et al* 2019). Several studies trying to unravel the biological function of EVs or focusing on
8 biomarker discovery also used high-resolution molecular profiling of EV content (protein, RNA and
9 lipids) using proteomics, genomics and lipidomics approaches (Hartjes *et al* 2019). Future progress in
10 this field will certainly lead to technology for rapid and reliable quantification and characterization of
11 Evs, which will provide reliable and reproducible data (Hartjes *et al* 2019). Over the past decade, there
12 has been a revolution in DNA methylation profiling technologies moving from analyses restricted to
13 specific loci towards microarrays and next generation sequencing platforms that allow the analysis on
14 a genome-scale and the characterization of entire methylomes of the cells at single-base-pair
15 resolution. With these advances, the numbers of candidate DNA methylation markers have
16 significantly increased (Ridker *et al* 2017). Many innovative technological approaches have been
17 developed to measure TL including FISH-based methods and the Telomere Shortest Length Assay
18 (TeSLA). These methods provide highly accurate and reliable results and allow detection of even subtle
19 changes in TLs. More importantly, they can identify the shortest telomeres (<3 kbp) which are critical
20 for cell viability, thus providing new opportunities in assessing biological age (Lai *et al* 2018).
21
22
23
24
25
26
27
28
29

30 **Concluding Remarks**

31 Many of assay developed to measure circulating biomarkers are used inappropriately or without due
32 experimental diligence, resulting in potential inaccuracies and artefacts. Development of new
33 analytical methodologies should focus on direct measurement of circulating biomarkers, using assays
34 that are user-friendly, practical, and of clinical utility. Because the ideal biomarker has not yet been
35 identified, it is prudent to measure multiple independent biomarkers.
36
37
38
39

40 **Acknowledgements**

41 This manuscript is based upon work from the European COST ACTION CA18216 "Network for Research
42 in Vascular Aging" supported by COST (European Cooperation in Science and Technology,
43 www.cost.eu). The authors thank Ioana Mozos for feedback on this section.
44
45
46
47

48 **References**

- 49 Bettin B, van der Pol E, Rienk N. Plasma extracellular vesicle test sample to standardize flow cytometry
50 measurements. *Research and Practice in Thrombosis and Haemostasis*. 2023; 7(4). 100181.
51 Brábek J, Jakubek M, Vellieux F, Novotný J, Kolář M, Lacina L, et al. Interleukin-6: Molecule in the intersection
52 of cancer, ageing and COVID-19. *Int J Mol Sci*. 2020;21(21):1–25.
53 Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into
54 effective treatments. *Nat Rev Rheumatol* [Internet]. 2020;16(6):335–45.
55 Doerstling S, Hedberg P, Öhrvik J, Leppert J, Henriksen E. Growth differentiation factor 15 in a community-
56 based sample: age-dependent reference limits and prognostic impact. *Ups J Med Sci*. 2018;123(2):86–93.
57 Femmino S, Penna C, Margarita S, Comita S, Brizzi MF, Pagliaro P. Extracellular vesicles and cardiovascular
58 system: Biomarkers and cardioprotective Effectors. *Vasc Farmacol* 2023;135, 106790.
59
60

- 1
2
3 Gkaliagkousi E, Gavriilaki E, Yiannaki E, Vasileiadis I, Nikolaidou B, Lazaridis A, et al Platelet microvesicles are
4 associated with the severity of coronary artery disease: comparison between peripheral and coronary
5 circulation. *J Thromb Thrombolysis*. 2021;51(4):1138-1143.
- 6
7 Gopcevic K, Gkaliagkousi E, Nemcsik J, Bernal-Lopez MR, Bruno RM, Climie RE et al. Pathophysiology of
8 Circulating Biomarkers and Relationships to Vascular Ageing: A Review of the Literature from the VascAgeNet
9 Group on Circulating Biomarkers , European Cooperation in Science and Technology Action 18216. *Front*
10 *Physiol* 2021;12 789690
- 11
12 Griendling KK, Touyz RM, Zweier JL, Dikalov S, Chilian W, Chen YR, et al. American Heart Association Council on
13 Basic Cardiovascular Sciences. Measurement of Reactive Oxygen Species, Reactive Nitrogen Species, and
14 Redox-Dependent Signaling in the Cardiovascular System: A Scientific Statement From the American Heart
15 Association. *Circ Res*. 2016 Aug 19;119(5):e39-75.
- 16
17 Hartjes TA, Mytnyk S, Jenster GW, van Steijn V, van Royen ME. Extracellular Vesicle Quantification and
18 Characterization: Common Methods and Emerging Approaches. *Bioengineering (Basel)*. 2019;6(1):7.
- 19
20 Jain S, Wojdacz TK, Su YH. Challenges for the application of DNA methylation biomarkers in molecular
21 diagnostic testing for cancer. *Expert Rev Mol Diagn*. 2013;13(3):283-94.
- 22
23 Kirchhain A, Poma N, Salvo P, Tedeschi L, Melai B, Vivaldi F et al. Biosensors for measuring matrix
24 metalloproteinases: An emerging research field. *Trends in Anal Chem*. 2019;110:35-50.
- 25
26 Naoe Kaneko, Mie Kurata, Toshihiro Yamamoto, Shinnosuke Morikawa, Junya Masumoto. The role
27 of interleukin-1 in general pathology. *Inflamm Regen* . 2019;39:12.
- 28
29 Kwon, Y., Park, J. Methods to analyze extracellular vesicles at single particle level. *Micro and Nano Syst Lett* **10**,
30 14 (2022).
- 31
32 Lai TP, Wright WE, Shay JW. Comparison of telomere length measurement methods. *Phil Trans R Soc B*.
33 2018;373(1741).
- 34
35 Lazaridis A, Gavriilaki E, Nikolaidou B, Yiannaki E, Dolgyras P, Anyfanti P, et al A study of endothelial and
36 platelet microvesicles across different hypertension phenotypes. *J Hum Hypertens*. 2022 Jun;36(6):561-569.
- 37
38 Marabita F, de Candia P, Torri A, Tener J, Abrignani S, RL. Normalization of circulating microRNA expression
39 data obtained by quantitative real-time RT-PCR. *Brief Bioinform*. 2016 Mar;17(2):204-12. EpubAug. 2015;3.
- 40
41 Mozos I, Jianu D, Gug C, Stoian D. Links between High-Sensitivity C-Reactive Protein and Pulse Wave Analysis in
42 Middle-Aged Patients with Hypertension and High Normal Blood Pressure. 2019 *Dis Markers*. 2019 Jul 17;
43 2568069.
- 44
45 Ouyang T, Liu Z, Han Z, Ge Q. MicroRNA Detection Specificity: Recent Advances and Future Perspective. *Anal*
46 *Chem*. 2019;91(5):3179-86.
- 47
48 Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy
49 with Canakinumab for Atherosclerotic Disease. *N Engl J Med*. 2017;377(12):1119-31.
- 50
51 Vaiserman A, Krasnienkov D. Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and
52 Future Perspectives. *Front Genet*. 2021;11(January).
- 53
54 Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al. The role of vascular
55 biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology
56 Working Group on peripheral circulation. Endorsed by the Association for Research into Arterial Structure and
57 Physiology (ARTERY. Atherosclerosis. 2015;241(2):507-32.
- 58
59 Wagner W. How to Translate DNA Methylation Biomarkers Into Clinical Practice. *Front Cell Dev Biol*.
60 2022;10(February):1-7.
- 61
62 Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel
63 Targetable Immune Checkpoint. *Front Immunol*. 2020;11(May).

8. Risk scores

Author(s): János Nemcsik MD, PhD

Institution(s): Department of Family Medicine, Semmelweis University, Budapest, Hungary

ORCID: 0000-0002-3573-0287

Status

The evaluation of the exact vascular age expressed in years or the identification of subjects with early vascular ageing based on already developed or newly constructed risk scores can help in the recognition of high cardiovascular (CV) risk patients. Additionally, it also can improve CV risk communication. For example, using the Systematic COronary Risk Evaluation (SCORE)-based vascular age calculation method (Cuende et al., 2010) the arteries of a 50 year old female smoker with a systolic blood pressure of 180 mmHg and total cholesterol level of 8 mmol/l are 70 years old. The fact that her arteries are 20 years older than her chronological age could be more convincing to follow the instructions of her physician compared with the communication of her SCORE-based 4% risk for CV mortality within the next 10 years.

The first vascular age risk score-based method was published in 2008 by D'Agostino et al., based on the Framingham Risk Score (FRS), which calculates the 10-year risk of CV events and CV mortality (D'Agostino et al., 2008). The FRS-based vascular age is the hypothetical age of a subject with the same CV risk (as assessed by FRS points) but with the remaining risk factors within normal ranges. FRS calculation is different for men and women and it considers age, total and high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, smoking and diabetes status (D'Agostino et al., 2008).

In 2010 Cuende et al. published the SCORE-based vascular age calculation method (Cuende et al., 2010). As the FRS-based vascular age, it also calculates the hypothetical age of a subject with the same CV risk but with the remaining risk factors within normal ranges, meaning that CV risk is only based on age and sex. This method considers fewer variables compared with the FRS-based method, namely age, sex, total cholesterol, systolic blood pressure and smoking status (Cuende et al., 2010). Although in 2021 the new SCORE2 was introduced (Score2 Working Group and ESC Cardiovascular Risk Collaboration, 2021), adjusted vascular age calculation method is not published yet.

There are also newly constructed risk scores, which do not provide an exact number of the age of the vasculature, but only aim to identify patients with early vascular ageing. These calculators are developed based on the comparison with the reference values of carotid-femoral pulse wave velocity (cfPWV). The Early Vascular Ageing Ambulatory Score requires ambulatory blood pressure monitoring and considers 24-hour systolic and diastolic blood pressure and heart rate, age, sex, body mass index, diabetes mellitus (yes/no) and estimated glomerular filtration rate (Antza et al., 2018). Recently, in patients with metabolic syndrome a score was also developed considering age, sex, weight, uric acid levels, history of type 2 diabetes mellitus and clinical markers of insulin resistance (IR) such as HOMA-IR (homeostatic model assessment of insulin resistance) and clinical IR (Nedogoda et al., 2021).

Current and Future Challenges

Although some methods are available to calculate vascular age and to screen patients with early vascular ageing, it is not obvious that these different methodologies identify the same subjects at risk. On the contrary, recent studies found marked differences.

Gyöngyösi et al. demonstrated on 172 subjects who participated in a CV screening program, that vascular age based on FRS and SCORE can provide markedly different results (**Figure 10**) (Gyöngyösi et al., 2021).




Figure 10. The chronological age, the vascular age calculated based on the Systematic COronary Risk Evaluation (Vasc Age SCORE) and the vascular age calculated based on Framingham Risk Score (Vasc Age FRS) of the study population. Data are presented as median (minimal and maximal values in error bars). * $p < 0.05$ compared with Chronological Age; # $p < 0.05$ compared with Vasc Age SCORE. Adapted from Gyöngyösi et al., 2021.

The observed difference was a consequence of the differences of the two methods. Since the FRS considers also hypertension and diabetes, the estimated FRS vascular age appears to be higher when compared to the SCORE vascular age for the same subject. In the absence of pathologies the two methods gave similar results (Gyöngyösi et al., 2021). In the same paper it was also demonstrated that the comparison of the proportion of subjects with elevated vascular age identified with FRS, SCORE or cfPWV (FRS+, SCORE+, PWV+, respectively) differed from each other. 84% of PWV+ and 85.4% of SCORE+ patients were found to be FRS+ as well. However, less acceptable overlap was found between PWV+ and SCORE+ subjects, as only 30.9% of SCORE+ patients was PWV+ as well, and only 24.6% of the PWV+ subjects had elevated vascular age based on SCORE (Gyöngyösi et al., 2021).

These results were confirmed by the study of Vecsey-Nagy et al. as well, as among 241 patients with stable angina referred to coronary CT angiography in subjects with treated hypertension and diabetes, FRS-based method resulted higher vascular age values compared with the SCORE-based method (Vecsey-Nagy et al., 2022). In the same study, coronary artery calcium score (CACS)-based vascular age calculation method identified a lower proportion of patients with elevated vascular age compared with the FRS and SCORE-methods (Vecsey-Nagy et al., 2022).

1
2
3 Finally, the difference between FRS and SCORE-based vascular age calculation methods was confirmed
4 by Kozakova et al as well, in 528 middle-aged individuals ([Kozakova et al., 2022](#)) and recently in a
5 population-based cohort including 99 231 subjects ([Gyöngyösi et al., 2023](#)).
6

7 Based on these studies it can be concluded that SCORE-based vascular age calculation methods should
8 be kept for apparently healthy subjects. Subjects who already have hypertension or diabetes would
9 probably benefit more from FRS-based vascular age-guided preventive strategies. However,
10 prospective studies are required to clarify the success of different risk score-based vascular age-
11 derived CV preventional strategies.
12
13
14
15

16 **Advances in Science and Technology to Meet Challenges**

17 There are still some open questions in this field which need to be clarified in the future. Results of the
18 above mentioned comparative studies ([Gyöngyösi et al., 2021](#), [Vecsey-Nagy et al., 2022](#)) suggest, that
19 risk score-based vascular age calculation methods identify a higher proportion of patients with early
20 vascular ageing compared with measurement-based methods using e.g. cfPWV or CACS. The future
21 approach might be a composite vascular age calculating method based on both a measurement and
22 components of risk scores. However, prospective studies are required to clarify this question as well.
23 Optimally these studies should be planned for patient randomization of the application of preventive
24 strategies based on the detection of early vascular ageing by different methods. As such studies are
25 costly and time-consuming, alternatively retrospective cohort studies could also provide useful data.
26 Those cohorts should be analyzed retrospectively in which both measurements of vascular ageing
27 biomarkers were performed and the variables of the risk score-based vascular ageing calculation
28 methods are also available.
29

30 Another important task which requires consensus is the definition of early vascular ageing based on
31 the calculations e.g. 1, 2 or 5 etc. years above chronological age? In the study of Antza et al. the
32 constructed score for the identification of patients with early vascular ageing was compared with
33 cfPWV above the age-adjusted value ([Antza et al., 2018](#)). In contrast, Nedogoda et al. defined early
34 vascular ageing with values of cfPWV exceeding expected for chronological age values by at least 2
35 standard deviations ([Nedogoda et al., 2021](#)), while Nilsson et al. defined early vascular ageing subjects
36 in the highest 10% of the standardised cfPWV distribution, adjusted for age intervals ([Nilsson et al.,
37 2018](#)).
38
39

40 Finally, the risk score-based vascular age calculation techniques should be validated in different
41 geographical regions and also besides different comorbidities which accelerate vascular ageing e.g.
42 chronic kidney disease or diabetes.
43
44
45
46
47
48
49

50 **Concluding Remarks**

51 Risk score-based vascular age calculation provides a simple possibility to identify patients with early
52 vascular ageing and to improve CV risk communication. However, there are differences between the
53 methods, e.g. they provide different values of vascular age and they sometimes identify different
54 patients with early vascular ageing, which are needed to be resolved. Application of the different
55 methods on proper patient populations or their combination with measurement techniques can
56 provide solution in the future. Additionally, prospective studies are required to clarify the strength of
57 preventive strategies based on different vascular age calculation methods.
58
59
60

References

- ANTZA, C., DOUNDOULAKIS, I., AKRIVOS, E., STABOULI, S., TRAKATELLI, C., DOUMAS, M. & KOTSIS, V. 2018. Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. *Am J Hypertens*, 31, 1197-1204.
- CUENDE, J. I., CUENDE, N. & CALAVERAS-LAGARTOS, J. 2010. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. *Eur Heart J*, 31, 2351-8.
- D'AGOSTINO, R. B., SR., VASAN, R. S., PENCINA, M. J., WOLF, P. A., COBAIN, M., MASSARO, J. M. & KANNEL, W. B. 2008. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*, 117, 743-53.
- GYÖNGYÖSI, H., KŐRÖSI, B., BATTÁ, D., NEMCSIK-BENCZE, Z., LÁSZLÓ, A., TISLÉR, A., CSEPREKÁL, O., TORZSA, P., EÖRSI, D. & NEMCSIK, J. 2021. Comparison of Different Cardiovascular Risk Score and Pulse Wave Velocity-Based Methods for Vascular Age Calculation. *Heart Lung Circ*, 30, 1744-1751.
- GYÖNGYÖSI, H., Szöllősi, G. J., Ccenteri, O., Jancsó, Z., Móczár, C., Torzsa, P., Andréka, P., Vajer, P., & Nemcsik, J. (2023). Differences between SCORE, Framingham Risk Score, and Estimated Pulse Wave Velocity-Based Vascular Age Calculation Methods Based on Data from the Three Generations Health Program in Hungary. *Journal of clinical medicine*, 13(1), 205.
- KOZAKOVA, M., MORIZZO, C., JAMAGIDZE, G., CHIAPPINO, D. & PALOMBO, C. 2022. Comparison between Carotid Distensibility-Based Vascular Age and Risk-Based Vascular Age in Middle-Aged Population Free of Cardiovascular Disease. *J Clin Med*, 11.
- NEDOGODA, S. V., SALASYUK, A. S., BARYKINA, I. N., LUTOVA, V. O. & POPOVA, E. A. 2021. Identifying Early Vascular Ageing in Patients With Metabolic Syndrome: Unresolved Issues and a Proposed Novel VAmets Score. *Heart Lung Circ*, 30, 1752-1761.
- NILSSON, P. M., LAURENT, S., CUNHA, P. G., OLSEN, M. H., RIETZSCHEL, E., FRANCO, O. H., RYLIŠKYTĖ, L., STRAZHESKO, I., VLACHOPOULOS, C., CHEN, C. H., BOUTOUYRIE, P., CUCCA, F., LAKATTA, E. G. & SCUTERI, A. 2018. Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global Metabolic syndrome and Artery REsearch Consortium. *J Hypertens*, 36, 2340-2349.
- VECSEY-NAGY, M., SZILVESZTER, B., KOLOSSVÁRY, M., BOUSSOUSSOU, M., VATTAY, B., MERKELY, B., MAUROVICH-HORVAT, P., RADOVITS, T. & NEMCSIK, J. 2022. Correlation between Coronary Artery Calcium- and Different Cardiovascular Risk Score-Based Methods for the Estimation of Vascular Age in Caucasian Patients. *J Clin Med*, 11.

DEVELOPMENT PIPELINE

9. Development using synthetic pulse wave data

Author(s): Jordi Alastruey

Institution(s): Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EU, UK.

ORCID(s): 0000-0003-3742-5259

Status

Pulse waves (PW) signals, such as arterial blood pressure and photoplethysmogram (PPG) waves, are produced by the beating heart interacting with flexible arteries. Vascular ageing (VA) changes the mechanical and structural properties of the vascular wall that determine the morphology of PW signals (Climie *et al* 2023), offering the opportunity to assess VA from PW signals. The development and testing of suitable PW analysis techniques require large PW datasets, but acquiring them is often a complex task subject to several problems (**Figure 11**, left). To facilitate this process, datasets of synthetic (simulated) PWs representative of data samples of real subjects have been created under a wide range of cardiovascular conditions. They complement human data and have many advantages (**Figure 11**, right), despite the obvious limitation of relying on modelling hypotheses.




Figure 11. (left) Current using *in vivo* human data to develop technologies to assess vascular ageing from pulse wave (PW) signals. (right) Advantages offered by synthetic data to overcome these. * Other properties may change concurrently. ** Individual properties can be altered independently of each other.

Datasets comprising thousands of virtual subjects have been generated using blood flow modelling with a 'population-specific' approach. In this modelling strategy, data from various real subject populations are amalgamated to calibrate model input parameters and validate simulated PWs

(Willemet et al 2015, Charlton et al 2019, Bikia et al 2020, Jones et al 2021). For each virtual subject, different types of PW signals (pressure, flow, luminal area/diameter, PPG) are available simultaneously at common measurement sites in large arteries (**Figure 12**), together with precise values of all cardiac and vascular biophysical properties that produced these signals; e.g., geometrical and material properties of the arterial network. Consequently, these datasets provide an opportunity to benchmark PW analysis techniques for VA assessment; e.g., the estimation of arterial stiffness (Willemet et al 2015, Charlton et al 2019, Jin et al 2021), central blood pressure (Vennin et al 2017, Bikia et al 2020), and identification of stenoses and aneurysms (Tianqi et al 2021, Jones et al 2021) from noninvasive PWs. Various techniques can be compared; e.g., different foot-to-foot methods (Willemet et al 2015) or machine learning models (Jin et al 2021) for estimating pulse wave velocity (an index of arterial stiffness). Synthetic PWs also make it possible to identify potential shortcomings of existing technologies; e.g., assessing endothelial function using flow-mediated dilation (Jin et al 2020). Furthermore, the effects of sampling rate and uncertainty in the PW data can be investigated (Jin et al 2021, Tianqi et al 2021, Hong et al 2023). Since synthetic PWs are generated using physics-based models, they facilitate the evaluation of haemodynamics; e.g., the identification of cardiac/vascular determinants of PPG-derived indices of arterial stiffness (Charlton et al 2019, Hong et al 2023). As synthetic PW modelling advances, combined with machine learning and the proliferation of PW wearable sensors, new opportunities for VA assessment in the clinic and daily life will emerge.




Figure 12. Examples of synthetic PW signals. (a) Arterial network used to simulate the signals. (b) The PPG at the finger changes with ageing, allowing the study of PPG-derived VA indices. (c) Central and peripheral blood pressure (BP) waves the estimation of the former from the latter, different age groups. (d) Cardiac cycle-averaged diameter (D) and flow velocity (U) during flow-mediated dilation (FMD). Panels (b) and (c) obtained using data from Charlton et al (2019). Panel (d) obtained using data from Jin et al (2020).

Current and Future Challenges

In silico studies, involving synthetic PW datasets, have been used to confirm findings from *in vivo* studies (Willemet et al 2015, Vennin et al 2017, Jin et al 2021, Wehenkel et al 2023), yet they lag behind other areas of biomedical engineering where simulated data have successfully replicated clinical trials (Sarrami-Foroushani et al 2021). In the future, synthetic PW datasets could potentially

1
2
3 reduce, refine, and even replace human and animal trials in developing reliable techniques for VA
4 assessment in the clinic and daily life. This will require addressing the following challenges.
5

6 Synthetic PW datasets have been used to train and test machine learning models under a wide range
7 of cardiovascular conditions and assist with their interpretability (Bikia et al 2020, Jin et al 2021, Tianqi
8 et al 2021, Jones et al 2021, Wehenkel et al 2023). For instance, synthetic data has demonstrated the
9 feasibility of assessing arterial stiffening from a single PW (e.g., measured on the arm) using pulse
10 wave analysis (Charlton et al 2019, Hong et al 2023) or machine-learning-based PW models (Jin et al
11 2021, Wehenkel et al 2023). Nevertheless, it remains unproven whether models trained with synthetic
12 PWs will provide accurate results when tested *in vivo*. Achieving this is likely to require improving
13 current computational blood flow models for generating synthetic PW datasets. Existing models
14 typically provide PWs in supine conditions over seconds, and lack important physiological feedback
15 and control mechanisms to simulate beat-to-beat variations under a wide range of dynamic
16 cardiovascular conditions over minutes/hours (e.g., exercise and postural changes) and over years
17 (e.g., sex-specific growth patterns and disease progression). Furthermore, current datasets lack
18 representation of virtual subjects of both sexes, various ethnicities, and all age ranges from infants to
19 adults, under physiological and pathological conditions affecting VA. Consequently, a technique that
20 works on synthetic PW datasets is not guaranteed to be applicable in an *in vivo* setting. Synthetic data
21 should also play a key role in developing algorithms based on artificial intelligence (AI) for the early
22 prediction of an individual's VA trajectory, from birth to old age, through automated interpretation of
23 PW signals acquired by noninvasive wearable devices in daily life. These algorithms could improve the
24 prevention of cardiovascular diseases associated with VA.
25
26
27
28
29
30
31
32

33 **Advances in Science and Technology to Meet Challenges**

34 The creation of synthetic PW datasets addressing the above-mentioned challenges could still be
35 approached using a 'population-specific' modelling strategy. However, this will necessitate
36 computational blood flow models where state-of-the-art governing equations are coupled with
37 additional equations describing short- and long- term dynamic aspects affecting PW signals. These
38 equations should consider physiological feedback and control mechanisms, as well as the evolution of
39 the arterial wall components (e.g., elastin and collagen) throughout life and account for the broad
40 spectrum of alterations produced by VA that affect functional and structural components of the
41 arterial wall (Climie *et al* 2023). Furthermore, models should quantify how uncertainty in input
42 parameters and artefacts (such as motion) translate into variability in synthetic PWs.
43
44
45
46

47 The development of AI-based algorithms for early prediction of an individual's VA trajectory should
48 benefit from having digital twins that improve at forecasting VA as they are fed, during life, with the
49 individual's *in vivo* PW signals and other basic clinical data such as age, sex, ethnicity, and body
50 dimensions. Morphing/scaling methods will be needed to automatically generate the arterial network
51 of an individual's digital twin to match their changing body dimensions throughout life. This may be
52 achieved using large datasets (e.g., UK Biobank) containing medical images of the arterial network of
53 thousands of individuals together with basic clinical data and body dimensions. The development and
54 training of these new technologies will likely require the combination of *in vivo* and synthetic PW data
55 to overcome the need to acquire large sets of *in vivo* data measurements over a lifetime. Final testing
56 will have to involve longitudinal studies in large populations of real subjects.
57
58
59
60

1
2
3 As new synthetic PW datasets are being created, they should be made freely available to the scientific,
4 clinical, medical device, and digital health communities to support further research, and promote and
5 facilitate their use in the development of technologies to assess VA. This can be achieved by creating
6 open access online repositories (*e.g.*, PhysioNet) containing the datasets and providing guidelines for
7 their use, accompanied by peer-reviewed articles describing their capabilities and limitations.
8 Engagement with all the above stakeholders will also be beneficial to receive valuable feedback on
9 how to improve datasets and ensure the adoption of techniques for VA assessment developed with
10 synthetic data, which will eventually require regulatory approval.
11
12
13
14
15

16 **Concluding Remarks**

17 Synthetic PW data are created through ‘population-specific’ modelling and offer a readily available
18 and cost-effective approach for the development and pre-clinical testing of technologies that assess
19 VA under a wide range of cardiovascular conditions. Successfully addressing the challenges discussed
20 in this report could provide a robust *in silico* framework for the development of trustworthy
21 techniques (with high accuracy and low uncertainty) for VA assessment in the clinic and daily life that
22 are ready for implementation in real subjects. These techniques may encompass AI-based algorithms
23 and digital twins capable of forecasting an individual’s VA trajectory throughout life through the
24 automated interpretation of PW signals acquired noninvasively by wearable devices.
25
26
27
28
29

30 **Acknowledgements**

31 This work was supported in part by the British Heart Foundation under Grant [PG/15/104/31913], in
32 part by the Wellcome EPSRC Centre for Medical Engineering at King’s College London under Grant [WT
33 203148/Z/16/Z], and in part by the Department of Health and Social Care (DHSC) through the National
34 Institute for Health and Care Research (NIHR) MedTech Co-operative award for Cardiovascular
35 Diseases to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London (MIC-
36 2016-019).
37
38
39
40
41

42 **References**

- 43
44 Bikia V, Papaioannou TG, Pagoulatou S, Rovas G, Oikonomou E, Siasos G, Tousoulis D and Stergiopoulos N 2020
45 Noninvasive estimation of aortic hemodynamics and cardiac contractility using machine learning *Sci. Rep.* **10**
46 15015
47
48 Charlton PH, Mariscal-Harana J, Vennin S, Li Y, Chowienzyk P and Alastruey J 2019 Modeling arterial pulse
49 waves in healthy aging: a database for in silico evaluation of hemodynamics and pulse wave indexes *Am. J.*
50 *Physiol. Heart Circ. Physiol.* **317** H1062–H1085
51
52 Climie R, Alastruey J, Mayer C, Schwarz A, Laucyte-Cibulskiene A, Voicehovska J, Bianchini E, Bruno RM,
53 Charlton P, Grillo A, Guala A, Hallab M, Hametner B, Jankowski P, Königsten K, Lebedeva A, Mozos I, Pucci G,
54 Puzantian H, Terentes-Printzios D, Yetik-Anacak G, Park C, Nilsson P, Weber T 2023 Vascular ageing – Moving
55 from bench towards bedside *Eur. J. Prev. Cardiol.*, **30** 1101–1117
56
57 Hong J, Nandi M, Charlton PH, Alastruey J 2023 Non-invasive haemodynamic indices of vascular ageing: An in
58 silico assessment. *Am. J. Physiol. Heart Circ. Physiol.*, **325** H1290–H1303
59
60 Jin W, Chowienzyk P and Alastruey J 2021 Estimating pulse wave velocity from the radial pressure wave using
machine learning algorithms *PLoS One* **16** e0245026

1
2
3 Jin W, Chowienczyk P and Alastruey J 2020 An in silico simulation of flow-mediated dilation reveals that blood
4 pressure and other factors may influence the response independent of endothelial function *Am. J. Physiol.*
5 *Heart Circ. Physiol.* **318** H1337–H1345

6
7 Jones G, Parr J, Nithiarasu P and Pant S 2021 Machine learning for detection of stenoses and aneurysms:
8 application in a physiologically realistic virtual patient database *Biomech. Model. Mechanobiol.* **20** 2097–2146

9
10 Sarrami-Foroushani A, Lassila T, MacRaid M, Asquith J, Roes KCB, Byrne JV, Frangi AF 2021 In-silico trial of
11 intracranial flow diverters replicates and expands insights from conventional clinical trials *Nat. Commun.* **12**
12 3861

13
14 Vennin S, Li Y, Willemet M, Fok H, Gu H, Charlton P, Alastruey J and Chowienczyk P 2017 Identifying
15 hemodynamic determinants of pulse pressure: a combined numerical and physiological approach.
16 *Hypertension* **70** 1176–1182

17
18 Wang T, Jin W, Liang F, Alastruey J 2021 Machine learning-based pulse wave analysis for early detection of
19 abdominal aortic aneurysms using in silico pulse waves *Am. J. Physiol. Heart Circ. Physiol.* **309** H663–H675

20
21 Wehenkel A, Behrmann J, Miller AC, Sapiro G, Sener O, Cuturi Cameto M, Jacobsen J-H 2023 Simulation-based
22 inference for cardiovascular models. *Proc. NeurIPS Workshop* (arXiv:2307.13918 [stat.ML], DOI:
23 10.48550/arXiv.2307.13918)

24
25 Willemet M, Chowienczyk P, Alastruey J 2015 A database of virtual healthy subjects to assess the accuracy of
26 foot-to-foot pulse wave velocities for estimation of aortic stiffness *Symmetry* **13** 804–H675
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10. In-vitro and ex-vivo models: Importance and challenges

Author(s): Ana Belen Amado Rey¹, Ana Carolina Gonçalves Seabra¹, Thomas Stieglitz^{1,2}

Institution(s): ¹Laboratory for Biomedical Microtechnology, Department of Microsystems Engineering - IMTEK, IMBIT - NeuroProbes, BrainLinks-BrainTools Center, University of Freiburg, Freiburg, Germany; ²Bernstein Center Freiburg, University of Freiburg, Freiburg, Germany

ORCID(s): 0000-0002-2845-7104, 0000-0003-1481-0998, 0000-0002-7349-4254

Status

The cardiovascular system (CVS) is intricately interdependent on complex biomechanics variables such as geometry and stiffness of the vessels, as well as blood viscosity. These variables are often difficult to study and measure directly within the body, which would need an invasive **in-vivo study**. Furthermore, in-vivo experiments need thorough preparation and approval from ethical committees, which is time and cost-consuming. The **need to model and study a living organism through a non-invasive approach**, where conditions can be designed for specific case studies, from low to high model specificity, is made possible through in-vitro and ex-vivo methods and models. **In-vitro studies** refer to experiments either with components of an organism that have been isolated, e.g. cells, or with technical models as benchtop experiments that aim to recreate in-vivo conditions through non-biological materials. In contrast, **ex-vivo studies** are performed with tissue or organs, e.g. arteries, that have been extracted from an organism post mortem. The ex-vivo studies take place in an artificial environment with minimum alteration of natural conditions. A key example is given for each model:

- **In-vitro:** Wisotzki *et al* (2022) developed an in-vitro hardware simulator of the CVS to generate physiologic flow conditions across a wide range of values to create a benchmark dataset of healthy and pathological conditions. The system consists of silicone tubes as mimicked arteries and a water-glycerine mixture as blood, with a ventricular-assisted device generating parametric flow.
- **Ex-vivo:** Cooper *et al* (2021) developed an ex-vivo vascular bioreactor system to assess acute arterial drug retention based on a porcine carotid artery under physiological flow.

In addition, these methods **allow the validation of vascular health device prototypes at different stages of product development** and under different cardiovascular conditions, ensuring strong reliability for in-vivo applications. Validation of novel technologies is done through the comparison of hemodynamic parameters extracted with the novel method and a reference standard (e.g. values from a commercially validated device) at the CVS model. Namely, Gonçalves Seabra *et al* (2022) evaluated ex-vivo a novel ultrasound sensor for blood pressure measurement (comparison to a commercial pressure sensor). The Technical Readiness Level (TRL) scale is used to assess the maturity level of a technology (EURAXESS 2020). In-vitro and ex-vivo studies are essential for a novel technology to move up the TRL scale (see **Figure 13**), from initial (TRL3) to demonstrated proof-of-concept (TRL4) and towards clinical trials (TRL5-8).




Figure 13. Novel technology evaluation methods' characteristics with associated TRL.

Ideally, in-vitro and ex-vivo models emulate healthy/pathological parameters, such as pulse wave velocity (PWV), the reference standard for arterial stiffness assessment and indicator of vascular age. Thus, **patient-specific, reliable and accurate in-vitro and ex-vivo CSV models offer enormous potential in the simulation of various (patho-) physiological conditions in the arteries, blood and tissue.** Furthermore, these models **aid the parameter verification and validation of medical devices prototypes** (e.g. ultrasonic, tonometric, oscillometric, optical devices) before performing in-vivo measurements. However, the CVS is a sophisticated structure that is indeed challenging to emulate.

Current and Future Challenges

An accurate determination of local PWV and stiffness indexes, concretely the acquisition of Peterson's Elastic Modulus (PEM) in patients, requires high levels of expertise (Ruesink *et al* 2018). Simplified models based on in-vitro and ex-vivo CVS, as well as long-lasting and reusable phantoms, improve the user experience and help to develop, validate, and optimize emerging devices to monitor vascular ageing. Thus, the costs and time required for the in-vivo validation in humans may be reduced when the user experience and the performance of the PWV device are optimized a priori. In-vitro and ex-vivo models can represent hemodynamics with high accuracy. As an example, Joseph *et al* (2018) developed a carotid flow phantom, in which acquisitions of the differential pressure (ΔP) with a new cuffless multimodal probe were compared to the reference ΔP values from a catheter. The reference differential pressure from the catheter showed a strong agreement with the estimated differential pressure from the cuffless multimodal probe (Pearson correlation of 0.93). However, several challenges need to be overcome to ensure in-vitro and ex-vivo models are accurately realistic and produce results which are replicated in in-vivo cases. The most important challenges are as follows:

- **Fabrication of realistic models that also emulate pathophysiological conditions.** For healthy subjects, the local PWV and carotid-femoral PWV are strongly correlated (Simova *et al* 2016). Thus, even simple ex-vivo models to assess local PWV can be applied. Yet, for patients with early vascular ageing or other cardiovascular diseases, no strong correlation exists. CVS models with changes in arterial stiffness, resistance, and compliance need to be developed and validated.
- **Accurate simulation of the heart and arteries.** In-vitro models emulate the heart using peristaltic pumps and mechanical valves to simulate the opening and closing of the aortic valve. Low blood flows (i.e. less than 15 ml/min) are challenging to simulate with these pumps and increasing blood flow introduces distortion, noise and bubbles in the flow that can produce false measurements. The development of artificial arteries with several stiffnesses, thicknesses and patient-specific geometries is also a complex challenge.

- **Modulation of correlated biomarkers.** Blood pressure, as well as blood flow and arterial stiffness, are biomarkers that strongly correlate to PWV values. Non-healthy patients with hypertension or hypotension as well as those with high arterial stiffness, or with elevated BP values while doing sports, are critical cases that need to be modelled in the in-vitro and ex-vivo systems. The fabrication of elastic arterial phantoms with a broad range of distensibility properties, together with the inclusion of compliance chambers, resistance valves and pressure bulbs in the CVS setup may help to simulate the physiological characteristics of the arteries.
- **Implementation of bi-modal tissue.** Ideally, in-vitro and ex-vivo models should be able to validate not only one but multiple medical devices. Thus, the modelled tissue (via phantoms) has to represent all physical properties for which the devices should be validated. Bi-modal tissue implementations, i.e. phantoms with optical and acoustical properties or phantoms with electrical and acoustical properties (Cannata *et al* 2022) are being recently researched. Multilayer phantoms including various skin layers on top of the muscles and arteries increase the complexity of the in-vitro model but show more realistic approaches (Chen *et al* 2016). For tonometry applications, not only the tissue but also the bone structure should be included in the phantom.

Advances in Science and Technology to Meet Challenges

Due to the individual variation of the characteristic values of PWV, blood pressure, arterial thickness and compliance, there is a high need for fundamental and clinical research for patient-specific in-vitro and ex-vivo models (Kalaskar 2017). High-resolution scans (i.e. MRI) from the patient can be manually or automatically computerized (with intensity threshold for boundary identification and segmentation of certain parts of the body). After meshing the organ or body structure and adding the 2D slices into a single 3D structure, the model can be printed via a high-resolution 3D printer. Soluble-resin materials help with the fabrication of patient-specific moulds that will be used for the construction of patient-specific phantoms for in-vitro validations.

The possibility of creating patient-specific models allows the emulation of heterogeneous arteries with multiple bifurcations, several thicknesses and also stiffness conditions. Furthermore, variations in the thickness of the tissue can be also accurately modelled by using biocompatible hydrogel phantoms, where polyvinyl-alcohol (PVA) flexible cryogenic materials can accurately assess arterial stiffness. In fact, by implementing realistic 3D heart models with 3D bioprinting (Mao and Wang 2022) the errors produced by the noise of peristaltic pumps can be suppressed.

Ex-vivo pre-clinical systems that include native blood vessels require bioreactor systems that simulate the physiological vessel flow conditions (Cooper *et al* 2021). The housing of the vessel in a cell culture medium (i.e. Dulbecco's Modified Eagle's Medium) at a constant temperature (37°C) and under sterile conditions allows simultaneous and multimodal measurements to be performed under diverse hemodynamic conditions.

Multimodal and newly developed devices require highly robust and reliable ex-vivo models. Validation of these prototypes is done by the acquisition of CVS signals, and comparing them point-to-point to a reference measurement (e.g. catheter for blood pressure measurements). Simultaneously, measurements using electrocardiograms as synchronization signals will give insights into the accuracy, variance and precision of diverse technologies. The extracted pulse waveforms from the in-vitro and

1
2
3 ex-vivo CVS can be better evaluated through probability analysis of Gaussian distribution and Bland-
4 Altman plots. The Gaussian distribution provides the information if the pulse waveforms measured in
5 the model are normally distributed. Furthermore, the mean and standard deviation of the
6 measurements can be determined. Thus, the accuracy, validity, and reproducibility of the model can
7 be predicted via the Gaussian probabilistic analysis (for example, when performing continuous
8 measurements during a day in the same in-vitro model). Thanks to the Bland-Altman plots the
9 agreement or disagreement between measurements performed by the newly developed device and
10 the reference device can be statistically quantified.
11
12
13
14
15
16
17
18

19 **Concluding Remarks**

20 In-vitro and ex-vivo models provide a controlled environment to study cardiovascular diseases and are
21 essential to the preliminary validation of technologies, moving them forward on the TRL scale. New
22 research is developing 3D models and more complex systems that would be able to emulate patient-
23 specific stiffness and give a better prediction of vascular age. Sophisticated full-body 3D models can
24 overcome some of the challenges of parameter evaluation and quantification in the lab.
25
26
27
28

29 **Acknowledgements**

30 A.B. Amado Rey was financially supported by the Margarethe von Wrangell-Programm (LaKoG BW,
31 Germany).
32
33
34

35 **References**

- 36
37 Cannata A, Pasian M, Di Meo S, Matrone G and Morganti S 2022 Dielectric, Mechanical and Acoustic
38 Characterization of Multi-Modal Tissue-Mimicking Breast Phantoms 2022 IEEE International Ultrasonics
39 Symposium (IUS) 2022 IEEE International Ultrasonics Symposium (IUS) (Venice, Italy, 10/10/2022 -
40 13/10/2022) (IEEE) pp 1–4
41
42 Chen A I, Balter M L, Chen M I, Gross D, Alam S K, Maguire T J and Yarmush M L 2016 Multilayered tissue
43 mimicking skin and vessel phantoms with tunable mechanical, optical, and acoustic properties *Medical physics*
44 43 3117–31
45
46 Cooper K, Cawthon C V, Goel E, Atigh M, Christians U and Yazdani S K 2021 The Development of an ex vivo
47 Flow System to Assess Acute Arterial Drug Retention of Cardiovascular Intravascular Devices *Front Med
48 Technol* 3 675188
49
50 EURAXESS 2020 TRL [https://euraxess.ec.europa.eu/career-development/researchers/manual-scientific-
51 entrepreneurship/major-steps/trl](https://euraxess.ec.europa.eu/career-development/researchers/manual-scientific-entrepreneurship/major-steps/trl) (accessed 24 Nov 2022)
52
53 Gonçalves Seabra A C, Da Silva A F, Stieglitz T and Amado-Rey A B 2022 In Silico Blood Pressure Models
54 Comparison *IEEE Sensors Journal* 22 23486–93
55
56 Joseph J, P M N, Shah M I and Sivaprakasam M 2018 Arterial compliance probe for cuffless evaluation of
57 carotid pulse pressure *PLoS One* 13 e0202480
58
59 Kalaskar D M (ed) 2017 *3D Printing in Medicine* (Oxford: Woodhead Publishing)
60
61 Mao X and Wang Z 2022 Research Progress of Three-Dimensional Bioprinting Artificial Cardiac Tissue *Tissue
62 Eng Regen Med*

1
2
3 Ruesink T, Medero R, Rutkowski D and Roldán-Alzate A 2018 In Vitro Validation of 4D Flow MRI for Local Pulse
4 Wave Velocity Estimation *Cardiovasc Eng Technol* 9 674–87

5 Simova I, Katova T, Santoro C and Galderisi M 2016 Comparison between Regional and Local Pulse-Wave
6 Velocity Data *Echocardiography (Mount Kisco, N.Y.)* 33 77–81

7
8 Wisotzki M, Mair A, Schlett P, Lindner B, Oberhardt M and Bernhard S 2022 In Vitro Major Arterial
9 Cardiovascular Simulator to Generate Benchmark Data Sets for In Silico Model Validation *Data* 7 145
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

11. Technical validation

Author(s): Alessandro Giudici^{1,2} and Bart Spronck^{1,3}

Institution(s): ¹Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University; ²GROW School for Oncology and Reproduction, Maastricht University; ³Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University

ORCID(s): 0000-0002-8288-3980; 0000-0003-1076-1922

Status

Vascular ageing can be assessed via many different metrics, each measuring a different aspect of vascular function and structure. A growing volume of scientific evidence supports the potential clinical utility of assessing these metrics to improve cardiovascular risk prediction. However, the publication of validation guidelines/consensus documents that promote standardisation and ensure reliability of novel measuring devices constitutes a crucial step to transform this potential into an actual benefit for healthcare. These documents should detail both practical (e.g., environmental conditions, the reference standard: i.e., the measuring technique to be used as reference, the data acquisition protocol) and statistical aspects (e.g., minimum requirements of the study cohort and the statistical methods for the data analysis) to follow for a trusted validation of new non-invasive devices. In the past 15 years, groups of experts have made some first efforts to promote standardisation of the assessment of vascular ageing metrics. It is, therefore, pivotal that validation studies are performed in compliance with these directives. In this section, we focus mainly on haemodynamics measuring devices such as those measuring arterial pulse wave velocity (PWV) and blood pressure (BP).

The Association for Research into Arterial Structure and Physiology (ARTERY) has had a leading role in writing guidelines/consensus documents for the validation of non-invasive haemodynamic measuring devices. In 2010, ARTERY published guidelines for the validation of devices which non-invasively measure arterial PWV (Wilkinson *et al.* 2010). These guidelines focus on two cardinal metrics: aortic PWV, for which an invasive catheter-based reference is recommended, and carotid-femoral PWV, which may be validated against a non-invasive tonometry-derived reference. This document was followed in 2017 by a consensus statement on the validation of non-invasive devices for estimating central BP (i.e., aortic pressure) (Sharman *et al.* 2017). As for aortic PWV, the reference standard for central BP is obtained invasively: aortic BP measured with intra-arterial catheters. Furthermore, given the widespread use of BP measurements in clinical practice, the validation of any cuff-based or non-cuff-based BP measuring device should also comply with relevant standards by international organisations (e.g., ISO 81060-2:2019 and ISO 81060-3:2022, respectively). Compared to the ARTERY consensus statement, these documents more broadly address the validation of any non-invasive BP measuring device.

Other vascular ageing metrics, such as flow mediated dilation, currently lack dedicated validation guidelines. In these cases, validation studies should, nonetheless, follow relevant measurement guidelines or consensus documents (e.g., Thijssen *et al.* 2019).

Overall, although the short-term objective of validation guidelines is regulating and standardising new measuring devices, in the long term, these documents will indirectly promote the measurement of

1
2
3 vascular ageing in clinical practice. As such, a concerted work towards standardisation will benefit all
4 stakeholders involved in developing, manufacturing and using vascular ageing measuring devices.
5
6
7

8 **Current and Future Challenges**

9
10 Despite previous efforts to standardise the validation of vascular age measuring devices, important
11 challenges deserve further consideration. The first important issue is the beat-to-beat variability of
12 human haemodynamics and, consequently, vascular ageing metrics (Parati *et al.* 2018; Xhyheri *et al.*
13 2021). This issue is practically relevant whenever readings of the reference standard and of the device-
14 under-test are not performed simultaneously or when their measuring principle/technique differs
15 considerably. In the context of BP measurements with sphygmomanometers, the 2019 ISO standard
16 (ISO 81060-2:2019) took significant steps to address this issue by providing separate directives when
17 using sphygmomanometers or a continuous invasive BP measurement as reference standard. Because
18 sphygmomanometers provide readings of systolic and diastolic BP over single heartbeats, their use as
19 a reference requires adopting an R-T-R-T-R-T-R validation design (with R and T indicating
20 measurements with reference sphygmomanometer and sphygmomanometer-under-test,
21 respectively). Each T measurement is then compared with the mean of the preceding and following R
22 readings. Conversely, when using continuous invasive BP as reference, the measurement with
23 sphygmomanometer-under-test must be performed within the acquisition period of the invasive
24 pressure. Furthermore, the measured beat-to-beat variability of the latter (± 1 standard deviation) is
25 used to define a range of acceptance for the measurement obtained with the sphygmomanometer-
26 under-test.
27
28
29
30
31

32 Another relevant issue is the repeatability and reproducibility of the measurements of vascular ageing
33 metrics. The potential clinical usefulness of assessing vascular ageing is gauging a patient's current
34 level of vascular health and, perhaps more importantly, monitoring its evolution over time. Hence,
35 high repeatability and reproducibility are paramount to ensuring that measured longitudinal changes
36 of vascular ageing metrics reflect actual changes in vascular health. By requiring repeated
37 measurements and assessing the bias and precision errors on both an individual patient and an
38 individual measurement level, the ISO standard for the validation of cuff-based BP measuring devices
39 (ISO 81060-2:2019) introduced significant steps to evaluate repeatability and reproducibility.
40 However, other guidelines (e.g., PWV) recommend performing repeated measurements solely to cope
41 with haemodynamic variability but maintain a cross-sectional design. Furthermore, to further improve
42 the reliability of vascular ageing devices, future guidelines should also recommend the direct
43 assessment of the ability of a device to detect longitudinal changes in response to induced alterations
44 in haemodynamics, which is currently not implemented in any guideline.
45
46
47
48

49 A third important issue is the rapidly expanding range of devices and techniques for measuring
50 vascular ageing and the ongoing shift of cardiovascular research and the healthcare market towards
51 automated and remote patient monitoring. While this approach has the potential to reduce operator
52 dependence and increase the frequency of assessment of vascular health, specific guidelines for the
53 validation of automated devices are currently lacking (Sharman *et al.* 2022; Mukkamala *et al.* 2023).
54 This fact is assuming growing relevance as new devices gradually shift from *measuring* to *estimating*
55 vascular age metrics (e.g., cuff-based central BP and PWV devices, wearables) (Mukkamala *et al.*
56 2021). While a *measuring* device directly and physically measures a vascular parameter of interest,
57 this new generation of devices relies on the combination of demographics, physical measurements of
58
59
60

1
2
3 accessible haemodynamic waveforms and mathematical transformations to yield an *estimate* of a
4 vascular ageing metric of interest (Mukkamala *et al.* 2021 and 2023). Because of this important
5 difference in their working principle, there is an urgent need to define adequate protocols for
6 validating this new class of devices, including the definition of appropriate reference standards and
7 study designs.
8
9

12 **Advances in Science and Technology to Meet Challenges**

14 The growing attention towards non-invasive, automated, remote, and continuous monitoring of
15 vascular health is steering the focus of cardiovascular research and technology towards the *estimation*
16 rather than the physical *measurement* of vascular ageing metrics. Because of their solid basis on
17 physical principles, the validation of new *measuring* devices or techniques is relatively straightforward
18 and reliable, provided that the observed range of the measured quantity is representative of the
19 general population (ISO 81060-2:2019). As such, a cross-sectional study design is sufficient to prove
20 that the new device is not only able to assess cross-sectional differences in the measured metric but
21 also to track its longitudinal changes (both acute and chronic) in one individual. Conversely, the same
22 conclusions cannot be as directly drawn for devices that *estimate* vascular ageing metrics. Firstly, this
23 class of devices may require periodic calibration against a validated *measuring* device, with the
24 estimation accuracy expected to drop with intercurrent time from the last calibration. In the context
25 of cuffless continuous BP monitoring, the Microsoft Research Aurora project analysed the ability of
26 current wearable technology (e.g., photoplethysmography, tonometry, accelerometry, and ECG) to
27 estimate BP one day from calibration (Mukkamala *et al.* 2021 and 2023). They found that estimation
28 errors were already above the current guidelines' acceptable threshold (Sharman *et al.* 2017, ISO
29 81060-2:2019). Therefore, future guidelines must involve validation study designs that allow for
30 verification of the tested device's longitudinal accuracy and set minimum requirements for their
31 approval.
32
33

34 The Aurora project illustrated a second significant challenge for the development and validation of
35 new wearable *estimating* devices. Ideally, such devices should exploit the information in the
36 haemodynamic waveforms they *measure* to produce more accurate *estimates* than could be obtained
37 from calibration and contextual variables alone. The Aurora project showed that measured data from
38 current wearable technology did not improve the accuracy of the BP estimation beyond baseline
39 regression models (i.e., models discarding any measurement from wearables and considering only the
40 calibration BP and the time of the day) (Mukkamala *et al.* 2021 and 2023). These findings highlight the
41 need for future guidelines to require transparency on the estimation accuracy of a "device" with and
42 without wearable-derived data and to set thresholds for improved accuracy to justify the use of
43 wearable technology (Mukkamala *et al.* 2021 and 2023).
44
45
46
47
48
49
50
51
52

53 **Concluding Remarks**

54 Fast advances in technology are rapidly revolutionising our idea of medicine and health care, allowing
55 for a remote, automated, personalised and potentially continuous assessment of clinical parameters.
56 This paradigm shift has the undoubted potential to improve patient monitoring, favour early diagnosis
57 of diseases, and reduce the economic burden of healthcare. However, a matching evolution of
58
59
60

validation guidelines is mandatory to ensure that this revolution achieves the desired objectives. The principal aspects that urgently need to be addressed are:

1. Defining clear rules on how to deal with beat-to-beat variability which match the working principle of the different devices under study;
2. Incorporating the assessment of repeatability and reproducibility;
3. Incorporating the evaluation of the longitudinal performance in response to haemodynamic changes; and
4. Requiring transparency on the estimation accuracy of wearables with and without wearable-derived data.

References

ISO 81060-2:2019 'Non-invasive sphygmomanometers. Part 2: Clinical investigation of intermittent automated measurement type'.

ISO 81060-3:2022 'Non-invasive sphygmomanometers. Part 3: Clinical investigation of continuous automated measurement type'.

Mukkamala R, Yavarimanesh M, Natarajan K, Hahn JO, Kyriakoulis KG, Avolio AP, Stergiou S. Evaluation of the Accuracy of Cuffless Blood Pressure Measurement Devices: Challenges and Proposals. *Hypertension*. 2021;78:1161–7, DOI: 10.1161/HYPERTENSIONAHA.121.17747

Mukkamala, R, Shroff, SG, Landry, K, Kyriakoulis, KG, Avolio, AP, Stergiou, GS 2023 'The Microsoft Research Aurora Project: Important findings on cuffless blood pressure measurements' *Hypertension* [in press], DOI: 10.1161/HYPERTENSIONAHA.122.20410.

Parati, G, Stergiou, GS, Dolan, E, Bilo, G 2018 'Blood pressure variability: clinical relevance and application' *Journal of Clinical Hypertension*, vol. 20, pp. 1133-1137, DOI: 10.1111/jch.13304.

Sharman, JE, Avolio, AP, Baulmann, J, Benetos, A, Blacher, J, Blizzard, CL, Boutouyrie, P, Chen, C-H, Chowienczyk, P, Cockcroft, JR, Cruickshank, JK, Ferreira, I, Ghiadoni, L, Hughes, A, Jankowski, P, Laurent, S, McDonnell, BJ, McEniery, C, Millaseau, SC, Papaioannou, TG, Parati, G, Park, JB, Protogerou, AD, Roman, MJ, Schillaci, G, Segers, P, Stergiou, GS, Tomiyama, H, Townsend, RR, van Bortel, LM, Wang, J, Wassertheurer, S, Weber, T, Wilkinson, IB, Vlachopoulos, C 2017 'Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization', *European Heart Journal*, vol. 38, pp. 2805-2812, DOI: 10.1093/eurheartj/ehw632

Sharman, JE, Ordunez, P, Brady, T, Parati, G, Stergiou, G, Whelton, PK, Padwal, R, Hecht Olsen, M, Delles, C, Schutte AE, Tomaszewski, M, Lackland, DT, Khan, N, McManus, RJ, Tsuyuki, RT, Zhang, X-H, Murphy, LD, Moran, AE, Schlaich, MP, Campbell, NR 2022 'The urgency to regulate validation of automated blood pressure measuring devices: a policy statement and call to action from the world hypertension league' *Journal of Human Hypertension*, DOI: 10.1038/s41371-022-00747-0.

Thijssen, DH, Bruno, RM, van Mil, ACCM, Holder, SM, Fata, F, Greyling, A, Zock, PL, Taddei, S, Deanfield, JE, Luscher, T, Green, DJ, Ghiadoni, L 2019 'Expert consensus and evidence based recommendations for the assessment of flow-mediated dilation in humans' *European Heart Journal*, vol. 40, pp. 2534-2547, DOI: 10.1093/eurheartj/ehz350.

Wilkinson, IB, McEniery, CM, Schillaci, G, Boutouyrie, P, Segers, P, Donald, A, Chowienczyk, PJ 2010 'ARTERY Society guidelines for validation of non-invasive hemodynamic measurement devices: Part 1, arterial pulse wave velocity', *Artery Research*, vol. 4, pp. 34-40, DOI: 10.1016/j.artres.2010.03.001.

Xhyheri, B, Manfrini, O, Mazzolini, M, Pizzi, C, Bugiardini, R 2012 'Heart rate variability today' *Progress in Cardiovascular Research*, vol. 55, pp. 321-331, DOI: 10.1016/j.pcad.2012.09.001.

12. Assessing clinical utility

Author(s): Rosa Maria Bruno (1,2), Pierre Boutouyrie (1,2), Thomas Weber (3)

Institution(s): (1) Université Paris Cité, INSERM, PARCC, F-75015 Paris, France; (2) Pharmacology and Hypertension Unit, AP-HP, Hôpital Européen Georges Pompidou, F-75015 Paris, France; (3) Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria.

ORCID(s): 0000-0002-6107-3356; 0000-0002-4375-3569; 0000-0003-0617-0417

Status

Any new technology assessing vascular ageing (VA) must demonstrate to be physiologically sound and accurate for what it claims to measure; furthermore its intended use, which represents its clinical utility, should be defined, in line to what requested by the current Medical Device Regulation (MDR). According to MDR classifications, VA measuring devices reasonably belong to the category diagnosis / monitoring of a disease. More specifically, an accurate assessment of vascular age, opposed to chronological age, is meant to identify those individuals with early vascular ageing (EVA), who have a risk of CV events greater than expected (based on their risk profile from traditional risk factors such as sex, lipids, blood pressure, smoking status and diabetes), and those with supernormal vascular ageing (SUPERNOVA), whose vascular age is lower than expected based on their risk profile (Bruno *et al.*, 2020). In other words, the new technology is meant to be used to improve risk stratification, which means to achieve a more accurate prediction of CV events than commonly used risk calculators (in the case of Europe, SCORE2 and SCORE-OP). Indeed, risk calculation is mainly driven by non-modifiable factors such as age and sex (Score2 Working Group and ESC Cardiovascular Risk Collaboration, 2021). For instance, being a man over 70 with one risk factor leads to very high risk, whereas being a woman aged 50 with 2 risk factors leads to low risk. This leads to imbalance in care resources. This is where biomarkers (Wang, 2011), also called risk modifiers (Visseren *et al.*, 2021) can be a game changer. Conceptually, individuals with EVA are either more susceptible than others to traditional CV risk factors, or exposed to unidentified (e.g. genetic) detrimental risk factors, whereas individuals with SUPERNOVA are either less susceptible than others to traditional CV risk factors, or protected by unidentified (e.g. genetic) factors. Given the proportions of the problem (CV disease being the first cause of morbidity and mortality worldwide), and the limitations of the current approach (a majority of CV events occur in people classified at low risk (Cooney *et al.*, 2009)), the clinical utility of such a technology is undeniable. The above-mentioned scenario of clinical utility implies thus a broad utilisation of the technology, especially in low-risk populations. A number of tests assessing vascular ageing are indeed currently prescribed (and reimbursed by national healthcare systems and health insurances) under this application worldwide: this is the case for computed tomography-based coronary calcium score and carotid ultrasound in Europe, and of many other tests (including flow-mediated dilation and brachial-ankle pulse wave velocity) in far-east countries such as Japan. An alternative scenario considers that the new technology will be used in a subset or disease for which a specific unmet need has been identified, to guide clinical decisions (i.e. to prescribe a confirmatory test, to treat/not to treat, indication to a specific drug...). The new technology will be thus used in a defined population in whom the actual gain in using it is maximal.

Current and future challenges

Demonstrating the clinical utility of VA biomarkers raises several challenges:

- 1) finding the best way to assess VA. This is not obvious, and includes finding the “best” single arterial measurement, or a combination of arterial measurements, reflecting both atherosclerosis (coronary artery calcium, carotid artery intima media thickness, etc) and arteriosclerosis (one of several pulse wave velocities, central hemodynamics such as central pulse pressure, amplitudes of forward or backward waves, etc);
- 2) finding the best metric to define VA, for instance age- and sex-adjusted cutoff-levels of completely healthy or population-derived samples, or single cutoff-values (as we use for blood pressure and lipids), or cut-off values which vary according to patient’s risk;
- 3) identifying the ideal target population, as previously discussed;
- 4) to develop a clinical management strategy based on VA, basically non-pharmacological and pharmacological approaches to slow or even reverse VA;
- 5) demonstrating that this strategy improves clinical outcomes: in other words, a treatment strategy based on the level of the studied biomarker is superior to usual care for prevention of CV events (Wang, 2011).

This implies the design of clinical trials in which individuals are randomised to a biomarker-based treatment strategy or usual care; in the active arm, those presenting an altered biomarker of vascular ageing will be treated accordingly. Recently, some trials testing coronary calcium score as VA biomarkers provided inconclusive results (Greenland and Polonsky, 2022); however, increased calcium score may capture individuals with advanced vascular disease, in which preventive strategies are less effective to slow or reverse VA.

Advances in science and technology to meet challenges

Many promising technologies assessing VA could be used in such trial designs because they demonstrated incremental predictive value over and above standard risk assessment, such as carotid-femoral and brachial-ankle pulse wave velocity (Ben-Shlomo *et al.*, 2014) (Ohkuma *et al.*, 2017). Governmental funding agencies, manufacturers, clinicians and researchers need to join forces to promote this kind of studies, run cost-effectiveness analyses, and promote effective targeted preventive strategies for a broad population. Novel trial designs, such as decentralised, pragmatic and registry-based clinical trials should be used to increase feasibility of such studies, as recently recommended by many scientific societies in cardiovascular medicine (Bowman *et al.*, 2022).

Another approach could be to perform smaller studies in subsets of the population in whom the measurement of VA conveys the maximal gain over usual care, or for which surrogate endpoints are accepted. For example: it has been repeatedly shown that development of arterial stiffness precedes the development of hypertension (Saz-Lara *et al.*, 2022). This may be used to screen for increased arterial stiffness in a defined subsample of the population at risk of developing hypertension, which then will require comprehensive non-pharmacological interventions, with development of hypertension as main outcome. The VA-technology would then be incorporated more quickly in clinical algorithms for specific conditions, and their use can be further extended as a subsequent step.

1
2
3 Finally, a third approach would be longitudinal monitoring, which implies the assessment of the VA
4 biomarker several times throughout the life span to guide therapy. Promising data about this approach
5 have been obtained for carotid-femoral pulse wave velocity.(Laurent *et al.*, 2021)
6
7
8
9

10 **Concluding Remarks**

11 In conclusion, assessing the clinical utility of any biomarker/risk modifier is a fundamental step of the
12 development of vascular ageing technologies and determines the application of the technology in
13 routine clinical practice. Although observational studies are the key to identify promising biomarkers,
14 the clinical utility can only be accurately determined by randomised clinical trials. Innovative study
15 designs are mandatory to do that cost-effectively in a timely manner. In summary, it is clear that
16 proper prospective trials and cost-effectiveness analyses are required for implementation of specific
17 measures/techniques/algorithms into clinical practice.
18
19
20
21
22

23 **Acknowledgements**

24 This article is based upon work from European COST Action CA18216 “Network for Research in
25 Vascular Aging”, supported by COST (European Cooperation in Science and Technology, www.cost.eu).
26
27
28
29

30 **References**

- 31 Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson S G, Benjamin E J, Boutouyrie P, Cameron J, Chen C H,
32 Cruickshank J K, Hwang S J, Lakatta E G, Laurent S, Maldonado J, Mitchell G F, Najjar S S, Newman A B, Ohishi
33 M, Pannier B, Pereira T, Vasan R S, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang K L, Webb D J, Willum Hansen
34 T, Zoungas S, McEnery C M, Cockcroft J R and Wilkinson I B 2014 Aortic pulse wave velocity improves
35 cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from
36 17,635 subjects *J Am Coll Cardiol* **63** 636-46
37
38 Bowman L, Weidinger F, Albert M A, Fry E T A, Pinto F J, Clinical Trial Expert G and Forum E S C P 2022
39 Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American
40 Heart Association, American College of Cardiology, and the World Heart Federation *Eur Heart J*
41
42 Bruno R M, Nilsson P M, Engstrom G, Wadstrom B N, Empana J P, Boutouyrie P and Laurent S 2020 Early and
43 Supernormal Vascular Aging: Clinical Characteristics and Association With Incident Cardiovascular Events
44 *Hypertension* **76** 1616-24
45
46 Cooney M T, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njolstad I, Oganov R, Thomsen T,
47 Tverdal A, Wedel H, Wilhelmsen L, Graham I and Investigators S 2009 Re-evaluating the Rose approach:
48 comparative benefits of the population and high-risk preventive strategies *Eur J Cardiovasc Prev Rehabil* **16**
49 541-9
50
51 Greenland P and Polonsky T S 2022 40 Years of Research on Coronary Artery Calcium and Still No Convincing
52 Clinical Trials? *JACC Cardiovasc Imaging* **15** 856-8
53
54 Laurent S, Chatellier G, Azizi M, Calvet D, Choukroun G, Danchin N, Delsart P, Girerd X, Gosse P, Khettab H,
55 London G, Mourad J J, Pannier B, Pereira H, Stephan D, Valensi P, Cunha P, Narkiewicz K, Bruno R M,
56 Boutouyrie P and Investigators S 2021 SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular
57 Events in Patients With Hypertension at Medium to Very High Risk *Hypertension* **78** 983-95
58
59 Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshida S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y,
60 Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C,

1
2
3 Yamashina A and Collaborative Group for J B 2017 Brachial-Ankle Pulse Wave Velocity and the Risk Prediction
4 of Cardiovascular Disease: An Individual Participant Data Meta-Analysis *Hypertension* **69** 1045-52

5 Saz-Lara A, Bruno R M, Cavero-Redondo I, Alvarez-Bueno C, Notario-Pacheco B and Martinez-Vizcaino V 2022
6 Association Between Arterial Stiffness and Blood Pressure Progression With Incident Hypertension: A
7 Systematic Review and Meta-Analysis *Front Cardiovasc Med* **9** 798934

8 Score2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: New
9 models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J* 2021;42:2439-54.

10 Visseren F L J, Mach F, Smulders Y M, Carballo D, Koskinas K C, Back M, Benetos A, Biffi A, Boavida J M,
11 Capodanno D, Cosyns B, Crawford C, Davos C H, Desormais I, Di Angelantonio E, Franco O H, Halvorsen S,
12 Hobbs F D R, Hollander M, Jankowska E A, Michal M, Sacco S, Sattar N, Tokgozoglul, Tonstad S, Tsioufis K P,
13 van Dis I, van Gelder I C, Wanner C, Williams B, Societies E S C N C and Group E S C S D 2021 2021 ESC
14 Guidelines on cardiovascular disease prevention in clinical practice *Eur Heart J* **42** 3227-337

15 Wang T J 2011 Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk
16 prediction *Circulation* **123** 551-65
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

13. From research to market: medical device regulation

Author(s): Elisabetta Bianchini¹ and Christopher Clemens Mayer²

Institution(s): ¹ Institute of Clinical Physiology, Italian National Research Council (CNR), Pisa, Italy; ² Center for Health & Bioresources, Medical Signal Analysis, AIT Austrian Institute of Technology GmbH, Vienna, Austria

ORCID(s): 0000-0002-1827-8866; 0000-0002-5612-5481

Status

Vascular ageing results in functional and structural alterations of the arteries (e.g. pulse wave characteristics, geometrical and elastic parameters, reactivity, pulse pressure, and vessel structural composition). These alterations can be assessed by analysing images or signals acquired through different technologies (Climie et al 2023). Devices on the market include medical imaging equipment (such as ultrasound, MRI, and CT/PET machines), non-invasive sensor-based methods like tonometry, oscillometry, photoplethysmography, and sphygmomanometry, intravascular systems (like catheters for plaque or hemodynamics analysis), and software for data processing, which may be standalone or integrated into other systems. Measures of vascular ageing can provide added value for diagnosis, prevention, monitoring, treatment, or alleviation of the related diseases; the adopted systems are generally qualified as *medical devices* and, hence, need to be developed and validated according to specific rules and to be approved by authorized entities for commercialization (Mayer et al. 2021). Regulation of medical devices was introduced in the 20th century to ensure safety for users and public health. More specifically, in 1976, with the Medical Device Amendments to the FD&C Act (Darrow et al. 2021), the USA introduced a new legislation specifically focused on devices. Nowadays, a regulatory pathway is a mandatory step to enter the world's main markets and, thus, allowing the transition of technologies from research to practice.

Generally, a risk-based approach is adopted within the whole lifecycle of a system focusing on users' safety [3]. When undergoing regulatory risk-based classification, most devices assessing vascular ageing fall into a medium-to-high risk class in many regulatory frameworks (e.g., MDR 2017/745 for the EU, 21 CFR Parts 800 – 1299 by FDA for the USA, TGA for Australia) (Mayer et al. 2021). These require dedicated procedures and competences by the manufacturer for the implementation of a successful strategy leading to the need for additional resources and structures, which might not be immediately available e.g., in small enterprises, in academia or for single inventors. Consequently, innovative systems might lack approval as medical device and start-ups might be forced to translate into other markets.

It is crucial to consider regulatory requirements starting from the design phase for the acceleration of innovation. These requirements can support effective processes for the developers aimed to guarantee users' safety and allowing the introduction of a new medical device on the market serving the society (Bianchini et al. 2022).

Dissemination of a regulatory culture in different fields, interaction between stakeholders, and subsequent updates to legislation, such as the recent European Medical Device Regulation (MDR) (EU2017), are very important for further advances to ensure a smooth transition from research to market. A robust transversal pipeline, based on the integration of different perspectives, leads to more effective processes. The increase in effectiveness follows the introduction of more specific

requirements and the implementation of references and tools to provide better transparency and traceability. A harmonized balance between regulation and innovation remains a crucial point to guarantee the best medical solution for the users.




Figure 14. Key actors involved in the development, maintenance and use process of a vascular ageing medical device. *Icons' source:* <https://www.flaticon.com>.

Current and Future Challenges

Challenges are mainly related to cultural and operative aspects. An effective regulatory framework implies active involvement of the main actors (see **Figure 14**) related to the development, maintenance, and use of medical devices in general and especially for assessing vascular ageing. A key point for a successful and safe adoption of medical technologies is awareness of the regulatory approach by all involved stakeholders. Without this awareness pitfalls emerge in different phases of a system's lifecycle to the disadvantage of patients and operators. A lack of regulatory culture can lead to the absence of mandatory requirements for the product slowing the transition to clinical practice, and even to deficiencies in aspects related to the users' safety, e.g., the post-market and surveillance activities.

Besides the cultural issue, also operative difficulties must be considered. Worldwide, ever-evolving and demanding regulation frameworks require additional resources challenging especially small companies developing innovative solutions; the scenario is fragmented, and, even if key concepts are in common for different parts of the world, requirements are not totally harmonized, and specific application processes are related to the geographical area. Moreover, recent legislations, such as the EU MDR, have increased requirements related to technical and clinical evidence, but guidelines for the validation of, e.g., vascular ageing biomarkers might not yet be fully harmonized or are not available at all. It is worth noting that, besides safety and technical performance, solid and harmonized scientific data are needed to show clinical benefit. This evidence cannot be delegated to manufacturers and can only be obtained by a common effort with a central role of science (Bianchini et al. 2022, Fraser et al. 2018).

1
2
3 Finally, complexity and updates of regulatory frameworks can lead to further concrete external
4 barriers for manufacturers of devices assessing vascular ageing. For example, the recently introduced
5 European legislation, MDR (EU 2017) has increased the time constraints due to the need of renewed
6 approval for all medical devices on the market and subsequent overload of notified bodies. For this
7 reason the transition period has been recently further extended.
8
9

10 Related to current/future challenges, specific attention should be placed on Medical Device Software
11 (MDSW). MDSW, being mainly based on processing of biomedical data, is central for personalized
12 medicine and for vascular ageing assessment. A more demanding approach for development and
13 maintenance of MDSW is now required and it can be satisfied only by a multidisciplinary approach
14 including a regulatory lifecycle mindset. The challenge is even more complex for the emerging AI
15 technologies (Bikia et al. 2021) since the consideration of further characteristics is needed to
16 guarantee safety and benefit for users. Attention around this topic is huge and international initiatives
17 are ongoing (Giansanti 2022). Harmonization and collaboration among different actors are needed
18 (Pesapane et al. 2018) to face with a key challenge: finding the best trade-off to not kill innovation and
19 guarantee safety.
20
21
22
23
24
25

26 **Advances in Science and Technology to Meet Challenges**

27 The challenges mentioned above can be primarily addressed by increasing interaction and mediation
28 between key actors involved in the development/maintenance process of vascular ageing medical
29 devices. Initiatives creating opportunities for exchange among scientists, clinicians, academia,
30 industry, and policy makers, like the COST Action VascAgeNet (Climie et al. 2020), are desirable since
31 they contribute to building a collective intelligence and a shared language able to increase not only
32 the communication among different roles, but also its quality and effectiveness. From an
33 entrepreneurial point of view, this could also increase the possibility for small start-up companies to
34 train internal resources in order to provide faster reaction to the ever-evolving challenges in the field.
35 In addition, education about medical device regulation for scientists, clinicians, and innovators can
36 help to improve their perception of their potential impact. An active and conscious attitude is essential
37 to provide/receive inputs to/from the policy makers and manufacturers and to underline the crucial
38 role of science in supporting the adoption of rigorous methodological approaches within different
39 phases of the innovation pipeline.
40
41
42
43

44 The introduction of a regulatory culture within the vascular ageing community is a fundamental step
45 that, by creating awareness of its importance, can also help to solve operative issues. Firstly, existing
46 research generally means innovation; thus, legislation should not be seen as a barrier to progress but
47 as a stimulus to consider safety and performance requirements since the design phase. Secondly, new
48 studies and the aggregation of clinical data from already existing registries could provide further
49 evidence regarding the added value of vascular ageing assessment in clinical practice supporting and
50 facilitating the development and approval of new solutions able to improve patient management.
51 Moreover, the availability of big data sources could ensure an unbiased validation process for
52 innovative medical devices for assessing vascular ageing, like those based on AI technologies. It is
53 worth noting that guidelines and standards by scientific experts are required and new projects
54 contributing to their development should be designed, since they can support concretely the paradigm
55 shift towards evidence-based modern regulation (Fraser et al. 2022). Moreover, ideas from an aware
56
57
58
59
60

community could lead to the invention and development of tools able to facilitate steps of the lifecycle of a medical device, such as traceability and documentation control.




Figure 15. Main regulatory challenges and potential steps that can be supported by the scientific community for improving the process of translation from research to practice in the vascular ageing field. Icons' source: <https://www.flaticon.com>

Concluding Remarks

The vascular ageing community can play a crucial role in the future of medical devices in the field. Addressing the mentioned challenges can concretely speed-up the introduction of new preventive and clinical paradigms into practice leading to innovation, safety, and a smooth transition from research to clinical practice. Summarized (see **Figure 15**), the regulated translation to market needs a regulatory mindset, i.e., awareness and an osmosis between different actors, and operative actions related to guidelines and standards for the evidence-based technical and clinical validation.

Acknowledgements

This paper is based upon work from the European COST Action CA18216 "Network for Research in Vascular Ageing", supported by COST (European Cooperation in Science and Technology, www.cost.eu).

Competing interests

Elisabetta Bianchini is co-founder of QUIPU s.r.l., Pisa, Italy a spin-off company of the Italian National Research Council and the University of Pisa developing software medical devices.

References

- Bianchini E, Mayer CC. 2022. Medical Device Regulation: Should We Care About It? *Artery Res.* 28(2):55-60. doi: 10.1007/s44200-022-00014-0. PMID: 35378951; PMCID: PMC8968778.
- Bikia V, Fong T, Climie RE, Bruno RM, Hametner B, Mayer C, Terentes-Printzios D, Charlton PH. 2021. Leveraging the potential of machine learning for assessing vascular ageing: state-of-the-art and future research. *Eur Heart J Digit Health.* Dec 29;2(4):676-690. doi: 10.1093/ehjdh/ztab089. Epub 2021 Oct 18. PMID: 35316972; PMCID: PMC7612526.
- Climie RE, Alastruey J, Mayer CC, Schwarz A, Laucyte-Cibulskiene A, Voicshovska J, Bianchini E, Bruno RM, Charlton P, Grillo A, Guala A, Hallab M, Hametner B, Jankowski P, Königsten K, Lebedeva A, Mozos I, Pucci G, Puzantian H, Terentes-Printzios D, Yetik-Anacak G, Park C, Nilsson PM, Weber T. 2023. Vascular Ageing - Moving from Bench towards Bedside. *Eur J Prev Cardiol.* Feb 4:zwad028. doi: 10.1093/eurjpc/zwad028. Epub ahead of print. PMID: 36738307.
- Climie RE, Mayer CC, Bruno RM, Hametner B. 2020. Addressing the unmet needs of measuring vascular ageing in clinical practice-European cooperation in science and technology action VascAgeNet. *Artery Res.* 26:71–5. <https://doi.org/10.2991/artres.k.200328.001>.
- Darrow JJ, Avorn J, Kesselheim AS. FDA Regulation and Approval of Medical Devices: 1976-2020. *JAMA.* 2021 Aug 3;326(5):420-432. doi: 10.1001/jama.2021.11171. PMID: 34342614.
- EU. 2017. "Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and Council Directives 90/385/EEC and 93/42/EEC." <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745&from=IT>
- Fraser AG, Butchart EG, Szymański P, Caiani EG, Crosby S, Kearney P, Van de Werf F. 2018 The need for transparency of clinical evidence for medical devices in Europe. *Lancet (London, England).* 392:521–30. [https://doi.org/10.1016/S0140-6736\(18\)31270-4](https://doi.org/10.1016/S0140-6736(18)31270-4).
- Fraser AG, Nelissen RGH, Kjærsgaard-Andersen P, Szymański P, Melvin T, Piscoi P; CORE-MD Investigators. 2022. Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices). *Eur Heart J Qual Care Clin Outcomes.* May 5;8(3):249-258. doi: 10.1093/ehjqcco/qcab059. PMID: 34448829; PMCID: PMC9071523.
- Giansanti D. 2022. The Regulation of Artificial Intelligence in Digital Radiology in the Scientific Literature: A Narrative Review of Reviews. *Healthcare (Basel).* Sep 21;10(10):1824. doi: 10.3390/healthcare10101824. PMID: 36292270; PMCID: PMC9601605.
- Mayer CC, Francesconi M, Grandi C, Mozos I, Tagliaferri S, Terentes-Printzios D, Testa M, Pucci G, Bianchini E. 2021. Regulatory Requirements For Medical Devices And Vascular Ageing: An Overview. *Heart Lung Circ.* Nov;30(11):1658-1666. doi: 10.1016/j.hlc.2021.06.517.
- Pesapane, F.; Volonté, C.; Codari, M.; Sardanelli, F. 2018. Artificial intelligence as a medical device in radiology: Ethical and regulatory issues in Europe and the United States. *Insights Imaging* 9, 745–753.

14. Commercial translation of academic innovations

Author(s): P. M. Nabeel¹ and Jayaraj Joseph²

Institution(s): ¹ Healthcare Technology Innovation Centre, IIT Madras, Chennai – 600 113, India; ² Department of Electrical Engineering, Indian Institute of Technology Madras, Chennai – 600 036, India

ORCID(s): 0000-0001-7280-0048; 0000-0002-7279-9099

Status

Translational research is a critical pathway in bridging the gap between laboratory discoveries and their practical application in improving patient outcomes, particularly in the realm of vascular ageing. The commercialization of new medical devices emerging from academic research plays a pivotal role in addressing the challenges associated with vascular ageing, such as the prevention and treatment of age-related vascular diseases. This process involves translating complex research findings, including those related to the mechanisms of vascular ageing and innovative interventions, into practical solutions that healthcare practitioners and industry stakeholders can effectively implement. As Mayer *et al* 2020 highlight, the journey from idea inception to market introduction is fraught with challenges, requiring not only significant investment and time but also a multidisciplinary approach that includes researchers, healthcare professionals, and industry participants to ensure successful commercialization. Despite these hurdles, the effective translation of research on medical devices targeting vascular ageing can lead to breakthroughs that significantly enhance clinical practices and patient care, underscoring the importance of rapid and efficient implementation of technological innovations in combating the effects of vascular ageing.

Universities increasingly focus on generating intellectual property (IP) and commercialising their patents at larger scales (Marr and Phan 2020). A common way of approaching this is to establish centres with a focus on academia-industry collaboration, which engages with leading industry players to develop commercialisation strategies for academic innovations. This often leads to technology licensing agreements, or spinoff companies focusing on commercial adaptations. The *open innovation* approach (Bigliardi *et al* 2020), understood as balancing the needs of collaborative idea-sharing with commercial interests and market adaptation, is generally accepted as producing greater innovation and technology transfer. However, innovations go through different stages of market expectations, as described by the Gartner Hype Cycle (**Figure 16**) (Gartner 2023). Innovations from academia, especially from the healthcare domain, have their own challenges and opportunities during the commercialisation process. Industry partnership is vital to enable the invention to pass from the university-push phase to the industry-pull phase (**Figure 16**), through the *Trough of Disillusionment*, and into an established presence in the market. In the following, a successful example is presented.




Figure 16. Gartner Hype Cycle (Gartner 2023). GARTNER is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.

The ARTSENS[®], developed by the Indian Institute of Technology (IIT) Madras's Healthcare Technology Innovation Centre (HTIC), is a successful academic-driven translational research in the early vascular ageing space. It is an image-free ultrasound device for automated measurement of clinically relevant vascular health markers, facilitating a quantifiable screening process for vascular ageing and enabling early intervention and preventive measures (Nabeel *et al* 2022). ARTSENS[®] is the result of a PhD research begun in 2008 with a commitment to producing an industry-ready device. It was achieved through a series of evolutionary developments, multidisciplinary collaborations, iterative verifications, and clinical validations. The result is an ergonomic product with a Technology Readiness Level (TRL) of ~8, ensuring a reliable and usable workflow that functions effectively not solely under laboratory conditions, but in clinical settings as well. The device was developed in consultation with physiologists, clinical and industry partners, and regulatory experts, who were involved in various parts of the developmental stage (**Figure 17**). IIT Madras's adoption of the open innovation approach, which strategically involves the right stakeholders and peer-to-peer collaboration (both among universities and university-industry), has enabled an academic institute to produce a high-TRL product. However, the percentage of such technology being commercially translated to the market is abysmally low compared to global academic publications (Brightman *et al* 2021).




Figure 17. Medical technology development pathway with an illustrative example of ARTSENS® device – an academic-driven vascular ageing and fitness assessment technology.

Current and Future Challenges

The innovation pipeline in healthcare technology research differs substantially from the overall research and development (R&D) culture in other academic fields, whose research outcomes have themselves been traditionally slow in being commercially implemented (Nabeel 2023). In spite of the high student and researcher turnover rates and the nature of research grants, medical device innovations and evidence-based research outcomes take more than a decade, on average, to be translated into standard practice (Morris *et al* 2011). The medical-innovation-to-healthcare-industry pipeline is clogged by interconnected barriers, such as: insufficient market research and relevant ideation; lack of effective design controls; poor risk management; inadequate documentation; and lack of quality management. Often, university faculty or academic research leads have an incomplete understanding of the market and the potential impact of their innovation, augmented by poor communication with industry stakeholders. The lack of business development and marketing skills in academia widens the communication gap between research departments and the fragmented healthcare device market. There are also academia-specific challenges in medical device development and translation, such as: proofs of concept failing to attract adequate funding; development slowed by ineffective project management; and inefficient, collaboration-hindering IP policies within or among universities (Nabeel 2023).

There is also the regulatory aspect to consider (see Section 13). Devices developed for screening of vascular ageing use are subject to regulatory approval before they can be commercially used (Mayer *et al* 2021). Different regulatory bodies worldwide have their own regulatory platforms and rigorous safety requirements. Universities tend to have limited knowledge of the regulatory framework and requirements that greatly influence the duration of market translation, such as classifications of

1
2
3 medical devices, quality management, risk assessment, clinical and technical evaluation standards,
4 regulatory submission, and marketing approval entities. However, from an academic standpoint, it is
5 impractical to implement and document the entire regulatory process at the R&D stage (Letourneur
6 *et al* 2021). Further, the regulatory requirements and complexity of the approvals process have been
7 increasing in recent years to ensure consistent health and safety protections in adapting scientific and
8 technological breakthroughs. Europe's new stringent regulatory environment, with full enforcement
9 of the Medical Device Regulation 2017/745 (Mayer *et al* 2021), changes the academia-to-industry
10 translation landscape, and contributes to an increase in product development and validation costs.
11 This is bound to reflect in higher investments, borne by industry and state enterprises.
12
13
14
15
16
17

18 **Advances in Science and Technology to Meet Challenges**

19 The market adaptation process for vascular ageing medical devices is different from the translational
20 pipelines for biologics and pharmaceuticals. This highlights the need for academic institutions to be
21 familiar with domain-specific knowledge, mechanisms, and best practices. A crucial first step is
22 improving academic research culture by including new, relevant educational and research approaches
23 among students, research scholars, and faculty (Brightman *et al* 2021). A focused, systematic approach
24 to overcome the structural barriers impeding academic research can significantly increase the rate at
25 which innovations are translated into the medical device market. For instance, many universities have
26 set up centres of excellence which focus on developing proof-of-concept prototypes (Manyazewal *et*
27 *al* 2022), facilitated by Technology Transfer Officers, who help academics hone their entrepreneurial,
28 market knowledge, and product development skills. Certain aspects, such as market search,
29 economics thinking, patent assignment, and obtaining clinical trial resources, would benefit from the
30 active involvement of industry-based advisors.
31
32
33
34

35 Alongside effective IP management (Marr and Phan 2020), it is also important for universities to adopt
36 the open innovation model, which enables timely knowledge-sharing, efficient publication rates, and
37 joint research among universities and peer industries (Bigliardi *et al* 2020). This approach, analogous
38 to a project with team members from multiple disciplines, helps to cover more bases and to make the
39 translational pipeline more efficient. Efforts should be made to strengthen and facilitate collaboration
40 among the global network of academicians, scientists, engineers, clinicians, and medical companies.
41 Researchers working on a medical technology should begin looking at its commercialisation potential
42 once it reaches a TRL of four or five. This could include industry collaboration, starting up, studying
43 the market landscape and identifying product placement strategies. These steps also enable the
44 technology to adhere to accepted design practice, clinical validation, and compliance with regulatory
45 processes (Lottes *et al* 2022) – which are often challenging to incorporate in an academic environment.
46 Support from societies such as VascAgeNet will help to develop streamlined multidisciplinary teams
47 in vascular ageing translational research. An R&D ecosystem (Lottes *et al* 2022), which emphasises
48 translational research, is critical to ensuring the sustained conversion of research innovations from
49 publications into products. An effort is also required to envision and create international resources,
50 core infrastructure facilities, and funding to support early-stage evaluations of medical technologies,
51 regulatory requirements, and efficiently tackle any other challenges unique to medical device
52 commercialisation.
53
54
55
56
57
58
59
60

Concluding Remarks

The commercialisation of breakthroughs in vascular ageing research holds the potential to profoundly extend lifespan and improve the quality of life by moving beyond traditional disease-centered treatments to address the root causes of vascular deterioration. Academic institutions, as leading contributors to this field, are at the forefront of developing innovative, patient-focused medical devices that target the mechanisms of vascular ageing. Despite this, the inherent research culture within universities has often hindered the seamless transition of their groundbreaking findings into viable commercial products. This gap underscores the urgent need for a more robust, multidisciplinary approach that bridges academia and industry. By fostering closer collaboration between clinical researchers and universities, encouraging entrepreneurial initiatives, and enhancing regulation-supportive ecosystems, we can significantly improve the translation of vascular ageing research into practice. Such a strategic shift is crucial for ensuring that the next generation of medical technologies—not only identifies but also effectively combats the complex processes of vascular ageing—can be rapidly and efficiently delivered from the laboratory to the market. This approach promises to revolutionize our ability to mitigate the effects of ageing on the vascular system, offering hope for longer, healthier lives through the innovative application of research breakthroughs.

References

- Bigliardi B, Ferraro G, Filippelli S and Galati F 2020 The past, present and future of open innovation Eur. J. Innov. Manag. 24 1130–61
- Brightman A O, Coffee R L, Garcia K, Lottes A E, Sors T G, Moe S M and Wodicka G R 2021 Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute's Medical Technology Advance Program – ERRATUM J. Clin. Transl. Sci. 5 1–8
- Gartner 2023 Understanding Gartner's Hype Cycles Online: <https://www.gartner.com/document/code/793868>
- Letourneur D, Joyce K, Chauvierre C, Bayon Y and Pandit A 2021 Enabling MedTech translation in academia: Redefining value proposition with updated regulations Adv. Healthc. Mater. 10 1–9
- Lottes A E, Cavanaugh K J, Chan Y Y F, Devlin V J, Goergen C J, Jean R, Linnes J C, Malone M, Peat R, Reuter D G, Taylor K and Wodicka G R 2022 Navigating the regulatory pathway for medical devices—a conversation with the FDA, clinicians, researchers, and industry experts J. Cardiovasc. Transl. Res. 15 927–43
- Manyazewal T, Woldeamanuel Y, Oppenheim C, Hailu A, Giday M, Medhin G, Belete A, Yimer G, Collins A, Makonnen E and Fekadu A 2022 Conceptualising centres of excellence: A scoping review of global evidence BMJ Open 12 1–9
- Marr K and Phan P 2020 The valorisation of non-patent intellectual property in academic medical centers J. Technol. Transf. 45 1823–41
- Mayer C C, Climie R E, Hametner B and Bruno R M 2020 The European cost action VascAgeNet fostering innovation - When industry comes to science Artery Res. 26 125–9
- Mayer C C, Francesconi M, Grandi C, Mozos I, Tagliaferri S, Terentes-Printzios D, Testa M, Pucci G and Bianchini E 2021 Regulatory requirements for medical devices and vascular ageing: An overview Hear. Lung Circ. 30 1658–66
- Morris Z S, Wooding S and Grant J 2011 The answer is 17 years, what is the question: Understanding time lags in translational research J. R. Soc. Med. 104 510–20
- Nabeel P M 2023 *Thrive through the ivory tower: A roadmap for triumph in academic research* (Chandigarh: White Falcon Publishing)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Nabeel P M, Raj Kiran V and Joseph J 2022 Image-free ultrasound for local and regional vascular stiffness assessment: The ARTSENS® Plus J. Hypertens. 40 1537–44

Accepted Manuscript

15. Influencing policy makers

Author(s): Chloe Park

Institution(s): University College London

ORCID(s): 0000-0001-8302-7484

Status

To have a lasting impact on society, scientific findings need to inform practice and policy. *The science-for-policy communication process can occur at all levels of governance (local, national, and international) and can be instigated by both scientists and policy officials in a bidirectional manner.*

Evidence-based science should be at the centre of policy making, however, becoming a successful policy influencer is not a priority when training to become a researcher, clinician or engineer in the vascular ageing field. Help is required to navigate the policy landscape as it requires public affairs expertise, knowledge of the current landscape and strategic planning for successful dissemination of well-timed, impactful outputs.

A 2020 systematic review (Cairney, 2020), targeted at academics, provides key tips to increase the success of influencing policy. The following section addresses these recommendations in the context of the vascular ageing field, including current strengths and future considerations.

1. Produce High Quality research

Policy evidence should be legitimate and unbiased, which requires an interdisciplinary approach. Each discipline provides a different perspective to performing critical analysis and suitable interpretation of results to ensure high quality outputs. Research should always be peer-reviewed and clearly communicate both the limitations and the strengths and weaknesses of the research.

An example of this interdisciplinary approach in the vascular ageing field is the COST Association European Vascular Ageing Network, (VascAgeNet). VascAgeNet is made up of over 350 experts from leading institutions across 40 different countries. The interdisciplinary and intersectoral nature of the network combines medical research and clinical aspects from various disciplines (hypertension, cardiology, nephrology, physiology, etc.), engineering (electrical engineering, mathematics, physics), hospitals, universities, research organisations and industry.

2. Make the research relevant and readable

Policy makers are aware that cardiovascular disease is a substantial public health challenge, as shown by the inclusion of cardiovascular disease in the European Commission's Healthier together – EU non-communicable diseases initiative. (European Commission, 2019). If individuals at increased cardiovascular risk can be identified at an asymptomatic, subclinical stage this will lead to a substantial decrease in both health and economic burden. Strategies for achieving healthy vascular ageing and preventing premature vascular ageing are both attractive and relevant to policy makers. To successfully engage with stakeholders the research needs to be tailored to its audience. Evidence must be framed appropriately using relevant language in brief, concise, open access reports.

Researchers in the vascular ageing field should be mindful of how their work fits into the bigger landscape. Although vascular ageing on its own may not be a current public health priority, many risk

factors associated with early vascular ageing are priorities and keeping up to date with current policies will help to increase future policy engagement success. These areas include:

Prevention Strategies: Many global CVD policies prioritise prevention efforts aimed at reducing risk factors associated with vascular ageing, such as hypertension, atherosclerosis, and arterial stiffness. These strategies often include promoting healthy lifestyles, reducing tobacco use, improving diet quality, and encouraging physical activity—all of which have direct implications for the vascular ageing field.

Public health campaigns and awareness-raising: Policymakers also invest in public health campaigns and initiatives to raise awareness about the importance of cardiovascular health and encourage healthy behaviours. These campaigns often target specific population groups or risk factors, such as smoking cessation programs, healthy eating campaigns, and initiatives to promote physical activity. Researchers should consider becoming a part of these initiatives.

Early Detection and Diagnosis: Screening programs and diagnostic guidelines can be designed to identify individuals at risk of developing vascular complications, allowing for timely interventions to slow down the ageing processes in blood vessels. Researchers should create policy documents to explain how the recent advances in the field (new evidence, technologies, early interventions and treatments) mentioned throughout this document can help with future efforts. Including how the work addresses cross-cutting factors like health inequalities, upscaling innovations and how these contribute to economic growth by ensuring that the workforce are healthier.

Research funding and collaboration: Policymakers support research initiatives and collaborations aimed at advancing the understanding of cardiovascular disease and developing innovative approaches for its prevention and treatment. Funding programs such as Horizon Europe allocate resources to support cardiovascular research projects and promote collaboration among researchers and institutions across Europe. Researchers should regularly scan calls to see if their vascular ageing research fits the remit. They should also highlight gaps that require funding by being involved in policy consultations and workshops.

Implementation Science: Policymakers are also interested to know what actually works in the real world. How can we successfully detect people with EVA, how do we best explain risk to individuals, how do we ensure that people stick to health modifications/interventions when EVA is detected and how do we evaluate all of the above.

3. Understand policy processes

Researchers in the vascular ageing field are required to understand that policy change does not only imply a change in legislation, but the research can also influence non-legislative decisions such as regulations and resource allocation. Regularly check recent political developments in the field via the website of any relevant departments. Investigate which policymakers work in this area, build a relationship with their special advisors, and disseminate research summaries to all relevant committees. Submit oral and written evidence whenever possible. Approaching officers of backbench committees for assistance in promoting an issue is a more informal way to put pressure on policy makers. (UKRI)

4. Be accessible to policy makers

Communication is essential to ensure that policy makers are made aware of the findings. How to best influence policy makers depend on their roles, therefore researchers need to strategically time and tailor communications with politicians and officials including central and local government, non-

1
2
3 departmental public bodies, regulatory bodies, non-ministerial departments, political parties and
4 activists in think tanks pressure groups. Remember that science advice can be provided at different
5 stages of the policy-making process. Build relationships with science-advisory bodies/structures that
6 act as intermediaries between scientific communities and policy makers. (UKRI)
7

8 **5. Build relationships with policy makers**

9
10 Building bidirectional relationships with policy makers is the key to success. Now is the time to seek
11 out which policy makers are interested in the vascular ageing vision and talk with them about the
12 research goals. An important consideration is that movement within political departments is common.
13 Therefore, forming relationships with those who remain in more stable roles (such as civil servants
14 who specialise in the technical aspects of policy) is advised.
15
16
17
18
19

20 **Current and Future Challenges**

21 The good news is that vascular ageing measures already feature in some policy documents. Recent
22 examples from 2022 include the effect of air pollution (Slater, 2022), vaping (WHO, 2022), smoking
23 and diabetes (Cadth, 2022) on arterial stiffness (see **Table 1** for more details and examples). The bad
24 news is that there is no policy document dedicated to vascular ageing. The biggest current challenge
25 is that the vascular ageing field is fragmented, and the technology is not ready to take to policy makers.
26 However, this should not deter the team from setting the groundwork required to build relationships
27 with key policy makers now to ensure that the channels of communication are open when impactful
28 outputs need to be shared in the future. This includes the preparation of influential materials and
29 recommendations, including interim ones.
30
31
32

33 A second challenge is that there is no simple way to know when the research will be in demand in a
34 policymaking system. While a senior politician may currently have cardiovascular disease prevention
35 and vascular ageing as a priority their priorities may shift, or they could move on and their successor
36 may not consider vascular ageing as a priority. The political process is complex and multi-channelled,
37 navigating the system successfully requires members of the action to be skilled in public affairs and
38 the policy landscape.
39
40

41 A third challenge is that influencing policy takes time especially when it is difficult to access some
42 networks or there is competition for the policy maker's attention. A strength to large multi-
43 disciplinary, multi-country networks, like VascAgeNet, is that policy makers can be approached from
44 various angles.
45

46 A fourth challenge is securing funding to support multidisciplinary collaborations that can advance the
47 vascular ageing field, in times of crises and an increasingly difficult funding environment.
48
49
50
51

52 **Advances in Science and Technology to Meet Challenges**

53 To meet the challenges, those in the vascular ageing field need funding and resources (both time and
54 people) dedicated to policy engagement. While the development pipeline steps are being refined,
55 clear and feasible objectives can be formulated to influence policy makers. **Pathways to building**
56 **relationships with policy makers include** signing up to an expert register or third science-policy party
57 organisations such as The [European Parliamentary Research Service](#) – EPRS and joining international
58
59
60

1
2
3 organisations focused on promoting cardiovascular health as a policy priority such as the European
4 Alliance for Cardiovascular Health.
5

6 Once the science behind the policy impact is ready high-level policy events can be organised such as
7 seminars, workshops, policy briefings and conferences on a European, national, local scale. The power
8 of the media and social media can also be harnessed to reach target stakeholders.
9

10 11 12 13 **Concluding Remarks**

14 Vascular ageing research outputs have the potential to have a lasting impact on society. Strategies for
15 achieving healthy vascular ageing and preventing premature vascular ageing are both appealing and
16 relevant to policy makers. Despite the challenges in this area, careful navigation of the political
17 landscape and timely strategic communication will ensure that the high-quality science generated in
18 the field will engage policy makers and inform practice and policy.
19
20
21
22

23 24 Policy Document	Date	Policy Maker	Link	Vascular Ageing evidence used in document
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Air pollution and the world of work: policies, initiatives and the current situation a scoping and evidence review for Southeast and East Asia	October 2022	Stockholm Environment al Institute	[1]	[2]
Nicotine vaping in England: 2022 evidence update	September 2022	The UK Government	[3]	[4]
Sodium-Glucose Cotransporter-2 Inhibitors for Type 2 Diabetes Mellitus	September 2022	Canadian Agency for Drugs and Technologies in Health	[5]	[6]

Maladie de Kawasaki	September 2022	Haute Autorite de Sante	[7]	[8]
Opinion on electronic cigarettes.	August 2022	Publications Office of the European Union	[9]	[10]
Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline on the prevalence of hypertension in young Saudi women	August 2022	World Health Organisation	[11]	[12]
Smoking and cardiovascular disease in the Eastern Mediterranean Region	August 2022	World Health Organisation	[13]	[14]
Tobacco: preventing uptake, promoting quitting and treating dependence	August 2022	NICE	[15]	[16]
Melatonin for the Treatment of Insomnia: A 2022 Update	May 2022	Canadian Agency for Drugs and Technologies in Health	[17]	[18]

<p>Mat vid diabetes Food in diabetes</p>	<p>May 2022</p>	<p>Swedish Agency for Health Technology and Assessment of Social Services</p>	<p>[19]</p>	<p>[20]</p>
<p>A matter of life and death</p>	<p>March 2022</p>	<p>Health Foundation</p>	<p>[21]</p>	<p>[22]</p>

Table 1. A list of recent policy documents from around the globe that use vascular ageing research as evidence to inform policy.

References

CADTH 2022. Sodium-Glucose Cotransporter-2 Inhibitors for Type 2 Diabetes Mellitus.

CAIRNEY, P. 2020. How Should Academics Engage in Policymaking to Achieve Impact? *Political Studies Review*, 18, 228-224.

EUROPEAN_COMMISSION. 2019. *Healthier together – EU non-communicable diseases initiative* [Online]. Available:

<https://ucldesktop.cloud.com/Citrix/StoreWeb/clients/HTML5Client/cdn/SessionWindow.html?launchid=1674224369245> [Accessed].

SLATER 2022. Air pollution and the world of work: policies, initiatives and the current situation – a scoping and evidence review for Southeast and East Asia. Stockholm Environment Institute.

UKRI. <https://www.ukri.org/councils/esrc/impact-toolkit-for-economic-and-social-sciences/how-to-influence-policymakers/working-with-parliament/#contents-list> [Online]. [Accessed].

WHO 2022. Smoking and cardiovascular disease in the Eastern Mediterranean Region. *In: MEDITERRANEAN*, W. H. O. R. O. F. T. E. (ed.).

Table References

[1] Slater, J., Jenny Yi-Chen Han, Charrlotte Adelina, Jae Nikam, Archer, D., Nguyen, H. and Kim, D. (2022). Air Pollution and the World of Work: Policies, Initiatives and the Current Situation – A Scoping and Evidence Review for Southeast and East Asia. [online] doi:<https://doi.org/10.51414/sei2022.040>.

[2] Wu, C., Kuo, I-Chun., Su, T.-C., Li, Y.-R., Lin, L.-Y., Chan, C.-C. and Hsu, S.-C. (2010). Effects of Personal Exposure to Particulate Matter and Ozone on Arterial Stiffness and Heart Rate Variability in Healthy Adults. *American Journal of Epidemiology*, [online] 171(12), pp.1299–1309. doi:<https://doi.org/10.1093/aje/kwq060>.

[3] Office for Health Improvement and Disparities (2022). Nicotine vaping in England: 2022 evidence update. [online] GOV.UK. Available at: <https://www.gov.uk/government/publications/nicotine-vaping-in-england-2022-evidence-update> [Accessed 12 Mar. 2024].

[4] Office (2022). Nicotine vaping in England: 2022 evidence update summary. [online] GOV.UK. Available at: <https://www.gov.uk/government/publications/nicotine-vaping-in-england-2022-evidence-update/nicotine->

vaping-in-england-2022-evidence-update-summary#chapter-11-cardiovascular-diseases [Accessed 12 Mar. 2024].

[5] Cadth.ca. (2022). Sodium-Glucose Cotransporter-2 Inhibitors for Type 2 Diabetes Mellitus | CADTH. [online] Available at: <https://www.cadth.ca/sodium-glucose-cotransporter-2-inhibitors-type-2-diabetes-mellitus> [Accessed 12 Mar. 2024].

[6] Wei, R., Wang, W., Pan, Q. and Guo, L. (2022). Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Frontiers in Endocrinology*, [online] 13. doi:<https://doi.org/10.3389/fendo.2022.826604>.

[7] Haute Autorité de Santé. (2022). Maladie de Kawasaki. [online] Available at: https://www.has-sante.fr/jcms/p_3363015/fr/maladie-de-kawasaki [Accessed 12 Mar. 2024].

[8] Cheung, Y., Yung, T., Sidney C.F Tam, Marco H.K Ho and Adolphus K.T Chau (2004). Novel and traditional cardiovascular risk factors in children after Kawasaki disease. *Journal of the American College of Cardiology*, [online] 43(1), pp.120–124. doi:<https://doi.org/10.1016/j.jacc.2003.08.030>.

[9] European Commission (2022). Opinion on electronic cigarettes - Publications Office of the EU. [online] Publications Office of the EU. Available at: <https://op.europa.eu/en/publication-detail/-/publication/08e05a0f-228c-11ed-8fa0-01aa75ed71a1/language-en/format-PDF> [Accessed 12 Mar. 2024].

[10] Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Mahmoud Abdelrasoul, Dimitrios Terentes-Printzios, Georgakopoulos, C., Pietri, P., Christodoulos Stefanadis and Dimitris Tousoulis (2016). Electronic Cigarette Smoking Increases Aortic Stiffness and Blood Pressure in Young Smokers. *Journal of the American College of Cardiology*, [online] 67(23), pp.2802–2803. doi:<https://doi.org/10.1016/j.jacc.2016.03.569>.

[11] Maha Al-Mohaisen, Qumasha Al-Obaid, AlGhamdi, W., Haneen Al-Alyani, Dahman, S., Al-Wahhabi, N., Noura Al-Awaji and Lee, T. (2020). Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline on the prevalence of hypertension in young Saudi women. *Eastern Mediterranean Health Journal*, [online] 26(04), pp.426–434. doi:<https://doi.org/10.26719/emhj.19.080>.

[12] Nicoll, R. and Henein, M.Y. (2018). Caloric Restriction and Its Effect on Blood Pressure, Heart Rate Variability and Arterial Stiffness and Dilatation: A Review of the Evidence. *International Journal of Molecular Sciences*, [online] 19(3), pp.751–751. doi:<https://doi.org/10.3390/ijms19030751>.

[13] World Health Organisation (2018). Smoking and cardiovascular disease in the Eastern Mediterranean Region. *Who.int*. [online] doi:<https://doi.org/WHO-EM/TFI/190/E>.

[14] Salahuddin, S., Prabhakaran, D. and Roy, A. (2012). Pathophysiological Mechanisms of Tobacco-Related CVD. *Global heart*, [online] 7(2), pp.113–113. doi:<https://doi.org/10.1016/j.ghart.2012.05.003>.

[15] NICE (2021). Overview | Tobacco: preventing uptake, promoting quitting and treating dependence | Guidance | NICE. [online] Available at: <https://www.nice.org.uk/guidance/ng209> [Accessed 12 Mar. 2024].

[16] Chaumont, M., Benjamin de Becker, Zaher, W., Culié, A., Deprez, G., Mélot, C., Reyé, F., Pierre Van Antwerpen, Cédric Delporte, Debbas, N., Karim Zouaoui Boudjeltia and van (2018). Differential Effects of E-Cigarette on Microvascular Endothelial Function, Arterial Stiffness and Oxidative Stress: A Randomized Crossover Trial. *Scientific Reports*, [online] 8(1). doi:<https://doi.org/10.1038/s41598-018-28723-0>.

[17] Cadth.ca. (2022). Melatonin for the Treatment of Insomnia: A 2022 Update | CADTH. [online] Available at: <https://www.cadth.ca/melatonin-treatment-insomnia-2022-update> [Accessed 12 Mar. 2024].

[18] Kim, Y., Kang, H.-T. and Lee, D.-C. (2021). Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study. *International Journal of Environmental Research and Public Health*, [online] 18(5), pp.2561–2561. doi:<https://doi.org/10.3390/ijerph18052561>.

[19] Swedish Agency for Health Technology and Assessment of Social Services (2022). Mat vid diabetes. [online] *Www.sbu.se*. Available at: <https://www.sbu.se/sv/publikationer/SBU-utvarderar/mat-vid-diabetes2/> [Accessed 12 Mar. 2024].

[20] Ahola, A.J., Gordin, D., C. Forsblom and P.-H. Groop (2018). Association between diet and measures of arterial stiffness in type 1 diabetes – Focus on dietary patterns and macronutrient substitutions. *Nutrition*,

1
2
3 Metabolism and Cardiovascular Diseases, [online] 28(11), pp.1166–1172.
4 doi:<https://doi.org/10.1016/j.numecd.2018.07.003>.

5 [21] The Health Foundation. (2022). A matter of life and death. [online] Available at:
6 <https://www.health.org.uk/publications/a-matter-of-life-or-death> [Accessed 12 Mar. 2024].

7 [22] Ikeda, A., Steptoe, A., Shipley, M., Abell, J., Kumari, M., Tanigawa, T., Hiroyasu Iso, Wilkinson, I.B.,
8 McEnery, C.M., Archana Singh-Manoux, Kivimaki, M. and Brunner, E.J. (2021). Diurnal pattern of salivary
9 cortisol and progression of aortic stiffness: Longitudinal study. *Psychoneuroendocrinology*, [online] 133,
10 pp.105372–105372. doi:<https://doi.org/10.1016/j.psyneuen.2021.105372>.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

CLINICAL APPLICATIONS

16. Cognitive decline and dementia

Author(s): Indra Steens, MSc¹ Thomas van Sloten, MD, PhD²

Institution(s): ¹ Dept of Internal Medicine, Maastricht University, Maastricht, the Netherlands; and ² Dept of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
ORCID(s): 0000-0002-9025-2011 (Indra Steens); 0000-0003-2870-482X (Thomas van Sloten)

Status

Dementia is a highly common and devastating disease, often caused by a combination of different underlying pathologies. Efforts to treat dementia have not been very successful. Early prevention of cognitive decline is challenging when the risk factors and causes are not fully understood. Hypertension is associated with an increased risk of cognitive decline and dementia. Early vascular ageing is increasingly recognized as an important contributor to the development of dementia and, thus, as a potential target for early preventive therapies. Observational studies have shown that a wide range of indicators of vascular ageing are associated with a higher risk of both vascular and other subtypes of dementia, including Alzheimer's disease (Vasan et al., 2022) (Bos et al., 2018) (Deal et al., 2019). These indicators include higher carotid artery and aortic stiffness and various markers of microvascular dysfunction and cerebral small vessel disease such as retinal microvascular parameters, white matter hyperintensities, cerebral microbleeds and lacunes. A better understanding of how vascular factors can contribute to the development of dementia is critical for identifying potential targets for preventive therapies.

A leading hypothesis is that arterial stiffness contributes to dementia via functional disorders or damage of the microcirculation. Arterial stiffness leads to an increased pulsatile pressure and flow load forwarded to the microcirculation of specific organs such as retina, kidney and brain. The microcirculation in the brain is particularly vulnerable for this increased load, as it is characterized by low impedance, allowing the pulsatile load to penetrate deeply into its microvascular bed without dampening the pulsatility by the windkessel function of the large and middle size arteries. Microvascular damage in the brain presents as white matter hyperintensities, cerebral microbleeds and lacunes. These remodelling processes can subsequently lead to cognitive impairment and dementia (Ainsworth and Rhodes, 1986). However, epidemiological data suggest that the potential impact of arterial stiffness on dementia may not be entirely through measurable microvascular dysfunction. For example, a recent study showed that microvascular dysfunction accounted for only 16% of the association between aortic stiffness and worse cognitive functioning. The researchers used a composite score based on various measures, including plasma biomarkers, retinal measures and markers of cerebral small vessel disease (Rensma et al., 2020).

Further studies focusing on independent risk factors and interaction between arterial stiffness, microvascular dysfunction and other pathologies such as inflammation and processes leading to neurodegeneration, are needed to understand the process leading to dementia. Recent advancements in imaging science now enable better phenotyping of the brain microvasculature and associated pathologies (see **Figure 18**).

Current and Future Challenges

Dementia is a heterogeneous disease that is often multifactorial. Currently, we do not know how early vascular ageing interacts with various other mechanisms, such as neurodegeneration and inflammation, that are thought to play a role in the development of cognitive impairment and dementia. Arterial stiffness may not only lead to increased pulsatile flow in the brain, but also contributes to inflammation, oxidative stress, and blood-brain barrier permeability, followed by neurodegeneration in regions needed for cognitive processing, thus contributing to cognitive decline and subsequently dementia (Iulita et al., 2018).

Further research is needed to investigate the potential interaction between these factors in their contribution to the development of cognitive impairment and dementia. Additional factors that may interact with early vascular ageing in the association with dementia are insulin resistance, high levels of advanced glycation end-products (AGEs), and glucose toxicity. In addition to investigating the downstream factors of vascular ageing, research should also focus on the role of the drivers of early vascular ageing (i.e., diabetes, hypertension, ageing, obesity) and their interaction with the above-mentioned processes, and whether currently available therapies are able to prevent these processes. Research is also needed to evaluate whether any of these processes are different according to sex. Due to the long preclinical phase of dementia, it is important to study the effect of these processes during midlife (or earlier in life) and evaluate the effect on cognitive performance in late-life (i.e., a life course approach).

Advances in Science and Technology to Meet Challenges

Developments have been made in the field of MRI imaging with techniques that are able to assess the cerebral vasculature with high resolution. Examples are 7T MRI that enables visualisation of the smallest cerebral vessels themselves and allows quantification of cerebrovascular reactivity, blood flow velocity and pulsatility at the level of the microvasculature. (Park et al., 2018) In addition, techniques are now available to quantify blood-brain barrier permeability (e.g., dynamic contrast-enhanced MR perfusion) (Canjels et al., 2021) and microvascular perfusion (e.g., intravoxel incoherent motion). Intravoxel incoherent motion imaging may be able to distinguish between microvascular perfusion and parenchymal diffusivity, thus providing information on tissue microcirculation and blood flow as well as tissue microstructure simultaneously. (Wong et al., 2017) Another example is the combination of ultrafast, high-resolution ultrasound and contrast agents. This technique may visualize the cerebral microvasculature at high resolution in humans, providing both both morphological and hemodynamic information (Demene et al., 2021).

However, most of these MRI imaging techniques are not suitable for large studies, because the techniques are expensive and time-consuming. Alternatively, the retina provides a unique window on the cerebral microvasculature. There are many similarities between the retina and brain vasculature, including embryological development, physiology and anatomy. (Kashani et al., 2021) Retinal imaging is non-invasive, less expensive and less time-consuming than MRI imaging.

Retinal imaging techniques that can be used to assess the microvasculature include optical coherence tomography angiography which can visualize the microvasculature in the retina; fundus photography and adaptive optics which can assess static retinal parameters (including arterial and venular

diameters, tortuosity, and fractals); and the dynamic vessel analyser which can assess dynamic retinal parameters (the vasodilation response, i.e., the increase in arterial and venular diameter upon flicker-light stimulation). (Li et al., 2020) Additionally, retinal imaging techniques can be used to assess neurodegeneration and study the early pathobiology of dementia. Optical coherence tomography can be used to assess the thickness of the retina and its individual layers, which can be used as a proxy for cerebral neurodegeneration as thinning of the retina is thought to correlate with degeneration in the brain. This also allows for investigation of the interaction between early neurodegeneration and microvasculature damage as underlying mechanisms of dementia.




Figure 18. Methods to phenotype the smallest blood vessels in the retina and brain. Retinal microvasculature may be a good proxy for cerebral microvasculature

Concluding Remarks

Vascular ageing is thought to contribute to the pathology of different types of dementia. A better understanding of how vascular factors that contribute to the development of dementia is critical for the prevention of this disease. Future research in the field should include sex disaggregated data analysis and include methods to measure gender aspects in future studies if appropriate. Moreover, focus on the interaction of arterial stiffness and microvascular dysfunction with other mechanisms underlying dementia, including neurodegeneration and inflammation, and the drivers of vascular ageing, such as diabetes, hypertension, ageing, obesity, using a lifetime approach. Novel techniques are now available that can measure microvascular function. Recent MRI techniques allow direct imaging of the smallest vessels in the brain. However, most of these techniques are not easily applied in large cohort studies. Retinal imaging may provide a non-invasive, less expensive, and less time-consuming technique for imaging of the microvasculature that can be used in large clinical trials.

References

Ainsworth S, Rhodes N. Calculation of Hill slopes predicted by the four ligand exponential model for a regulatory enzyme. *Int J Biomed Comput.* 1986;19(3-4):279-288. doi:10.1016/0020-7101(86)90070-x

- 1
2
3 BOS, D., WOLTERS, F. J., DARWEESH, S. K. L., VERNOOIJ, M. W., DE WOLF, F., IKRAM, M. A. & HOFMAN, A.
4 2018. Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of
5 population-based evidence. *Alzheimers Dement*, 14, 1482-1492.
6
7 CANJELS, L. P. W., JANSEN, J. F. A., VAN DEN KERKHOFF, M., ALERS, R. J., POSER, B. A., WIGGINS, C. J., SCHIFFER,
8 V., VAN DE VEN, V., ROUHL, R. P. W., PALM, W. M., VAN OOSTENBRUGGE, R. J., ALDENKAMP, A. P., GHOSSEIN-
9 DOHA, C., SPAANDERMAN, M. E. A. & BACKES, W. H. 2021. 7T dynamic contrast-enhanced MRI for the
10 detection of subtle blood-brain barrier leakage. *J Neuroimaging*, 31, 902-911.
11
12 DEAL, J. A., SHARRETT, A. R., ALBERT, M., BANDEEN-ROCHE, K., BURGARD, S., THOMAS, S. D., GOTTESMAN, R.
13 F., KNOPMAN, D., MOSLEY, T., KLEIN, B. & KLEIN, R. 2019. Retinal signs and risk of incident dementia in the
14 Atherosclerosis Risk in Communities study. *Alzheimers Dement*, 15, 477-486.
15
16 Demené C, Robin J, Dizeux A, et al. Transcranial ultrafast ultrasound localization microscopy of brain
17 vasculature in patients. *Nat Biomed Eng*. 2021;5(3):219-228. doi:10.1038/s41551-021-00697-x
18
19 IULITA, M. F., NORIEGA DE LA COLINA, A. & GIROUARD, H. 2018. Arterial stiffness, cognitive impairment and
20 dementia: confounding factor or real risk? *J Neurochem*, 144, 527-548.
21
22 KASHANI, A. H., ASANAD, S., CHAN, J. W., SINGER, M. B., ZHANG, J., SHARIFI, M., KHANSARI, M. M., ABDOLAH,
23 F., SHI, Y., BIFFI, A., CHUI, H. & RINGMAN, J. M. 2021. Past, present and future role of retinal imaging in
24 neurodegenerative disease. *Prog Retin Eye Res*, 83, 100938.
25
26 LI, W., SCHRAM, M. T., SORENSEN, B. M., VAN AGTMAAL, M. J. M., BERENDSCHOT, T., WEBERS, C. A. B.,
27 JANSEN, J. F. A., BACKES, W. H., GRONENSCHILD, E., SCHALKWIJK, C. G., STEHOUWER, C. D. A. & HOUBEN, A.
28 2020. Microvascular Phenotyping in the Maastricht Study: Design and Main Findings, 2010-2018. *Am J*
29 *Epidemiol*, 189, 873-884.
30
31 PARK, C. A., KANG, C. K., KIM, Y. B. & CHO, Z. H. 2018. Advances in MR angiography with 7T MRI: From
32 microvascular imaging to functional angiography. *Neuroimage*, 168, 269-278.
33
34 RENSMAN, S. P., STEHOUWER, C. D. A., VAN BOXTEL, M. P. J., HOUBEN, A., BERENDSCHOT, T., JANSEN, J. F. A.,
35 SCHALKWIJK, C. G., VERHEY, F. R. J., KROON, A. A., HENRY, R. M. A., BACKES, W. H., DAGNELIE, P. C., VAN
36 DONGEN, M., EUSSEN, S., BOSMA, H., KOHLER, S., REESINK, K. D., SCHRAM, M. T. & VAN SLOTEN, T. T. 2020.
37 Associations of Arterial Stiffness With Cognitive Performance, and the Role of Microvascular Dysfunction: The
38 Maastricht Study. *Hypertension*, 75, 1607-1614.
39
40 VASAN, R. S., PAN, S., XANTHAKIS, V., BEISER, A., LARSON, M. G., SESHADRI, S. & MITCHELL, G. F. 2022. Arterial
41 Stiffness and Long-Term Risk of Health Outcomes: The Framingham Heart Study. *Hypertension*, 79, 1045-1056.
42
43 WONG, S. M., ZHANG, C. E., VAN BUSSEL, F. C., STAALS, J., JEUKENS, C. R., HOFMAN, P. A., VAN
44 OOSTENBRUGGE, R. J., BACKES, W. H. & JANSEN, J. F. 2017. Simultaneous investigation of microvasculature
45 and parenchyma in cerebral small vessel disease using intravoxel incoherent motion imaging. *Neuroimage Clin*,
46 14, 216-221.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17. Heart failure

Authors: Thomas Weber, MD, Associate Professor, FESC (1); Siegfried Wassertheurer, Dr. (2); Stefan Orter, DI (2);

Institution: (1) Cardiology Department, Klinikum Wels-Grieskirchen, Austria; (2) Center for Health & Bioresources, Medical Signal Analysis, AIT Austrian Institute of Technology, Vienna, Austria

ORCID: 0000-0003-0617-0417

Status

Heart failure is a growing problem, due to the ageing population worldwide. The condition is associated with impaired quality of life, repeated hospitalizations (challenging already highly stressed healthcare systems) and premature death, despite impressive improvements in treatment during the last decades (McDonagh et al., 2021). Current guidelines recommend a distinction between heart failure with preserved (EF \geq 50%; HFpEF), mildly reduced (EF 41-49%; HFmrEF) and reduced (EF \leq 40%; HFrEF) ejection fraction (EF) (McDonagh et al., 2021). Although recently new treatments (e.g. SGLT2 antagonists) show benefits across the entire EF spectrum, leading some experts to a proposal to skip the EF-based classification, the bulk of medical and device-based treatments have proven benefits only in the HFrEF category. In Western-type and developed countries, arterial hypertension and coronary artery disease are the predominant causes of HF. Vascular ageing (VA) has been recently identified not only as a consequence, but also as a precursor of arterial hypertension. Moreover, disturbed pulsatile hemodynamics (arterial stiffness, central hemodynamics, wave reflections, which can be expressed as premature or early VA (Climie et al., 2023)) have been shown to be closely related to every single step in the development and progression of CAD (Kim and Weber, 2021). Therefore, VA is closely related to the two most important causes of HF, and measures of VA might be helpful for different aspects of HF management.

Current and Future Challenges

It is obvious, that HF prevention programs are urgently needed to reduce the burden of the disease. Given the evidence outlined above, programs aiming for detection of VA, followed by adequate treatment, are ideally suited for this purpose and might ultimately reduce the burden of HF.

Major gaps in evidence in HF, outlined in the latest HF Guidelines of the European Society of Cardiology (McDonagh et al., 2021), include, among others: a) better phenotyping and understanding of the pathophysiology of HFpEF, b) studies on the role of biomarkers in the diagnosis of HF and in screening of asymptomatic patients with HF, c) validated diagnostic protocols for the diagnosis of HFpEF and HfmrEF, and d) identification of novel treatments particularly for HFpEF. With respect to a) and c), in a recent scientific statement in the Journal of the American College of Cardiology (Borlaug et al., 2023), it was emphasized that the incidence and prevalence of HFpEF continue to rise in tandem with the increasing age and burdens of obesity, sedentariness, and cardiometabolic disorders. HFpEF remains under-recognized in everyday practice, and careful, pathophysiological-based phenotyping to improve patient characterization and to better individualize treatment plays a major role (Borlaug et al., 2023). Regarding b), although the role of laboratory testing for natriuretic peptides has simplified the

1
2
3 diagnosis of HF in general medicine (McDonagh et al., 2021), this test is not easily available in all
4 countries, and cannot be used for screening of asymptomatic patients.
5
6
7

8 **Advances in Science and Technology to Meet Challenges**

9
10 **1. Screening for VA:** Similar to screening projects for hypertension, low-threshold services for
11 screening for VA have been performed successfully (Danninger et al., 2019), for instance on public
12 spaces or in pharmacies. For screening, simplified measurement techniques or even estimations of
13 VA, embedded in brachial BP cuffs, may be sufficient, given that further detailed examinations will be
14 performed in case of abnormal results. The use of machine learning (ML) and artificial intelligence (AI),
15 however, may allow better VA estimations from single-site waveform recordings (Jin et al., 2021).
16
17

18 **2. Pathophysiology and phenotyping of HFpEF:** Arterial hypertension is present in the vast majority
19 (in many studies > 90%) of HFpEF patients, accompanied by increased VA (increased arterial stiffness,
20 premature/enhanced wave reflections). Due to ventriculo-arterial coupling, increased VA is closely
21 related to left ventricular late systolic afterload, ventricular remodeling, diastolic dysfunction, exercise
22 capacity, and, in the long-term, the risk of atrial fibrillation and new-onset HF (Weber and Chirinos,
23 2018). In the next step, increased wave reflections may also represent a suitable therapeutic target in
24 HFpEF (Weber and Chirinos, 2018, Weber, 2020).
25
26

27 **3. Diagnosis of HFpEF:** Reflecting the complexity of the pathophysiology of HFpEF, making the correct
28 diagnosis / exclusion is not easy, and with the use of diagnostic scores, many patients with unexplained
29 exertional dyspnea may end up in a diagnostic grey zone. At least for the HFpEF subtype with increased
30 afterload and hypertension, markers of VA and pulsatile hemodynamics (including arterial stiffness,
31 wave reflections and central pressures) may simplify the diagnostic process (Weber et al., 2013). In
32 fact, it has been shown that, based on ROC analysis, the diagnostic ability to separate HFpEF patients
33 from non-HFpEF individuals among those with unexplained exertional dyspnea, is the same for the
34 most commonly used echocardiographic parameter E/E' and for most measures of VA / pulsatile
35 hemodynamics (Weber et al., 2013). However, the optimal way to add VA information to existing
36 diagnosis scores of HFpEF is not yet known.
37
38
39

40 **4. Early diagnosis of HFrEF:** In patients with HFrEF, the weak left ventricle cannot overcome the
41 additional afterload from reflected waves, and ejection is terminated prematurely. The corresponding
42 changes in pressure waveforms can be detected with the use of non-invasive tonometry, and can
43 discriminate severely reduced from normal EF (Parragh et al., 2015) - **Figure 19**. For quantification of
44 the changes, several indices can be used, including ejection duration (ED), augmentation index (AIx;
45 derived from pulse wave analysis), and S to D ratio (SDR; derived from wave intensity analysis). In a
46 study in 50 children and adolescents, using a machine learning method based on intrinsic frequencies
47 from carotid pressure waveforms (Cheng et al., 2023), abnormal LV EF (< 50%) could be detected with
48 a accuracy of 92%. In a pilot study, using a slightly different approach, dedicated waveform features,
49 assessed with photoplethysmography and accelerometry, were used to differentiate patients with
50 heart failure from controls successfully with an area under the curve of 0.80 (Shah et al., 2020). We
51 envision a broad use, for instance by implementing discriminating algorithms into regular blood
52 pressure cuffs or wearables, which would allow wide-spread screening for HFrEF.
53
54
55
56
57
58
59
60




Figure 19. Changes in aortic waveforms in a patient with heart failure with reduced ejection fraction, from treatment initiation to the 6 month visit. Within this time period, ejection duration increased from 0.252 to 0.288 sec, Augmentation Index increased from 26.1 to 35.1, and S to D ratio increased from 1.457 to 1.761.

Concluding Remarks

We envision that assessment of VA can have an important role in the prevention and the diagnostic workup of HF. In addition, pathophysiologically-oriented treatments may play a role, given the close relationships between VA and HF.

References

- BORLAUG, B. A., SHARMA, K., SHAH, S. J. & HO, J. E. 2023. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. *J Am Coll Cardiol*, 81, 1810-1834.
- CHENG, A. L., LIU, J., BRAVO, S., MILLER, J. C. & PAHLEVAN, N. M. 2023. Screening left ventricular systolic dysfunction in children using intrinsic frequencies of carotid pressure waveforms measured by a novel smartphone-based device. *Physiol Meas*, 44.
- CLIMIE, R. E., ALASTRUEY, J., MAYER, C. C., SCHWARZ, A., LAUCYTE-CIBULSKIENE, A., VOICEHOVSKA, J., BIANCHINI, E., BRUNO, R. M., CHARLTON, P., GRILLO, A., GUALA, A., HALLAB, M., HAMETNER, B., JANKOWSKI, P., KONIGSTEN, K., LEBEDEVA, A., MOZOS, I., PUCCI, G., PUZANTIAN, H., TERENTES-PRINTZIOS, D., YETIK-

- 1
2
3 ANACAK, G., PARK, C., NILSSON, P. M. & WEBER, T. 2023. Vascular Ageing - Moving from Bench towards
4 Bedside. *Eur J Prev Cardiol*.
- 5 DANNINGER, K., HAFEZ, A., BINDER, R. K., AICHBERGER, M., HAMETNER, B., WASSERTHEURER, S. & WEBER, T.
6 2019. High prevalence of hypertension and early vascular aging: a screening program in pharmacies in Upper
7 Austria. *J Hum Hypertens*.
- 8 JIN, W., CHOWIENCZYK, P. & ALASTRUEY, J. 2021. Estimating pulse wave velocity from the radial pressure wave
9 using machine learning algorithms. *PLoS One*, 16, e0245026.
- 10 KIM, H. L. & WEBER, T. 2021. Pulsatile Hemodynamics and Coronary Artery Disease. *Korean Circ J*, 51, 881-898.
- 11 MCDONAGH, T. A., METRA, M., ADAMO, M., GARDNER, R. S., BAUMBACH, A., BOHM, M., BURRI, H., BUTLER,
12 J., CELUTKIENE, J., CHIONCEL, O., CLELAND, J. G. F., COATS, A. J. S., CRESPO-LEIRO, M. G., FARMAKIS, D.,
13 GILARD, M., HEYMANS, S., HOES, A. W., JAARSMA, T., JANKOWSKA, E. A., LAINSCAK, M., LAM, C. S. P., LYON, A.
14 R., MCMURRAY, J. J. V., MEBAZAA, A., MINDHAM, R., MUNERETTO, C., FRANCESCO PIEPOLI, M., PRICE, S.,
15 ROSANO, G. M. C., RUSCHITZKA, F., KATHRINE SKIBELUND, A. & GROUP, E. S. C. S. D. 2021. 2021 ESC Guidelines
16 for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 42, 3599-3726.
- 17 PARRAGH, S., HAMETNER, B., BACHLER, M., WEBER, T., EBER, B. & WASSERTHEURER, S. 2015. Non-invasive
18 wave reflection quantification in patients with reduced ejection fraction. *Physiol Meas*, 36, 179-90.
- 19 SHAH, A. J., ISAKADZE, N., LEVANTSEVYCH, O., VEST, A., CLIFFORD, G. & NEMAT, S. 2020. Detecting heart
20 failure using wearables: a pilot study. *Physiol Meas*, 41, 044001.
- 21 WEBER, T. 2020. The Role of Arterial Stiffness and Central Hemodynamics in Heart Failure. *Int J Heart Fail*, 2,
22 209-230.
- 23 WEBER, T. & CHIRINOS, J. A. 2018. Pulsatile arterial haemodynamics in heart failure. *Eur Heart J*, 39, 3847-
24 3854.
- 25 WEBER, T., WASSERTHEURER, S., O'ROURKE, M. F., HAIDEN, A., ZWEIKER, R., RAMMER, M., HAMETNER, B. &
26 EBER, B. 2013. Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the
27 diagnostic evaluation of suspected heart failure with preserved ejection fraction. *J Am Coll Cardiol*, 61, 1874-
28 83.
- 29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

18. Peripheral arterial disease

Author(s): John Allen^{1,2} and Gerard Stansby^{2,3}

Institution(s): ¹Research Centre for Intelligent Healthcare, Coventry University, Coventry CV1 5RW, UK; ²Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; ³Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.

ORCID(s): 0000-0002-7263-0533; 0000-0001-5539-3049

Status

Peripheral arterial disease (PAD) affecting the legs is common and a marker of widespread atherosclerosis. PAD of increasing severity progressively leads to exercise-induced pain (intermittent claudication), and if more severe potentially to rest pain, gangrene and amputation. PAD is also relevant to the field of vascular ageing since disease prevalence increases with age, with symptomatic PAD affecting about 5% of people over 55 years old. PAD is also associated with an increased risk (i.e., x6) of heart disease or stroke and is also an increasing problem in diabetics, with an increasing number of leg amputations [1]. It is, therefore, important to establish the exact diagnosis for leg pain in middle aged and older subjects, since other conditions, such as musculoskeletal or venous disease, can mimic the symptoms of PAD. Most PAD patients are initially asymptomatic and so there is also a need not just for diagnosis but also for screening. Early disease detection can allow atherosclerotic risk factors to be controlled before potentially fatal cardiovascular complications occur. Additionally, PAD assessment technologies could be also used for monitoring patients who have undergone interventions, such as bypass grafting or stenting. Patients with abdominal aortic aneurysm (AAA) also share vascular risk factors with PAD patients, the early detection and treatment of these factors and premature vascular ageing would likely reduce incidence of / increase age at development of an AAA. Standard objective PAD testing methods include blood pressure (BP) measurements (e.g., Ankle Brachial Pressure Index [ABPI], Toe Brachial Pressure Index [TBPI]) and/or Duplex Vascular Ultrasound (DVU) or imaging with contrast Computerised Tomography (CT) or Magnetic Resonance Angiography (MRA). There are also pulse techniques under development such as photoplethysmography (PPG) and impedance plethysmography (IPG). In the UK the ABPI has been recommended for primary care but is time-consuming and not all healthcare professionals have been trained in the technique. CT and MRA imaging are usually only available in hospitals and specialist clinical centres. DVU could be in principle be carried out in primary care but needs a trained operator. Recent NICE guidance recommends treatment for early-stage PAD which can be delivered by GPs, but despite the move to get care closer to home and for patients to be assessed outside of specialist centres, screening assessments for PAD are seldom carried out except in the private healthcare sector. New technologies are needed to overcome the barriers of high cost, test accessibility and risks from ionising radiation as well as enhanced care pathways to be introduced for the benefit of patients and for the healthy subjects where PAD can be quickly ruled out, ideally in primary care. With recent technological advances including Wearable Sensors and Artificial Intelligence (AI) analytics there is great scope to develop existing PAD assessment techniques to make them more accessible, to deskill the processes involved in measurement and diagnosis, and to reduce cost burden to healthcare systems globally.

Current and Future Challenges

A) Medical technology:

- BP-based measurements, e.g. ABPI, give quantitative measures for PAD diagnosis as well as gauging disease severity. Conventional manual ABPI measurement requires skill although the equipment required is relatively cheap and widely available (hand-held Doppler probe and manual sphygmomanometer). Automatic “oscillometric” pressure measurement methods are being introduced but the literature on efficacy and optimal thresholds needs establishing. There is also reduced ABPI reliability with calcified leg (e.g., in diabetes/renal disease) which can mask the presence of PAD. Instead, toe systolic BPs can be used (giving Toe Systolic Pressure Index (TSPI)) although methods/diagnostic thresholds lack standardisation.
- Duplex Vascular Ultrasound (DVU) imaging can give excellent visualisation of major peripheral arteries along with identifying raised blood velocities across a stenosis. Imaging in areas of blood vessel calcification can be suboptimal but usually a series of images and measurements are taken from which disease significance can be assessed, including degree of stenosis. Various PAD grading/reporting schemes are available, including the recent holistic system by Huthart et al [2]. A challenge would be semi-automating the image interpretation. Detection of AAA requires Imaging, most commonly with ultrasound scanning but improved resolution and greater portability of devices are needed for screening.
- Magnetic Resonance Angiography (MRA) can be used to visualise the peripheral arteries, for example to identify stenosis, occlusion or aneurysm [3]. Approaches tend to be classified as flow-dependent (e.g., ‘phase contrast’) and flow-independent. The most frequently applied MRA methods have involved the use of intravenous contrast enhancing agents, particularly those containing Gadolinium. MRA requires significant skill to interpret / report but semi-automation of the process could support a practitioner.
- Computerised Tomography Angiography (CTA) is an X-Ray tomography technique to image the blood vessels [3]. It was initially limited by the use of single slice scanners that image a specific section of the arterial tree at a time but with the advent of multidetector row (e.g., 64-detectors) there is wider scope with contrast material injection to obtain the information in a single acquisition. The smaller distal arteries can be visualized. There are challenges in imaging blood vessels with dense calcification as this can have high attenuation of the X-rays leading to over-estimation of stenosis. Amongst potential side effects including radiation exposure, CT contrast is potentially nephrotoxic and is relatively contraindicated in those with poor renal function and additionally image quality can be poor in the presence of vessel calcification/metallic implant.
- Plethysmography techniques have shown promise for PAD detection. Photoplethysmography (PPG) is an apparently simple optical technique which shines light onto tissue and measures the pulsatile reflected light with each heartbeat. Research has shown that the toe PPG pulse usually becomes damped and delayed with the development of progressive PAD [4,5] (**Figure 20**). There is also impedance plethysmography (IPG) which uses a high frequency alternating current stimulus applied to electrodes on the study limb alongside a set of receiving electrodes to measure impedance change with each heart beat [6]. There are opportunities for PPG (and IPG) but currently there is little standardisation in methods and technology applied. PPG (and IPG) have considerable advantages, i.e. low-cost, ease-of-use needing only minimal training, portability (wearables capability) and the signals offer composite macro- and micro-vascular

information. The PPG waveform, however, is not fully understood and there are challenges with its interpretation and classification. PPG measurements can be prone to high levels of artefact, e.g. from sensor – tissue movement artefact or in patients with tremor.

- Techniques to assess tissue perfusion and its impairment with PAD [7], include transcutaneous partial pressure of oxygen (tcPO₂) using an electro-chemical sensor ('Clark-electrode') method or optically using a fluorescence sensing method; spectrophotometry-based methods that can assess the tissue oxygen saturation to very low levels for example by measuring the shape of the visible light absorption spectra in the green region of the spectrum. There are protocol issues for these techniques, for example the optical techniques can be impacted by the degree of melanin in tissue, and diagnostic thresholds can be device (manufacturer) specific.
- As well as the above medical device technologies there are also blood biomarker testing and genetic screening opportunities for identifying those likely to have PAD and/or cardiovascular risk [8]. Giving great scope for personalised medicine although with implementation challenges, e.g. ethical considerations and the taking of blood samples and their storage.

Bilateral great toe pulse analysis: PAD in 1 leg only



Figure 20. PPG has potential as an accessible, low-cost and fast method of PAD detection. The toe PPG trace for the leg with PAD is clearly damped and delayed compared to the leg that has normal arteries.

B) How best to identify undiagnosed PAD:

PAD is a marker for more generalised atherosclerosis. PAD prevalence generally increases with age (e.g., in UK estimated at 20% at age 65 years, with about a third of these being symptomatic) [9]. In PAD it is important to note that a 50% or greater stenosis in the peripheral arteries would be regarded as diagnostically important, i.e. as a marker of vascular risk, but probably a stenosis has to reach 70-80% to become haemodynamically significant and cause significant symptoms [10]. Also, that many older patients do not walk sufficiently to provoke claudication. As such the "pressure" based techniques such as ABPI may be less "accurate" in diagnosing the asymptomatic cohort.

1
2
3 Routine PAD screening is not usually performed in the NHS or most developed countries and people
4 do not tend to go to their doctors unless they are significantly symptomatic, leaving many older people
5 undiagnosed. There are many challenges, however, to offering routine PAD screening, including an
6 appropriate assessment technology and the resources including suitably skilled staff to deliver this.
7 Diagnostic thresholds would need to be established and careful targeting would also be undertaken
8 to reduce the risk and health care costs and unnecessary patient anxiety of an excessive false positive
9 rate and follow-on in the wider care pathway. There are approaches to identifying undiagnosed PAD
10 that could be considered such as opportunistic screening and the use of new technologies such as
11 Wearable Sensing and AI analytics.
12
13
14
15

16 **C) Translation of new PAD technologies and techniques into clinical practice:**

17
18 With clinical validation of the device/technique sufficient studies, including prospective assessments,
19 are needed through the formal pathway and ultimately undertaking a Health Technology and
20 Innovation (HTI) assessment that covers test efficacy, safety and health economics. The costs and cost
21 effectiveness of PAD diagnostics will have to be demonstrated to justify use of and investment in new
22 diagnostic technologies. There is, however, no perfect reference test for determining
23 haemodynamically significant PAD, and the ones established in the literature do not always agree as
24 they measure different aspects of the peripheral blood flow, e.g., ABPI pressures vs DVU imaging.
25 Furthermore, there is no standard reference test stipulated for formal diagnostic test accuracy studies
26 and usually there is no reference standard for the reporting of test results.
27
28
29

30 Medical device development also now includes proving safety testing and designing with usability in
31 mind. Incorporation of co-creation techniques is essential for these aspects, including all relevant
32 stakeholders in the design process. Knowing what the clinical practitioner requires for a PAD test is
33 very important. Devices should ideally be developed for an appropriate level of automation and
34 minimal training requirements and to be suitable for use by a wide range of clinical staff in both
35 primary and secondary care. Furthermore, denoising of physiological data, i.e. signals and/or images
36 and minimising false positives and negatives is important for real-world device solutions.
37
38
39
40
41

42 **Advances in Science and Technology to Meet Challenges**

43 **A) Medical technology:**

- 44 ● BP-based measurements, e.g., the ABPI. Automated “oscillometric” methods are being
45 introduced and using parallel inflated limb cuffs which can make a rapid ABPI assessment. An
46 automated approach should also help reduce subjectivity (“operator independent”) in
47 measurements. The system would apply a threshold test which indicates PAD based on the
48 evidence base generated from earlier clinical trials. The problem of rigid leg arteries will likely
49 remain a challenge with pressure-based measurement systems although there is potentially
50 scope for an AI-analytics approach to consider the morphology of the oscillometric pulse
51 waveforms to detect and compensate for calcified blood vessels. ABPI type assessment
52 utilising toe blood pressures is also now possible.
53
54 ● Imaging. DVU: Scope to semi-automate the image interpretation, including AI analytics to
55 support the practitioner for PAD as well as AAA assessments. MRA: There have been many
56
57
58
59
60

advances in acquisition speed, processing techniques and high-field MR systems such as 7 T field strength. Images, however, require significant skill to interpret and report, but as with DVU there are technological opportunities with AI for supporting this role.

- CTA: There have been advances in post-processing techniques including 3-D reconstruction. Dual-energy CTA post-processing to subtract voxels containing calcium in the vessel wall is a promising technique for evaluation of calcified vessels. Images require significant skill to interpret and report, there are technological opportunities with AI for this role.
- PPG continues to show promise for PAD assessment. There are still unknowns about what the technique actually measures but the pattern of pulse damping and delay in the majority of cases of significant disease has been shown in multi-site PPG studies for hospital and primary care settings. Its ease of use, low cost and portability are enablers for the technology to assess vascular disease (e.g., <https://www.isrctn.com/ISRCTN13301188>). PPG has the advantage of miniaturisation using advanced microelectronics and sensors, with new multi-site systems being developed for cardiovascular assessments, including for PAD [11] (**Figure 21**) and vascular ageing [12]. Advances continue in analytics include signal denoising, cardiovascular modelling and data synthesis, arrhythmia detection, AI-classification of diseases including PAD with the potential power of explainable AI, new insights into vascular ageing, and the novel communication of disease [5]. There is scope for further innovation and for bespoke devices for use in primary care to bring care closer to the patient [13]. Bespoke wearable PPG sensing offers accessible testing and with advanced analytics in the cloud that are possible. With IPG there is also great scope here for PAD testing and incorporating analytic approaches similar to PPG, IPG however has the potential advantage compared to optical techniques of not being influenced by the amount of melanin in skin ('skin tone'). PPG and IPG could be combined.




Figure 21. Example of a prototype PAD assessment device development offering a low-cost and easy-to-do PAD test for primary care and which is based on the optical pulse technique of photoplethysmography (PPG). The multi-site PPG system concept, PPG probes and main

processing unit are shown [11]. There is great scope for the miniaturisation of such technology. Figure from our published paper by Stansby et al. *Angiology* <https://doi.org/10.1177/00033197221121614> [11]. Copyright © 2022. Reprinted by Permission of SAGE Publications.

B) How best to identify undiagnosed PAD:

There are new digital health technologies for opportunistic screening e.g., accelerometer and walking patterns revealing abnormal gait linked to intermittent claudication. These could also be tailored to better inform the public in vascular diseases including PAD, and to improve lifestyles including diet, smoking and exercise. Diabetic patients, who are at growing risk for lower limb amputation, need accessible PAD screening in the care pathway. There is also self-testing (e.g., using a mobile phone with PPG sensor to take a pulse recording for analysis). Improved analytics with de-noising will be needed for a host of ambulatory assessments. There can be the secondary analysis of MRI / CT scans which were obtained for other purposes. Genetics / blood marker testing has a future role as one of a number of novel approaches to help ensure that those at greatest PAD risk can receive appropriate health checks. A further important consideration is for the screening for PAD in countries having strongly resource-constrained settings, noting that a single type of PAD assessment technology may not suit all settings worldwide. It is also vital that the signal / image algorithms are developed and tested for a range of clinical settings (e.g., hospital vascular setting vs. primary care). It is possible that different PPG features best suit specific settings / disease prevalence.

C) Translation of new technologies and techniques into clinical practice:

There are many challenges along the innovation pathway from an initial idea for a PAD assessment technology to clinical validation and introduction into a care pathway. Many facets of research should be undertaken including device design through co-creation with all key stakeholders, full compliance with medical device regulations (area covered elsewhere in Roadmap), clinical validation (qualitative and quantitative research), safety, robustness to artefact, device usability, health economics, and commissioning research to align although potentially reconfigure a care pathway. As well as efficacy the costs and cost effectiveness need to be demonstrated to justify the use of and investment in new diagnostic technologies. An international perspective should also be considered, for example applicability to lower-income countries and the requirements for technologies to be used in resource-constrained settings, including a consideration of the resources needed to treat such patients.

Concluding Remarks

The clinical need for the timely and accessible detection of PAD has been highlighted. There are some clear limitations with the current technologies for initial patient assessments, as many are hospital based and require highly skilled staff to assess and report the test. There are though newer technologies coming through plethysmography techniques, particularly PPG and IPG, show promise for accessible and low-cost first stage PAD assessments – these can be implemented in digital healthcare devices and utilise miniaturised sensors including wearables and advanced analytics including AI and Cloud-based approaches. PPG has already been explored for the assessment of general vascular ageing. There is work across the board to do though and many challenges with the introduction of new technologies into existing / new care pathways.

References

- [1] Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. *Nat Rev Cardiol.* 2017;14(3):156-170. <https://doi.org/10.1038/nrcardio.2016.179>. Epub 2016 Nov 17. PMID: 27853158.
- [2] Huthart S, Oates C, Allen J, Fiaschi K, Sims AJ, Stansby G. Validation of a standardised duplex ultrasound system for the reporting and grading of peripheral arterial disease. *European J Vasc Endovasc Surg* 2022. <https://doi.org/10.1016/j.ejvs.2022.04.013>
- [3] Leiner T, Carr JC. Noninvasive Angiography of Peripheral Arteries. 2019 Feb 20. In: Hodler J, Kubik-Huch RA, von Schulthess GK (eds). *Diseases of the Chest, Breast, Heart and Vessels 2019-2022: Diagnostic and Interventional Imaging* [Internet]. Cham (CH): Springer; 2019. Chapter 20.
- [4] Allen J. Photoplethysmography and its application in clinical physiological measurement. *Physiol Meas* 2007;28:R1-39.
- [5] *Photoplethysmography: Technology, Signal Analysis & Applications*. Kyriacou PA & Allen J (eds). Elsevier.
- [6] Haapala M, Lyytikäinen L-P, Peltokangas M, et al. Impedance plethysmography-based method in the assessment of subclinical atherosclerosis. *Atherosclerosis* 2021;319:101-107. <https://doi:10.1016/j.atherosclerosis.2021.01.006>
- [7] Ma KF, Kleiss SF, Schuurmann RCL, Nijboer TS, El Moumni M, Bokkers RPH, de Vries J-P PM. Laser Doppler flowmetry combined with spectroscopy to determine peripheral tissue perfusion and oxygen saturation: A pilot study in healthy volunteers and patients with peripheral arterial disease. *J Pers Med* 2022;12(6):853-867. <https://doi.org/10.3390/jpm12060853>
- [8] Klarin D, Tsao PS, Damrauer SM. Genetic determinants of peripheral artery disease. *Circ Res* 2021;128(12):1805-1817. <https://doi:10.1161/CIRCRESAHA.121.318327> Epub 2021 Jun 10.
- [9] Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res.* 2015 Apr 24;116(9):1509-26.
- [10] Udoff EJ, Barth KH, Harrington DP, Kaufman SL, White RI. Hemodynamic significance of iliac artery stenosis: pressure measurements during angiography. *Radiology.* 1979;132(2):289-93.
- [11] Stansby G, Sims A, Wilson L, Beale T, Wightman J, Guri I, Wilkes S, Haining S, Allen J. Prospective assessment of the diagnostic accuracy of multi-site photoplethysmography pulse measurements for diagnosis of peripheral artery disease in primary care. *Angiol* 2022 <https://doi.org/10.1177/00033197221121614>
- [12] Charlton PH, Paliakaite B, Pilt K, Bachler M, Zanelli S, Kulin D M, Bianchini E, Mayer CC, Terentes-Printzios D, Dittrich V, Hametner B, Veerasingam D, Zikic D, Marozas V. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular age: A review from VascAgeNet. *AJP – Heart & Circ Physiol* 2022;322(4):H493-H522
- [13] Allen J, Hedley S. Simple photoplethysmography pulse encoding technique for communicating the detection of peripheral arterial disease – a proof of concept study. *Physiol Meas* 2019;40 08NT01. <https://doi.org/10.1088/1361-6579/ab3545>

19. Challenges in vascular ageing and atrial fibrillation

Author(s): Giacomo Pucci^{1,2}, Andrea Grillo³, Davide Agnoletti^{4,5}

Institution(s): ¹ Department of Medicine and Surgery, University of Perugia, Perugia, Italy; ² Unit of Internal Medicine, "Santa Maria" Terni Hospital, Terni, Italy; ³ Department of Medical, Surgical and Health Sciences, University of Trieste, Italy; ⁴ Department of Medical and Surgical Sciences, University of Bologna, Italy; ⁵ IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Bologna, Italy.

ORCID(s): 0000-0003-0180-859X; 0000-0002-4455-4991; 0000-0001-8108-7133

Status

The worldwide incidence and prevalence of atrial fibrillation (AF) are increasing, and AF is the most common cardiac arrhythmia. The prevalence of AF increased 3-fold over the last 50 years, and its burden on global cumulative mortality showed an 81% relative increase during the past 20 years (Lippi G et al, 2021). The exacerbation of AF prevalence is associated with an increasing prevalence of AF risk factors, such as advancing age, hypertension, obesity, diabetes, heart failure, ischemic heart disease and kidney disease.

From a pathophysiological point of view, AF could be conceived as the result of an accelerated vascular ageing. When a subject is exposed to progressive stiffening of the arterial tree, for any reason, the central pulse pressure rises together with the left ventricular afterload. This eventually leads to atrial remodelling and exposes the subject to an increased risk of AF. It follows that worsening of arterial stiffness may precede AF development (Cremer et al 2015). Therefore, it seems worth noting that identifying subjects with accelerated vascular ageing could enable a stricter follow up strategy, in order to detect AF early. Besides, increased arterial stiffness, as a marker of vascular ageing, and AF show similar risk factors such as hypertension, diabetes, coronary heart disease, or kidney disease. This is also witnessed by the evidence that increased arterial stiffness is more frequently observed in patients with than without AF (Pauklin et al 2021).

The development of new algorithms for rhythm monitoring contributed to the implementation of AF detection by the new smart portable devices (e.g. smartphones and wearables), increasing the chance of opportunistic AF detection (Perez et al 2019). Prompt diagnosis of AF is pivotal to initiate the therapeutic management and reduce the global AF burden. Besides, the availability of tools for early identification of individuals at high risk of developing AF will lead to more appropriate screening programs in the general population and to preventive campaigns targeted to selected individuals.

Ideally, the simultaneous assessment of blood pressure, arterial stiffness and AF by a single device would be of extreme usefulness in clinical practice, and at the same time is a challenge from a theoretical and practical point of view.




Figure 22. Schematic representation of an “ideal” device allowing simultaneous and integrated measurement of blood pressure, vascular ageing and AF screening, and potential areas of application into devices currently used for clinical (left) or out-of-office (right) evaluation based on the analysis of biological signals recorded during activities of daily living.

Current and Future Challenges

Given the close relationship between AF and vascular ageing, the implementation of algorithms for AF detection into devices that measure vascular ageing is a desirable goal. Increasing the screening rate of the arrhythmia may potentially reduce the disease burden and be cost-effective, especially in elderly individuals with hypertension and other risk factors. Nevertheless, the large number of devices purporting to measure vascular ageing does not permit a single strategy to diagnose AF.

The preferred screening approach may be by devices offering a high-quality ECG trace integrated in their equipment (some arterial tonometry, echocardiography, ultrasound of carotid arteries, cardiac magnetic resonance imaging [MRI]). The automated detection of AF from single-lead ECG is currently based on proprietary algorithms which identify the absence of P waves and RR irregularity, and marketed on wearable or handheld AF screening devices (**Figure 22**).

Devices using oscillometric techniques may also contribute to AF screening. Blood pressure monitors which detect AF from oscillometry-based algorithms have been in the market for a few years, with very high sensitivity and specificity rates, ranging from 90 to 100% (Park SH 2019). The algorithm for diagnosis, based on pulse irregularity, could be implemented in devices measuring central blood pressure or pulse wave velocity from oscillometric cuffs.

Ambulatory blood pressure monitor (ABPM) devices, traditionally used in clinical practice to evaluate the BP behaviour over the 24-h period and under dynamic conditions, are particularly promising on this purpose. Some marketed devices already combine measurement of arterial stiffness parameters, such as pulse wave velocity and central BP, with peripheral BP measurement over 24 hours

1
2
3 (Papaioannou et al 2013). Other ambulatory BP monitors have been equipped with algorithms for
4 automated AF detection during each automated oscillometric BP measurement (Kollias A et al 2018).
5
6 Even if the choice of implementing ABPM with vascular ageing measures could be questionable for a
7 large-scale application, due to its intrinsic tolerability issues, its added value in terms of accuracy and
8 circadian assessment is not negligible. By contrast, technologies based on smartwatches/smartphone
9 applications, while undoubtedly more tolerated and widely available, lack accuracy in vascular
10 assessment.
11

12 Combining these technologies into a single device could not only prolong the window of AF detection
13 over the 24-hour period, but also enable simultaneous measurement of blood pressure and arterial
14 stiffness, together with AF detection, during conditions known to increase the risk of paroxysmal AF,
15 such as stressful periods, with the potential to unveil novel pathophysiological mechanisms.
16
17

18 All these three clinical conditions are frequently undiagnosed even for very long periods because of
19 their asymptotic behaviour. According to the WHO, an estimated 46% of adults with hypertension are
20 unaware that they have the condition, and undiagnosed AF accounts for 20% of all AF episodes and
21 for 3-6% of all ischemic strokes (Liao J et al 2017).
22
23
24
25

26 **Advances in Science and Technology to Meet Challenges**

27 Any chance to screen for the presence of elevated BP, AF and accelerated vascular ageing should be
28 regarded as an opportunity to identify individuals at very high CV risk. The possibility of detecting AF
29 from photoplethysmography techniques is very appealing and largely tested on a variety of wearable
30 devices, ranging from smartwatches, fingertips and smartphones (Pereira T et al 2020). Advances are
31 warranted in improving the accuracy of testing. Machine and deep learning algorithms may offer the
32 possibility of reaching a clinical grade reliability of screening for these tools, which may be also
33 included in vascular ageing measurement devices based on photoplethysmography.
34
35
36

37 AF detection, either interpreted by the physician or automatically performed by an algorithm, could
38 become of routine use, although specific medical recommendations are lacking for implementing
39 detection of AF in devices not designed for this purpose. The detection rate of asymptomatic or
40 symptomatic AF could be improved both in the general and in the high-risk population if appropriate
41 algorithms are implemented on vascular ageing measurement devices.
42
43

44 Another major scientific issue, which is not adequately answered by current literature, is the accuracy
45 of vascular ageing measures in patients with established AF. Indeed, the irregularity of heart rate could
46 influence the measurement of vascular ageing indices. This would depend on both the technique used
47 and the baseline hemodynamic status. Tonometric PWV and doppler based techniques seem to be
48 unaffected by heart rate irregularity (Halfon et al 2018). BP oscillometric devices are suitable for BP
49 measurement in AF at least in presence of normal ventricular rate ranges, while the use of oscillometry
50 may be flawed in AF for measurement of certain indices, such as ankle-brachial index (Dąbrowski et al
51 2021). Further research is needed, considering the high prevalence of this arrhythmia in the
52 population tested with these devices, for both establishing the reliability of each vascular ageing
53 measurement tool and improving the signal quality with pulse irregularity, in order to provide a clear
54 recommendation for the clinical use.
55
56
57

58 A long-time perspective for vascular ageing assessment is the development of a device that reliably
59 measures blood pressure, vascular ageing and detects AF at the same time. To date, however, there
60

1
2
3 is no device available on the market combining all these technologies into a single device, and this
4 remains an unmet need.
5

6 Oscillometry and photoplethysmography are considered the most promising techniques in this regard
7 as they may be able to expand the opportunities to assess arterial stiffness and blood pressure levels
8 under dynamic conditions, such as by wearing a photoplethysmography-based device or an
9 oscillometric ABPM. This might increase the chance to evaluate which parameter of arterial stiffness
10 would better predict clinically relevant outcomes over the short and long term. However, the ability
11 to accurately measure blood pressure with photoplethysmography-based cuffless devices has been
12 questioned and their use should be discouraged until further data and developments become
13 available (Mukkamala et al 2023).
14

15
16 These and other challenges await developing technologies on devices allowing simultaneous
17 multiparametric assessment of CV health markers.
18
19
20
21

22 **Concluding Remarks**

23 AF, elevated blood pressure and accelerated vascular ageing, from a pathophysiological and clinical
24 perspective, are strongly linked to each other. Given that a considerable proportion of patients are
25 undiagnosed, further technological developments could help increase the screening and detection
26 rate of these conditions. Screening technologies need to be accurate enough to reduce the risks of
27 overdiagnosis and overtreatment, and accessible enough to be applied to high-risk populations
28 without added risks and costs. Which is the most effective screening approach, and which could be
29 the potential outcome from combining different screening approaches into one single device, are two
30 important questions that should be answered in the future.
31
32
33
34
35
36

37 **Acknowledgment**

38 This work was supported by COST Action CA18216 VascAgeNet, supported by COST (European
39 Cooperation in Science and Technology, www.cost.eu).
40
41
42

43 **References**

- 44 Cremer, A., Lainé, M., Papaioannou, G., Yeim, S., and Gosse P. (2015) 'Increased arterial stiffness is an
45 independent predictor of atrial fibrillation in hypertensive patients'. *Journal of Hypertension*, 33, pp. 2150-
46 2105
47
48 Dąbrowski, M., Lewandowski, J., Szmigielski, C., and Siński, M. (2021) 'Atrial fibrillation influences automatic
49 oscillometric ankle-brachial index measurement'. *Archives of Medical Science*, 17, pp. 621-627
50
51 Halfon, M., Wuerzner, G., Marques-Vidal, P., Taffe, P., Vaucher, J., Waeber, B., Liaudet, L., Ltaief, Z., Popov, M.,
52 and Waeber, G. (2018) 'Use of oscillometric devices in atrial fibrillation: a comparison of three devices and
53 invasive blood pressure measurement. *Blood Pressure*, 27, pp. 48-55
54 Kollias, A., Destounis, A., Kalogeropoulos, P., Kyriakoulis, K.G., Ntineri, A., and Stergiou GS. (2018) 'Atrial Fibrillation Detection During 24-Hour
55 Ambulatory Blood Pressure Monitoring: Comparison With 24-Hour Electrocardiography'. *Hypertension*, 72, pp.
56 110-115
57
58 Liao, J., Khalid, Z., Scallan, C., Morillo, C., and O'Donnell, M. (2007) 'Noninvasive cardiac monitoring for
59 detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review'. *Stroke*, 38,
60 pp. 2935-2940

1
2
3 Lippi, G., Sanchis-Gomar, F., and Cervellin, G. (2021) 'Global epidemiology of atrial fibrillation: An increasing
4 epidemic and public health challenge'. *International journal of stroke: official journal of the International*
5 *Stroke Society*, 16, pp. 217-221

6 Mukkamala, R., Shroff, S.G., Landry, C., Kyriakoulis, K.G., Avolio, A.P., and Stergiou G.S. (2023) 'The Microsoft
7 Research Aurora Project: Important Findings on Cuffless Blood Pressure Measurement'. *Hypertension*, 80, pp.
8 534-540

9
10 Papaioannou, T.G., Argyris, A., Protogerou, A.D., Vrachatis, D., Nasothimiou, E.G., Sfikakis, P.P., Stergiou, G.S.,
11 and Stefanadis C.I. (2013) 'Non-invasive 24 hour ambulatory monitoring of aortic wave reflection and arterial
12 stiffness by a novel oscillometric device: the first feasibility and reproducibility study'. *International journal of*
13 *cardiology*, 169, pp. 57-61

14
15 Park, S.H., June, K.J., and Choi, Y.K. (2019) 'Predictive validity of automated oscillometric blood pressure
16 monitors for screening atrial fibrillation: a systematic review and meta-analysis'. *Expert Review of Medical*
17 *Devices*, 16, pp. 503-514

18
19 Pauklin, P., Eha, J., Tootsi, K., Kolk, R., Paju, R., Kals, M., and Kampus, P. (2021) 'Atrial fibrillation is associated
20 with increased central blood pressure and arterial stiffness'. *Journal of Clinical Hypertension (Greenwich)*, 23,
21 pp. 1581-1587

22
23 Pereira, T., Tran, N., Gadhoumi, K., Pelter, M.M., Do, D.H., Lee, R.J., Colorado, R., Meisel, K., and Hu, X. (2020)
24 'Photoplethysmography based atrial fibrillation detection: a review'. *NPJ Digital Medicine*, 3, p. 3.

25
26 Perez, M.V., Mahaffey, K.W., Hedlin, H., Rumsfeld, J.S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A.M.,
27 Rajmane, A., Cheung, L., Hung, G., Lee, J., Kowey, P., Talati, N., Nag, D., Gummidipundi, S.E., Beatty, A., Hills,
28 M.T., Desai, S., Granger, C.B., Desai, M., and Turakhia, M.P.; Apple Heart Study Investigators. (2019) 'Large-
29 Scale Assessment of a Smartwatch to Identify Atrial Fibrillation'. *The New England Journal of Medicine*, 381,
30 pp. 1909-1917.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Accepted Manuscript

FUTURE RESEARCH DIRECTIONS

20. Young people

Author(s): Rachel E Climie¹, Vimarsha Kodithuwakku¹

Institution(s): ¹Menzies Institute for Medical Research, University of Tasmania

ORCID(s): 0000-0002-7960-360X; 0000-0002-0657-3251

Status

Although overt cardiovascular disease (CVD) may not appear until later in life, the risk factors for CVD begin to develop in early life. Importantly, recently published findings now demonstrate a direct association between childhood cardiovascular risk factors and adult cardiovascular events and mortality (1). This is significant given the high prevalence of childhood cardiovascular risk factors globally. For example, in 2016, approximately 81% of adolescents worldwide (aged 11-17 years, 85% of girls, 78% of boys) were not meeting physical activity recommendations (60 minutes of moderate to vigorous intensity physical activity per day) (2). Childhood obesity has become overwhelmingly challenging, with simulated growth trajectories predicting 57% of today's children will be obese by the time they are aged 35 years (3) and likely as a consequence, global rates of hypertension in children and adolescents have increased by 75% from 2000 to 2015 (4).

Exposure to cardiovascular risk factors as early as during fetal life, promotes the development and accumulation of subclinical vascular changes that direct an individual towards a trajectory of early vascular ageing (EVA) (5). Indeed, the atherosclerotic process begins in early life, with an accumulation of lipid in the intima of arteries (fatty streaks) observed in most children. Postmortem studies show that this phenomenon is accelerated in the presence of traditional cardiovascular risk factors (6). The arteriosclerosis process also commences at a young age and is influenced by risk factors such as obesity, blood pressure and young onset type 2 diabetes. Importantly, EVA in early life is associated with subclinical disease in adulthood. Ample evidence shows that elevated blood pressure in young people (children and adolescents) is associated with cardiovascular adaptations both cross-sectionally (7) and longitudinally (8). Children with stiff arteries (>95th percentile) have accompanying increased left ventricular mass (9) and reduced left ventricular function (10), compared to children with more favorable stiffness measures. In childhood, increased IMT is associated with increased left ventricular mass (11) and poorer cardiac function (10). Furthermore, central blood pressure appears to be more tightly associated with cardiovascular dysfunction than brachial blood pressure in young people (12). Thus, given the aforementioned worsening of health in young people globally, it is likely that increasing numbers of children and adolescents will display EVA, compared to their healthy age and sex matched counterparts, putting them at increased risk of CVD later in life. Characterising vascular ageing from youth may, therefore, provide a window into cardiovascular risk later in life (5). While there are several methods that could be used to assess vascular age in young people, there are limitations to these, as summarised below. There are also a number of research challenges that need to be addressed.

Current and Future Challenges

Before vascular age can be routinely measured in clinical practice in young people, a number of research questions need to be answered. Firstly, there is a lack of consensus in general in terms of how to define EVA and this also applies to young people, where growth and development also need to be considered. Secondly, to accommodate the perfusion needs of the developing body, vascular wall and lumen dimensions change as the child grows. However, it is currently unknown what is “normal”, or healthy, vascular ageing (i.e., development of the vasculature) and what is pathological, or how this differs between boys and girls, as reference values for vascular ageing in young people are currently not available. Thirdly, although it appears that EVA in early life is associated with subclinical outcomes, more data with longer term follow up is required. In line with this, it is unclear how different markers of vascular age are differently associated with cardiometabolic risk factors in young people as no direct head-to-head comparison has been performed. Furthermore, there are inconsistencies in studies examining the impact of intervening on vascular age in young people, due to differences in the types and lengths of interventions, methodologies employed to quantify the intervention, the vascular ageing biomarker examined or the health and age of the study population. Finally, there appears to be a lack of awareness regarding the potential benefit of measuring vascular age in pediatric populations among clinicians, however, this still needs to be definitively confirmed. Taken together, it remains unclear which vascular ageing biomarker/s should be the focus for technological advances. In **Table 2** we summarise the most common techniques for measuring vascular ageing biomarkers in clinical practice and their advantages and challenges related to use in young people.

Table 2. Techniques for measuring vascular ageing biomarkers in clinical practice and their advantages and challenges related to use in young people.

Technique	Method of measurement	Insights provided on vascular ageing	Current use in young people	Advantages of measuring in young people	Challenges to measuring in young people
Intima media thickness (IMT)	Ultrasound (B mode or radio-frequency ultrasound)	Large artery structure (Measured manually, semi-automatic or automatic)	Widely used in clinical settings for adults Frequently used for research purposes in both adults and young people	<ul style="list-style-type: none"> • Non-invasive 	<ul style="list-style-type: none"> • Values may differ due to different ultrasound settings, the intima media edge detection algorithms, and off-line reading systems (13) • Require technique-specific reference intervals
Carotid to femoral pulse wave velocity (PWV)	Oscillometric technique	Arterial stiffness	Frequently used in research settings	<ul style="list-style-type: none"> • Non-invasive • Validated in children and 	<ul style="list-style-type: none"> • Time consuming • Standardisation between different

	Piezo-electric method			adolescent (14)	<p>techniques and devices required in order to compare values</p> <ul style="list-style-type: none"> • Require technique-specific reference intervals • Tolerability in young people
Distensibility and stiffness index	MRI/ultrasound + Oscillometric method (BP)	Arterial stiffness at a single vascular site (e.g., carotid artery)	<p>Mostly used for research purpose</p> <p>Not commonly used in clinical settings</p>	<ul style="list-style-type: none"> • Non-invasive 	<ul style="list-style-type: none"> • Requires a local pressure measurement for the calculation and this can be influenced by human error and appropriateness of the cuff

Central Blood Pressure	Direct intra-arterial measurement - Invasive technique (Intra-arterial catheters)	Blood pressure, waveform	In surgical procedures and intensive care Not commonly measured in children	<ul style="list-style-type: none"> • Constant monitoring of blood pressure in hemodynamically unstable patients • Waveform graph can be obtained • High accuracy of the blood pressure measurement 	<ul style="list-style-type: none"> • Invasive • Time consuming
	Cuff-Based Device	Blood pressure, waveform	Commonly used in clinical and research settings	<ul style="list-style-type: none"> • Non-invasive • Waveform graph can be obtained 	<ul style="list-style-type: none"> • Measurements can be impacted by the difficulty of finding appropriately sized cuffs for young people

Peripheral Blood Pressure	Korotkoff sound method (manual) Oscillometric method (automatic)	Surrogate of ventricular afterload	Most widely used in clinical and research settings	<ul style="list-style-type: none"> • Non-invasive 	<ul style="list-style-type: none"> • Less precise due to the difficulty of finding appropriately sized cuffs for young people • High observer bias if using manual method • White coat effect is frequent among children (15).
Augmentation index and reflection magnitude	Applanation tonometry Automated oscillometry	Arterial function (quantifies wave reflection)	Used in both clinical and research settings	<ul style="list-style-type: none"> • Non-invasive 	<ul style="list-style-type: none"> • Low agreement and consistency between the different devices • Central augmentation index and reflection magnitude may be poorly estimated by brachial oscillometric

					devices in young people (16).
Flow Mediated Dilation	Ultrasound (High-resolution B-mode)	Endothelium-dependent vasodilatory reserve of muscular conduit arteries	Used in both clinical and research settings	<ul style="list-style-type: none"> • Non-invasive • Specific reference intervals are available for children. 	<ul style="list-style-type: none"> • Influenced by cuff placement
Reactive hyperemia-peripheral arterial tonometry (RH-PAT - digital)	Plethysmographic technique - EndoPAT device	Endothelium-dependent vasodilatory reserve of peripheral arterial bed	Not commonly used in either clinical or research settings	<ul style="list-style-type: none"> • Non-invasive 	<ul style="list-style-type: none"> • Difficult to perform in young people due to discomfort due to upper arm compression • No specific devices for young people

3500 **Advances in Science and Technology to Meet Challenges**

3501 There are a number of advances in technology that may aid in the routine measurement of vascular
3502 age in young people. Firstly, the development of a tool or device that is efficient, user friendly,
3503 tolerable by young people, validated, cost effective and proven to be associated with outcomes
3504 (cardiometabolic risk, subclinical CVD) would significantly advance the use. One of the key factors to
3505 consider in development of such a tool is the growth and development of the child. For example,
3506 consideration of how to account for children of different heights, heart rates and pubertal status which
3507 may influence the vascular age value. It is also important to minimise any operator interference
3508 required to improve precision and accuracy. As an example, many ultrasound systems now include an
3509 automated analysis package to ascertain vascular ageing measurements such as carotid IMT. These
3510 automated systems have proven efficiency over manual measuring techniques. However, reliability of
3511 these measurements, specifically related to young people, has not been widely explored and would
3512 be of value for the advancement of such technology (17).

3513 Photoplethysmography-based devices are an advanced technique that could be considered as a more
3514 convenient approach to assess vascular ageing but are not widely used to measure vascular ageing
3515 among children. Even though this technique is used in RH-PAT, it can be uncomfortable for young
3516 people (18). However, photoplethysmography could potentially be developed and adopted as a
3517 convenient modality such as mobile apps/smart phones/ children-friendly/ portable devices to assess
3518 vascular ageing. Furthermore, machine learning methods have been a significant advancement in
3519 science and technology which may be applied to the measurement of vascular ageing in young people
3520 (19). Machine learning techniques are now being developed to assess other vascular ageing
3521 measurements such as PWV in routine care (19). These techniques could be further developed and
3522 validated in young people, to facilitate regular use in clinical settings and for research purposes.

3523 The establishment of reference intervals for young people for the various vascular ageing
3524 biomarkers is also required. The Youth Vascular Consortium (20) is a collaborative effort involving
3525 more than 40 research groups worldwide and it is hoped that reference intervals for vascular ageing
3526 will be the result of the ongoing work of the Consortium.

3527

3528 **Concluding Remarks**

3529 Characterising vascular ageing in young people will provide a window into cardiovascular risk later in
3530 life. The development of a tool or device that is efficient, user friendly, tolerable by young people,
3531 validated and cost efficient, would significantly advance the field and aid in the routine measurement
3532 of vascular age. However, a number of research questions remain regarding vascular ageing in young
3533 people that need to be addressed, perhaps alongside the development of such technology. If
3534 grounded in scientific evidence, this could make a profound impact on the number of today's young
3535 people expected to develop CVD in future.

3536

3537 **Acknowledgements**

3538 R.E.C is supported by the National Health and Medical Research Council of Australia (reference:
3539 2009005) and by a National Heart Foundation Future Leader Fellowship (reference: 105636).

3540

3541 **References**

- 3542 1. Jacobs Jr DR, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood cardiovascular risk
3543 factors and adult cardiovascular events. *New England Journal of Medicine*. 2022;386(20):1877-88.
- 3544 2. Guthold R, Stevens GA, Riley LM, Bull FC. Global trends in insufficient physical activity among
3545 adolescents: a pooled analysis of 298 population-based surveys with 1·6 million participants. *The Lancet Child
3546 & Adolescent Health*. 2020;4(1):23-35.
- 3547 3. Ward ZJ, Long MW, Resch SC, Giles CM, Craddock AL, Gortmaker SL. Simulation of growth trajectories
3548 of childhood obesity into adulthood. *N Engl J Med*. 2017;377:2145-53.
- 3549 4. Song P, Zhang Y, Yu J, Zha M, Zhu Y, Rahimi K, et al. Global prevalence of hypertension in children: a
3550 systematic review and meta-analysis. *JAMA pediatrics*. 2019;173(12):1154-63.
- 3551 5. Climie RE, Park C, Avolio A, Mynard JP, Kruger R, Bruno R-M. Vascular ageing in youth: a call to action.
3552 *Heart, Lung and Circulation*. 2021;30(11):1613-26.
- 3553 6. McGill H. Relationship of atherosclerosis in young men to serum-lipoprotein cholesterol
3554 concentrations and smoking-a preliminary-report from the pathobiological-determinants-of-atherosclerosis-in-
3555 youth-(pday)-research-group. *Jama-Journal of the American Medical Association*. 1990;264(23):3018-24.
- 3556 7. Kollias A, Dafni M, Poulidakis E, Ntineri A, Stergiou GS. Out-of-office blood pressure and target organ
3557 damage in children and adolescents: a systematic review and meta-analysis. *Journal of Hypertension*.
3558 2014;32(12):2315-31.
- 3559 8. Juhola J, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al. Combined effects of child
3560 and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular
3561 Cohort Consortium. *Circulation*. 2013;128(3):217-24.
- 3562 9. Urbina EM, Dolan LM, McCoy CE, Khoury PR, Daniels SR, Kimball TR. Relationship between elevated
3563 arterial stiffness and increased left ventricular mass in adolescents and young adults. *The Journal of pediatrics*.
3564 2011;158(5):715-21.
- 3565 10. Mehta S, Khoury PR, Madsen NL, Dolan LM, Kimball TR, Urbina EM. Arterial thickness and stiffness are
3566 independently associated with left ventricular strain. *Journal of the American Society of Echocardiography*.
3567 2018;31(1):99-104.
- 3568 11. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left
3569 ventricular hypertrophy in children with elevated blood pressure. *Pediatrics*. 2003;111(1):61-6.
- 3570 12. Peluso G, García-Espinosa V, Curcio S, Marota M, Castro J, Chiesa P, et al. High central aortic rather
3571 than brachial blood pressure is associated with carotid wall remodeling and increased arterial stiffness in
3572 childhood. *High Blood Pressure & Cardiovascular Prevention*. 2017;24(1):49-60.
- 3573 13. Drole Torkar A, Plesnik E, Groselj U, Battelino T, Kotnik P. Carotid intima-media thickness in healthy
3574 children and adolescents: normative data and systematic literature review. *Frontiers in cardiovascular
3575 medicine*. 2020;7:597768.
- 3576 14. Kracht D, Shroff R, Baig S, Doyon A, Jacobi C, Zeller R, et al. Validating a new oscillometric device for
3577 aortic pulse wave velocity measurements in children and adolescents. *American journal of hypertension*.
3578 2011;24(12):1294-9.
- 3579 15. Jurko A, Jr., Minarik M, Jurko T, Tonhajzerova I. White coat hypertension in pediatrics. *Ital J Pediatr*.
3580 2016;42:4.
- 3581 16. Mynard J, Goldsmith G, Kowalski R, Eastaugh L, Lane G, Springall G, et al. P49 Quantifying wave
3582 reflection in children: Invasive vs non-invasive central augmentation index and reflection magnitude and their
3583 association with left ventricular mass. *Artery Research*. 2018;24(C):92-.

- 1
2
3 3584 17. Shenouda N, Proudfoot NA, Currie KD, Timmons BW, MacDonald MJ. Automated ultrasound edge-
4 3585 tracking software comparable to established semi-automated reference software for carotid intima-media
5 3586 thickness analysis. *Clinical Physiology and Functional Imaging*. 2018;38(3):396-401.
- 6
7 3587 18. Mueller UM, Walther C, Adam J, Fikenzer K, Erbs S, Mende M, et al. Endothelial Function in Children
8 3588 and Adolescents Is Mainly Influenced by Age, Sex and Physical Activity—An Analysis of Reactive Hyperemic
9 3589 Peripheral Artery Tonometry—. *Circulation Journal*. 2017;81(5):717-25.
- 10 3590 19. Bikia V, Fong T, Climie RE, Bruno R-M, Hametner B, Mayer C, et al. Leveraging the potential of
11 3591 machine learning for assessing vascular ageing: state-of-the-art and future research. *European Heart Journal-*
12 3592 *Digital Health*. 2021;2(4):676-90.
- 13
14 3593 20. Fong TS, Urbina EM, Howden EJ, Wallace I, Park C, Gall S, et al. Youth Vascular Consortium (YVC)
15 3594 Protocol: Establishing Reference Intervals for Vascular Ageing in Children, Adolescents and Young Adults.
16 3595 *Heart, Lung and Circulation*. 2021;30(11):1710-5.
- 17 3596
18 3597
19 3598
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

21. Using machine learning in vascular ageing assessment

Author(s): Vasiliki Bikia

Institution(s): Stanford University; Swiss Federal Institute of Technology of Lausanne

ORCID(s): 0000-0002-4660-1560

Status

Machine learning (ML) is a subset of artificial intelligence – defined as computers' ability to emulate intelligence – that provides systems with the capacity to learn automatically from data without explicit human input. In the realm of machine learning, two fundamental paradigms, supervised and unsupervised learning, play distinct roles. Supervised learning involves training models on labelled datasets, enabling algorithms to map inputs to corresponding outputs. In contrast, unsupervised learning deals with unlabelled data, allowing algorithms to explore underlying patterns or structures without predefined outputs. In vascular medicine, physicians have traditionally focused on synthesizing various observations to identify diagnostic patterns for guiding treatment and patient management. Sophisticated ML models can offer significant support to clinical experts in some of these tasks.

Learning from data through traditional statistical approaches (such as linear regression) has long been a part of vascular medicine. With recent advancements in ML models and the increased availability of data, there is growing potential to tackle some of the most challenging problems. In vascular ageing assessment, ML is applied via two main types of models: parameter estimation models and risk classification models (**Figure 23**) (Bikia, 2021). Parameter estimation models, for instance, can estimate a target parameter from more easily obtained measurements, such as estimating (invasive) central hemodynamic from non-invasive peripheral blood pressure (BP) data (Bikia et al., 2020). Risk classification models, on the other hand, might classify a subject according to their risk of a particular outcome, such as estimation the risk of cardiovascular event from pulse wave velocity (PWV), risk factors, and laboratory data (Garcia-Carretero et al., 2019). While vascular ageing is primarily evaluated using classical algorithms (e.g. decision trees or support vector machines), there is a noticeable shift towards the adoption of deep learning algorithms [<https://doi.org/10.21037%2Fcdt-22-438>]; a class of ML algorithms which allow for evaluating large datasets without the need for predetermined assumptions, by using multiple-layer structures to extract higher-level information from the raw data.

ML may unlock a variety of possibilities in the assessment of vascular ageing. Currently, patient management in primary care is mainly guided by BP measurement, as a number of issues limit the use of other markers of vascular age. ML-based techniques could offer a streamlined addition to primary care with minimal additional workload, such as using easily obtained clinical data to estimate central pressure or assessing vascular age from photoplethysmogram (PPG) pulse waves. Furthermore, these ML techniques may even have the potential to outperform traditional statistical modelling techniques in many clinical scenarios. Additional benefits of ML tools could include: (i) the analysis of data from electronic health records to provide clinical decision support and automated insights through the effective handling and analysis of data of multifaceted nature and high dimensionality; or (ii) the application of deep learning on large datasets collected through multiple registries that could improve risk stratification and enable precise long-term risk prediction.




Figure 23. Using machine learning to assess vascular ageing from readily available clinical data. Figure adapted from (Bikia et al., 2021), under CC BY 4.0.

3642

3643

3644

3645

3646 **Current and Future Challenges**

3647 While healthcare systems collect vast amounts of data, vascular medicine carries distinct challenges
 3648 unlike other data-driven industries where ML has thrived. Large datasets are essential to develop and
 3649 validate ML-based techniques. For ML to achieve adequate performance in a clinical context, it
 3650 requires training data that are not only large in volume but also diverse and reproducible. Often,
 3651 datasets only record traditional risk factors as binary variables; thus, relevant features may not be
 3652 captured, or lack the granularity and volume required for ML to effectively uncover relevant
 3653 relationships (London, 2022).

3654 Furthermore, pulse wave data are not routinely recorded; ultrasound methods, albeit well-established
 3655 in the clinical monitoring, are not typically employed to generate large datasets of pulse waves; other
 3656 pulse wave acquisition techniques, such as applanation tonometry, are not widely adopted in the
 3657 clinical setting; and, finally, although PPG-based wearables can monitor the pulse wave effectively,
 3658 accessing or storing the raw data from these devices is often challenging. In addition, although devices
 3659 for acquiring arterial pulse waves in the clinic may output data in a format suitable for analysis, they
 3660 usually require a skilled operator and are not widely used for collecting datasets for research.

3661 Uncoordinated data assembly and sharing practices can result in two major issues: the need for
 3662 extensive data curation to prepare datasets for building ML models, and, more importantly, can result
 3663 in models providing inaccurate results and potentially enabling false medical decisions. A recent
 3664 review highlighted shortcomings in the methodology used to develop clinical prediction models using
 3665 ML (Christodoulou et al., 2019). A common challenge in applying data-driven algorithms for vascular
 3666 health assessment and the main limitation to their application to real life clinical situations (Zech et
 3667 al., 2018), is overfitting. Overfitting occurs when an ML model learns rules that perform very well on

1
2
3 3668 the training data but underperform on new, unseen data (test data), leading to models that are not
4 3669 generalizable. To prevent biased results, it is crucial to ensure that the same data instances are not
5 3670 used in both the train-set and test-set.

7 3671 Despite evidence suggesting that ML algorithms may improve accuracy of predicting clinical outcomes
8 3672 (Kakadiaris et al., 2018), the lack of interpretability of ML models has often been considered as a
9 3673 limitation for the use of ML in clinical applications. This is attributed to the fact that the rules by which
10 3674 ML models have achieved their performance are not clear, given the high complexity of the neural
11 3675 networks or other mathematical structures. This lack of easy interpretability of the models' decision-
12 3676 making means that it can be difficult to verify whether the learned rules have indeed generalized to
13 3677 real life clinical situations (Prakash and Tucker, 2018).

16
17 3678

19 3679 **Advances in Science and Technology to Meet Challenges**

20 3680 Benchmark datasets could play a key role in meeting the need for large and high-quality datasets and
21 3681 provide a standardised approach for developing and testing ML-based techniques to assess vascular
22 3682 age. These datasets act as a reference "standard" for a model to be evaluated against. They should
23 3683 contain data reflective of the target population and ideally contain a wide range of characteristics to
24 3684 allow the strengths and weaknesses of ML-based techniques to be assessed. Future research efforts
25 3685 should consider the establishment of a registry containing data with relevant markers of vascular
26 3686 ageing, that has both adequate sample size and is reflective of the target population. Concurrently, it
27 3687 is of great importance to ensure appropriate reporting of ML-based methods, so that it is feasible to
28 3688 verify the absence of overfitting or methodological misconduct. In conjunction to clear and concise
29 3689 reporting of the methods, further quality assessment through external validation is critical for quality
30 3690 assurance [<https://doi.org/10.1186/s13054-022-04088-9>].

35 3691 Moreover, focus should be directed to those measuring techniques that can provide access to valuable
36 3692 clinical information from pulse wave data, such as applanation tonometry. In this respect, pulse wave
37 3693 monitoring techniques should be standardised to be suitable and effective for generating large
38 3694 datasets, which can then be used for training and testing ML-enabled parameter estimators and/or
39 3695 risk classifiers. In addition, consumer devices that obtain pulse wave signals can be used as an
40 3696 alternative to the measurements derived in the clinic. With regards to the use of mobile and wearable
41 3697 technologies, advances should target the establishment of methodological concepts and protocols
42 3698 that will render digital data easily accessible and stored/managed effectively on cloud platforms,
43 3699 always ensuring data quality and interoperability (namely the possibility that data can be integrated
44 3700 and used together with other types of data). Especially, a high level of interoperability is key to collect
45 3701 and exploit new and large digital datasets [<https://doi.org/10.1038/s41591-023-02783-w>].

49 3702 Research is ongoing to improve the interpretability of ML models, using innovative concepts, such as
50 3703 explainable ML and parallel models, where one is used for core computation and the other for
51 3704 interpretation (Barredo Arrieta et al., 2020). An alternative approach could involve simulated data,
52 3705 generated from a computer simulator, that could significantly aid interpretability, as they are derived
53 3706 from deterministic models in which relationships between variables may be more easily explained
54 3707 (see Section 9).

57 3708

58
59 3709
60

3710 Concluding Remarks

3711 ML presents high potential in developing new techniques to assess vascular ageing and enable risk
3712 stratification in vascular patients. When combined with effective interventions these new techniques
3713 could help reduce cardiovascular morbidity and mortality. The plethora of data routinely collected in
3714 healthcare settings and in daily life provides opportunity to identify individuals at risk and to monitor
3715 their vascular health. Yet, additional work is required to develop adequately validated and
3716 standardised ML-based methods. These methods should not only predict biomarkers and/or
3717 cardiovascular events accurately, but also identify the specific clinical scenarios in which their use is
3718 beneficial and cost-effective.

3719

3720 References

- 3721 Barredo Arrieta, A., Díaz-Rodríguez, N., Del Ser, J., Bennetot, A., Tabik, S., Barbado, A., Garcia, S., Gil-Lopez, S.,
3722 Molina, D., Benjamins, R., Chatila, R., Herrera, F., 2020. Explainable Artificial Intelligence (XAI): Concepts,
3723 taxonomies, opportunities and challenges toward responsible AI. *Information Fusion* 58, 82–115.
3724 <https://doi.org/10.1016/j.inffus.2019.12.012>
- 3725 Bikia, V., Fong, T., Climie, R.E., Bruno, R.-M., Hametner, B., Mayer, C., Terentes-Printzios, D., Charlton, P.H.,
3726 2021. Leveraging the potential of machine learning for assessing vascular ageing: state-of-the-art and future
3727 research. *European Heart Journal - Digital Health* 2, 676–690. <https://doi.org/10.1093/ehjdh/ztob089>
- 3728 Bikia, V., Papaioannou, T.G., Pagoulatou, S., Rovas, G., Oikonomou, E., Siasos, G., Tousoulis, D., Stergiopoulos,
3729 N., 2020. Noninvasive estimation of aortic hemodynamics and cardiac contractility using machine learning. *Sci*
3730 *Rep* 10, 15015. <https://doi.org/10.1038/s41598-020-72147-8>
- 3731 Christodoulou, E., Ma, J., Collins, G.S., Steyerberg, E.W., Verbakel, J.Y., Van Calster, B., 2019. A systematic
3732 review shows no performance benefit of machine learning over logistic regression for clinical prediction
3733 models. *J Clin Epidemiol* 110, 12–22. <https://doi.org/10.1016/j.jclinepi.2019.02.004>
- 3734 Collins, G.S., Reitsma, J.B., Altman, D.G., Moons, K., 2015. Transparent reporting of a multivariable prediction
3735 model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. *BMC Med* 13, 1.
3736 <https://doi.org/10.1186/s12916-014-0241-z>
- 3737 Garcia-Carretero, R., Vigil-Medina, L., Barquero-Perez, O., Ramos-Lopez, J., 2019. Pulse Wave Velocity and
3738 Machine Learning to Predict Cardiovascular Outcomes in Prediabetic and Diabetic Populations. *J Med Syst* 44,
3739 16. <https://doi.org/10.1007/s10916-019-1479-y>
- 3740 Kakadiaris, I.A., Vrigkas, M., Yen, A.A., Kuznetsova, T., Budoff, M., Naghavi, M., 2018. Machine Learning
3741 Outperforms ACC/AHA CVD Risk Calculator in MESA. *J Am Heart Assoc* 7.
3742 <https://doi.org/10.1161/JAHA.118.009476>
- 3743 London, A.J., 2022. Artificial intelligence in medicine: Overcoming or recapitulating structural challenges to
3744 improving patient care? *Cell Reports Medicine* 3, 100622. <https://doi.org/10.1016/j.xcrm.2022.100622>
- 3745 Prakash, S.K.A., Tucker, C.S., 2018. Bounded Kalman filter method for motion-robust, non-contact heart rate
3746 estimation. *Biomed. Opt. Express* 9, 873. <https://doi.org/10.1364/BOE.9.000873>
- 3747 Zech, J.R., Badgeley, M.A., Liu, M., Costa, A.B., Titano, J.J., Oermann, E.K., 2018. Variable generalization
3748 performance of a deep learning model to detect pneumonia in chest radiographs: A cross-sectional study. *PLoS*
3749 *Med* 15, e1002683. <https://doi.org/10.1371/journal.pmed.1002683>

3750

22. Sex and gender-based differences in vascular ageing

Author(s): Mai Tone Lønnebakken, M.D, phd¹, Ute Seeland, M.D, phd²

Institution(s): ¹ Department of Heart Disease, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway; ² Institute of Social Medicine, Epidemiology and Health Economics, Charité – Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

ORCID(s): 0000-0002-5600-8859; 0000-0002-1979-386X

Status

Sex is the biological differences between women and men, while gender is the psychosocial differences leading to differences in roles, behaviors, exposures, expression and identity between women and men. Both sex and gender modify vascular ageing by influencing the gradual age-dependent changes in vascular structure and function that leads to increased arterial stiffness, arteriosclerosis, atherosclerosis, and cardiovascular disease development (Seeland et al, 2021). A meta-analysis demonstrates that early vascular ageing is associated with risk of cardiovascular events and mortality in both sexes (Ben-Shlomo et al, 2014). However, early vascular ageing is more common in women than in men (Bruno RM et al. 2020).

Sexual dimorphism in gene expression (different genes and gene dosing based on XX and XY sex chromosomes), sex differences in epigenetic regulation and function, sex hormones and sex-specific lifespan transitions result in important sex differences in vascular physiology and pathophysiology (**Figure 24**). Puberty, pregnancy, menopause and andropause, represent important lifespan transitions that impacts vascular ageing. In women, contraceptives, pregnancy associated hypertensive disorders, hormone disturbances, premature menopause and inflammatory autoimmune diseases have been demonstrated to be associated with increased arterial stiffness. Cardiovascular risk factors like hypertension, diabetes, and obesity, accelerate vascular ageing differently in women and men. Furthermore, there are also sex differences in risk factor trajectories (how risk factors change with age). Blood pressure and arterial stiffness increase more rapidly with age in women than in men, and the predicted risk of cardiovascular events increases at lower blood pressure values in women (Ji et al, 2021). Likewise, diabetes induces more pronounced and greater age-related stiffening of the aorta in women compared to men [De Angelis, L. et al 2004]. These differences are further modified by gender-related factors, like sociocultural factors, environmental risk factor exposure, as well as availability and utilization of the healthcare system. In particular, psychological stress, violence and abuse, sleep deprivation, pollution, low socioeconomic and educational status are associated with accelerated vascular ageing and cardiovascular disease in women (Seeland et al, 2021; Vogel et al, 2021).

Sex differences in body size, fat distribution, cardiovascular anatomy and hemodynamics must be considered in assessment and interpretation of vascular ageing. However, anatomical differences due to weight and size are of secondary importance compared to the hemodynamic and functional cardiovascular differences due to genetic and hormonal modifiers of vascular ageing. Smaller aortic and arterial dimensions in women are balanced by smaller heart chambers, lower stroke volume and increased heart rate compared to men. However, the differing responses to risk factors by men and women result in the development of distinct sex-specific high-risk cardiovascular phenotypes (**Figure 25**). Women exhibit accelerated arterial stiffening, more pronounced pulse wave propagation, earlier

3795 wave reflection and higher augmented pressure (Seeland et al, 2020; Seeland et al, 2021). This
 3796 suggests that both arterial stiffening and vascular tone, mediated through effects on smooth muscle
 3797 cells in the arterial wall, contribute to cardiovascular ageing in women. A decline in endothelial NO-
 3798 mediated vasodilation in women, in particularly in concomitant hypertension, also results in
 3799 microvascular dysfunction and associated increased cardiovascular risk; while macrovascular
 3800 accelerated atherosclerosis is more common in men.

3801 Advances in the understanding of sex- and gender specific accelerated vascular ageing have the
 3802 potential to improve detection of high-risk individuals, preclinical disease and disease mechanisms.
 3803 The aim of this sex- and gender-sensitive medical approach is to offer the population a non-
 3804 discriminatory, improved medical care and health prevention for all sexes.

	Women	Men
Sex	Genetics Epigenetics Estrogen (sex hormone)	Genetics Epigenetics Testosterone (sex hormone)
Lifespan transitions	Puberty (contraceptives) Pregnancy (hypertensive disorders, gestational diabetes) Menopause	Puberty Andropause
Risk factors	Hypertension Diabetes type II Obesity Smoking Autoimmune diseases Rheumatological diseases	Diabetes type II Smoking Hypertension Obesity
Gender	Psychological stress (depression and anxiety) Sleep disorders Violence and abuse Environmental pollution Low socioeconomic status Low educational status Lifestyle Diet Physical exercise Alcohol consumption	Lifestyle Diet Physical exercise Alcohol consumption

3805
 3806 **Figure 24.** Factors contributing to vascular ageing in women and men separately.

3807 3808 **Current and Future Challenges**

3809 Cross-sectional studies have demonstrated that early vascular ageing is associated with poorer
 3810 prognoses in mixed populations (Ben-Shlomo et al, 2014). Prospective studies including sex-
 3811 disaggregated data on the impact of early vascular ageing on the short- and long-term risk of
 3812 cardiovascular disease are still missing. Furthermore, age and sex-specific normal values for vascular
 3813 structure and function, as well as sex-specific cut-off values associated with increased cardiovascular
 3814 risk, are still to be established.

3815 Current recommended cardiovascular risk score models underestimate risk and contribute to under
 3816 treatment, particularly among women (Sedlak et al, 2020). There is reason to believe that the inclusion
 3817 of markers of early vascular ageing in current risk score models may add to cardiovascular risk
 3818 prediction. In addition, including sex differences in lifespan transitions, risk factor and risk factors
 3819 trajectories, sex-specific risk factors and gender-related factors in cardiovascular risk assessment may
 3820 further improve risk stratification (Vogel et al, 2021). Importantly, in clinical practise and research,
 3821 gender-related factors known to contribute to accelerated vascular ageing are often ignored. The
 3822 development of simple, user-friendly tools to assess gender-related risk factors has potential to add

1
2
3 3823 to cardiovascular risk stratification. Furthermore, current understanding of the underlying
4 3824 pathophysiological mechanisms resulting in early vascular ageing is sparse and limits the possibility to
5 3825 target prevention and treatment against specific disease mechanisms.

7 3826 Non-obstructive coronary artery disease and heart failure with preserved ejection fraction (HFpEF)
8 3827 represent key clinical challenges mainly affecting women. Sex differences in cardiac and vascular
9 3828 remodelling and dysfunction may be important in disease development. Non-obstructive coronary
10 3829 artery disease is associated with both myocardial ischemia and myocardial infarction, and this may be
11 3830 due to microvascular and/or vasospastic coronary artery disease. In patients with HFpEF, cardiac
12 3831 remodelling associated with hypertension and increased arterial stiffness, results in diastolic
13 3832 dysfunction and heart failure (Triposkiadis et al, 2019). Whether intervention against accelerated
14 3833 vascular ageing may impact disease progression, reduce symptoms, and improve survival in these
15 3834 patients should be explored. Intervention to delay vascular ageing in women and men needs to be
16 3835 investigated through randomized trials demonstrating not only benefit on vascular structure and
17 3836 function but also on long-term outcome. It is not yet clear whether vascular ageing could be delayed
18 3837 by postmenopausal hormone therapy, new and sex-specific treatment targets, or more aggressive and
19 3838 early onset treatment with lifestyle intervention and antihypertensive medication at lower blood
20 3839 pressure values.

25
26 3840

28 3841 **Advances in Science and Technology to Meet Challenges**


29 3842 Prospective studies powered to assess the separate prognostic impact of early vascular ageing in
30 3843 women and men, are needed to advance our current knowledge on sex differences in vascular ageing
31 3844 and implement this in clinical practise. Future big data analysis may also contribute to completing our
32 3845 understanding of the impact of sex and gender in vascular ageing. This may generate new hypotheses
33 3846 and contribute to the identification of sex-specific mechanisms of vascular ageing and potential sex-
34 3847 specific treatment targets. Specific treatment recommendations to prevent and delay vascular ageing
35 3848 and reduce cardiovascular risk in women and men must be established through randomized clinical
36 3849 trials. In particular, sex-specific indications, treatment targets and timing of therapy should be
37 3850 explored.

38 3851 A comprehensive evaluation of both cardiac and vascular structure and function are necessary to
39 3852 detect preclinical and clinical vascular ageing. The current diagnostic procedures to detect signs of
40 3853 vascular ageing are time-consuming, lack standardisation, and are limited by availability. Technological
41 3854 development of new and user-friendly devices for easy and reliable assessment of vascular structure
42 3855 and function to improve cardiovascular risk assessment, detect subclinical vascular disease, and
43 3856 identify high-risk individuals, must be validated in both women and men (Qiu et al, 2021).
44 3857 Furthermore, wearable devices controlled by smartphones may be used as a screening tool to detect
45 3858 high-risk individuals with early vascular ageing in the future. However, to diminish gender disparities,
46 3859 it is crucial that the devices are customized, available for both sexes, and include gender-specific
47 3860 questionnaires.

48 3861 Deep learning and machine learning algorithms of indices of vascular ageing may improve the
49 3862 reproducibility, standardisation, and availability of vascular age assessment. Recently proposed basic
50 3863 machine learning models based on parameter estimation or risk classification to quickly and accurately
51 3864 assess vascular ageing have been suggested (Bikia et al, 2021). However, it is critically important that
52 3865 patient-specific input data also include sex-specific risk factors for vascular ageing and that validation

3866 cohorts include a significant number of both women and men to ensure that the algorithm is valid to
 3867 assess vascular ageing in both sexes.

3868



3869

3870 **Figure 25.** The sex-specific cardiovascular phenotype of ageing in women and men

3871

3872 Concluding Remarks

3873 The importance of sex and gender as modifiers of vascular ageing and cardiovascular disease
 3874 development is well documented. Future research and technological advances should focus on
 3875 identification of clinical biomarkers and sex-specific vascular phenotypes associated with accelerated
 3876 vascular ageing, as well as subclinical and clinical cardiovascular disease. Risk score models
 3877 implementing sex differences in vascular physiology, lifespan transitions, risk factors and risk factors
 3878 trajectories, gender-related factors and validated sex-specific cut-off values of vascular structure and
 3879 function may contribute to improving detection of accelerated vascular ageing. Accordingly,
 3880 identifying high-risk cardiovascular phenotypes in combination with better knowledge of the
 3881 underlying sex-specific disease mechanisms may contribute to more personalized and targeted
 3882 prevention and treatment that may improve the prognosis and reduce the burden of cardiovascular
 3883 disease in both women and men.

3884

3885 References

3886 Ben-Shlomo, Y., Spears, M., Boustred, C., May, M., Anderson, S. G., Benjamin, E. J., Boutouyrie, P., Cameron, J.,
 3887 Chen, C. H., Cruickshank, J. K., Hwang, S. J., Lakatta, E. G., Laurent, S., Maldonado, J., Mitchell, G. F., Najjar, S.
 3888 S., Newman, A. B., Ohishi, M., Pannier, B., Pereira, T., Vasan, R. S., Shokawa, T., Sutton-Tyrell, K., Verbeke, F.,
 3889 Wang, K. L., Webb, D. J., Willum Hansen, T., Zoungas, S., McEniery, C. M., Cockcroft, J. R. & Wilkinson, I. B.
 3890 (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-
 3891 analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*, 63(7), 636-646.
 3892 Bikia, V., Fong, T., Climie, R. E., Bruno, R. M., Hametner, B., Mayer, C., Terentes-Printzios, D. & Charlton, P. H.
 3893 (2021) Leveraging the potential of machine learning for assessing vascular ageing: state-of-the-art and future
 3894 research. *Eur Heart J Digit Health*, 2(4), 676-690.

- 1
2
3 3895 Bruno RM, Nilsson PM, Engström G, Wadström BN, Empana JP, Boutouyrie P, Laurent S. Early and Supernormal
4 3896 Vascular Aging: Clinical Characteristics and Association With Incident Cardiovascular Events. *Hypertension*.
5 3897 2020 Nov;76(5):1616-1624. doi: 10.1161/HYPERTENSIONAHA.120.14971. Epub 2020 Sep 8. PMID: 32895017.
6
7 3898 Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease.
8 3899 *Nat Rev Nephrol*. 2018 Mar;14(3):185-201.
9 3900 De Angelis, L.; Millasseau, S.C.; Smith, A.; Viberti, G.; Jones, R.H.; Ritter, J.M.; Chowienczyk, P.J. Sex differences
10 3901 in age-related stiffening of the aorta in subjects with type 2 diabetes. *Hypertension* 2004, 44, 67–71.
11 3902 Ji, H., Niiranen, T. J., Rader, F., Henglin, M., Kim, A., Ebinger, J. E., Claggett, B., Merz, C. N. B. & Cheng, S. (2021)
12 3903 Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. *Circulation*, 143(7), 761-763.
13 3904 Ji H, Kwan AC, Chen MT, Ouyang D, Ebinger JE, Bell SP, Niiranen TJ, Bello NA, Cheng S. (2022) Sex Differences in
14 3905 Myocardial and Vascular Aging. *Circ Res*. 18;130(4):566-577.
15
16 3906 Qiu, Y., Liu, Y. & Tao, J. (2021) Progress of Clinical Evaluation for Vascular Aging in Humans. *J Transl Int Med*,
17 3907 9(1), 17-23.
18
19 3908 Sedlak, T., Herscovici, R., Cook-Wiens, G., Handberg, E., Wei, J., Shufelt, C., Bittner, V., Reis, S. E., Reichek, N.,
20 3909 Pepine, C. & Bairey Merz, C. N. (2020) Predicted Versus Observed Major Adverse Cardiac Event Risk in Women
21 3910 With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's
22 3911 Ischemia Syndrome Evaluation). *J Am Heart Assoc*, 9(7), e013234.
23
24 3912 Seeland, U., Demuth, I., Regitz-Zagrosek, V., Steinhagen-Thiessen, E. & König, M. (2020) Sex differences in
25 3913 arterial wave reflection and the role of exogenous and endogenous sex hormones: results of the Berlin Aging
26 3914 Study II. *J Hypertens*, 38(6), 1040-1046.
27
28 3915 Seeland, U., Nemcsik, J., Lønnebakken, M. T., Kublickiene, K., Schluchter, H., Park, C., Pucci, G., Mozos, I. &
29 3916 Bruno, R. M. (2021) Sex and Gender Aspects in Vascular Ageing - Focus on Epidemiology, Pathophysiology, and
30 3917 Outcomes. *Heart Lung Circ*, 30(11), 1637-1646.
31 3918 Triposkiadis, F., Xanthopoulos, A. & Butler, J. (2019) Cardiovascular Aging and Heart Failure: JACC Review Topic
32 3919 of the Week. *J Am Coll Cardiol*, 74(6), 804-813.
33
34 3920 Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V.,
35 3921 Lam, C. S. P., Maas, A., Mihailidou, A. S., Olszanecka, A., Poole, J. E., Saldarriaga, C., Saw, J., Zühlke, L. &
36 3922 Mehran, R. (2021) The Lancet women and cardiovascular disease Commission: reducing the global burden by
37 3923 2030. *Lancet*, 397(10292), 2385-2438.
38
39 3924

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript

23. Mathematical modelling for understanding of pulse wave analysis

Author(s): Berend E. Westerhof^{1,2}

Institution(s): ¹Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; ²Department of Neonatology, Radboud University Medical Center, Radboud Institute for Health Sciences, Amalia Children's Hospital, Nijmegen, the Netherlands

ORCID(s): 0000-0003-4753-2461

Status

Waveform analysis

Waveform analysis is the area of research that aims to gain information about the cardiovascular system by investigating features of arterial pressure (Nichols, 2005), flow (Hashimoto et al., 2018), or plethysmography waveforms (Charlton et al., 2022).

Several parameters to describe a wave shape exist (**Figure 26**), with varying degrees of clinical relevance, and varying degrees of physiological underpinning. A well-known example is the augmentation index (AIx), quantifying the secondary rise in blood pressure that is frequently seen in early systole (Nichols, 2005). It has commonly been regarded as a measure of pressure wave reflection and arterial stiffness, and, accordingly, as a measure of vascular ageing. The AIx derives its acceptance as a useful surrogate end-point from studies where relations with clinical outcome were shown in specific patient groups. The case for the AIx is thus largely empirical, although the following simple physiological model has been suggested for its origins: a forward wave is generated by the ventricle, travels down the aorta, reflects at the aortic bifurcation, and the reflected wave travels back to the heart. When the aorta becomes stiffer with age or disease, pulse wave velocity increases and the reflected wave arrives back at the heart sooner, increasing blood pressure in systole.




Figure 26. Parameters describing a pressure waveform, based on characteristic points on the pressure wave (upper curve). From left to right: start of upstroke and diastolic pressure, (P_{dia}), maximal rate of change ($\max-dP/dt$), shoulder point (P_{sho}), inflection point (P_{inf}), systolic pressure (P_{sys}), incisura (P_{inc}), dicrotic wave (P_{dic}). The augmentation index $AIx = [(P_{sys} - P_{sho}) / (P_{sys} - P_{dia})] \cdot 100\%$. Wave separation provides the forward and reflected pressure waves (lower curves).

Mathematical modelling

Mathematical modelling is the approach to describe (with formulae, e.g., physics-based differential equations) a system such that it produces the outputs that are measured in real life.

Many different forms of models are used in cardiovascular research. Zero-dimensional models describe variables over time but not in space, like the “Windkessel model”, relating pressure and flow at a certain point in the circulation (Alastruey et al., 2023). One-dimensional models do take distance into account, for instance the single tube model to interpret wave reflection with a distinct reflection site, or for the calculation of wave speed. More complex one-dimensional models use a network of arteries to represent reality more closely (Alastruey et al., 2023).

Models can assist in understanding of a certain system. The parameters of the system, for example the radii of the vasculature, or wall stiffness, can be easily changed in the model, and the effect on the blood pressure waveform can be studied. Sometimes, the outputs do not entirely conform to reality, prompting rethinking of the assumptions that were made, and perhaps concluding another or more sophisticated model is needed.

When a sufficiently accurate model is used, and its output fits to the measurements, it can be assumed that the model has been correctly “parameterised”. Parameters may then be interpreted, e.g., the arterial stiffness of the vascular system.

1
2
3 3974 Nowadays, measurements and waveform analyses are frequently performed, and many mathematical
4 3975 models, simple and complex, are available (Alastruey et al., 2023). However, determining the
5 3976 parameters of the model so that the measurements are correctly reproduced, a process called “system
6 3977 identification”, is not widespread.
7
8

9 3978

11 3979 **Current and future challenges**

12 3980 In general, the challenge with modelling aimed at getting a better insight into the physiological basis
13 3981 underlying pulse waves, is to find the balance between obtaining a good description of reality versus
14 3982 system complexity, or number of parameters. Very simple models as for instance the Windkessel
15 3983 model may reproduce the global features such as systolic and diastolic pressures, but are not adequate
16 3984 to explain wave shape parameters like the AIx. Even the single tube model with a reflection site at the
17 3985 end is too simple to understand wave reflection in the aorta (Westerhof and Westerhof, 2018).
18 3986 Reflections occur not at one main reflection site, but at many sites (Westerhof and Westerhof, 2012),
19 3987 and reflections are not “complete” as would be the case at a closed end, but partial and with a phase
20 3988 delay (Westerhof et al., 2008). Comprehensive distributed models, incorporating these refinements,
21 3989 do explain actual findings, for instance the limited decrease of the return time of the reflected
22 3990 pressure wave with ageing (Westerhof and Westerhof, 2012, Baksi et al., 2009). A single tube model
23 3991 for the calculation of carotid-to-femoral pulse wave velocity is obviously an oversimplification since
24 3992 the wave does not travel from the carotid artery to the femoral artery. Another parameter that is
25 3993 typically neglected is the radius of the tube in which pulse wave velocity is determined. Radius may
26 3994 differ less between subjects than vascular stiffness, but mathematically they have equal impact on
27 3995 pulse wave velocity.
28
29

30 3996 Currently, there are several challenges that need to be addressed to advance the use of models
31 3997 underlying the generation of the arterial waveform. A first challenge, as introduced in the previous
32 3998 paragraph, is that comprehensive models are needed for the correct interpretation of arterial pulse
33 3999 waves. This comes with a second challenge: more comprehensive models have more parameters, and
34 4000 how can these be determined? Additional challenges are presented by the introduction of new devices
35 4001 and measurement techniques. Wearables can provide continuous waveform data, however, may be
36 4002 corrupted artefacts, e.g. caused by motion. Novel modelling techniques are needed to improve the
37 4003 signal quality and reliability. At present, photoplethysmography is used more frequently, but it is not
38 4004 related to arterial pressure in a straightforward manner and may require modelling to retrieve the
39 4005 underlying physiology.
40
41

42 4006 It makes sense to first develop comprehensive models on a population level: the model is correct for
43 4007 the “average patient”. The main future challenge is the individualisation of a model to represent a
44 4008 particular patient. Such an individualised model is referred to as: “digital twin”.
45
46

47 4009

49 4010 **Advances in science to meet challenges**

51 4011 ***Comprehensive model***

52 4012 Many models developed for specific applications are already available. Combining these models to
53 4013 reach the required level of refinement could advance the successful use of models to explain arterial
54 4014 waveforms. Improvements can be achieved by taking in geometry of the vasculature into account with
55 4015 more detail. The distribution of stiffness may be seen as a part of geometry, the aorta being more
56
57
58
59
60

1
2
3 4016 compliant than conduit arteries. Stiffness increases with age and elastic vessels stiffen more with age
4 4017 than conduit vessels. Also, stiffness of all vessels is highly dependent on distending pressure, in a
5 4018 nonlinear manner. Then, there is the influence of ventricular function on the arterial wave shape, with
6 4019 heart rate and ventricular preload (van de Velde et al., 2018) major contributing factors.
7 4020 Cardiorespiratory interaction introduces a beat-to-beat variation in the waveform. Also, physical and
8 4021 mental stress, and autonomic function, have effects on the wave shape.

9
10
11 4022 Models with more complexity need more measurements to determine the additional parameters. To
12 4023 better describe geometry of the vasculature, MRI imaging may be used. Pulse wave velocities may be
13 4024 established over diverse trajectories and for different ages. Heart rate and respiration rate may be
14 4025 obtained from a simple electrocardiogram to improve hemodynamic modelling.

15 4026 **Individualisation / digital twin**

16
17
18 4027 Simple patient data such as age, sex, height and weight may help towards individualisation of a certain
19 4028 model. An electrocardiogram is easily obtained, but due to costs, MRI measurements to improve the
20 4029 geometry of a specific individual model are not feasible for all patients. Better descriptions of the
21 4030 evolution of parameters with ageing, and of deviations with pathologies may help improve models at
22 4031 population level, reducing the additional measurements needed for individualisation. Citizen science
23 4032 and the use of wearables may present a new avenue for the accumulation of large datasets.

24
25
26 4033 Machine learning can be deployed as a powerful tool for parameter estimation and system
27 4034 identification. With present day computing power, large datasets can be easily analysed. Currently,
28 4035 machine learning is mainly used to develop black box models helpful for prediction or classification,
29 4036 however, a system identification approach (white box model) would allow finding the affected
30 4037 “parameter” related to pathology in a group and eventually in an individual.

31
32
33 4038 A very interesting approach is to generate wave shapes with comprehensive models, in which
34 4039 parameters are varied over wide a range of physiological and even pathophysiological values. In this
35 4040 way, large populations of “virtual” healthy subjects and “virtual” patients can be created (Charlton et
36 4041 al., 2019). Measured wave shapes could be matched to the waveshapes in the virtual database to
37 4042 identify the most likely underlying set of parameters, thus giving insight into the origins of the
38 4043 waveshape.

39 4044

40 4045 **Concluding remarks**

41
42
43 4046 Waveform analysis of arterial pressure, flow, or plethysmogram can reveal information about the
44 4047 cardiovascular system; mathematical modelling can be used to find the physiological basis of the
45 4048 observed waveform features. The used models should be sufficiently detailed for a correct description
46 4049 of the cardiovascular system; however, higher levels of complexity require more model parameters.
47 4050 The ultimate goal is the individualisation of models; a suitable digital twin will make it possible to
48 4051 predict clinical outcome and to virtually test the effect of therapeutic interventions. Where
49 4052 measurement and modelling meet, real knowledge of the cardiovascular system can be found.

50 4053

51 4054 **References**

52 4055 ALASTRUEY, J., CHARLTON, P. H., BIKIA, V., PALIAKAITE, B., HAMETNER, B., BRUNO, R. M., MULDER, M. P.,
53 4056 VENNIN, S., PISKIN, S., KHIR, A. W., GUALA, A., MAYER, C. C., MYNARD, J., HUGHES, A. D., SEGERS, P. &

54
55
56
57
58
59
60

- 1
2
3 4057 WESTERHOF, B. E. 2023. Arterial pulse wave modelling and analysis for vascular age studies: a review from
4 4058 VascAgeNet. *Am J Physiol Heart Circ Physiol*, 325, H1-H29.
- 5 4059 BAKSI, A. J., TREIBEL, T. A., DAVIES, J. E., HADJILOIZOU, N., FOALE, R. A., PARKER, K. H., FRANCIS, D. P., MAYET,
6 4060 J. & HUGHES, A. D. 2009. A meta-analysis of the mechanism of blood pressure change with aging. *J Am Coll*
7 4061 *Cardiol*, 54, 2087-92.
- 8 4062 CHARLTON, P. H., MARISCAL HARANA, J., VENNIN, S., LI, Y., CHOWIENCZYK, P. & ALASTRUEY, J. 2019. Modeling
9 4063 arterial pulse waves in healthy aging: a database for in silico evaluation of hemodynamics and pulse wave
10 4064 indexes. *Am J Physiol Heart Circ Physiol*, 317, H1062-H1085.
- 11 4065 CHARLTON, P. H., PALIAKAITE, B., PILT, K., BACHLER, M., ZANELLI, S., KULIN, D., ALLEN, J., HALLAB, M.,
12 4066 BIANCHINI, E., MAYER, C. C., TERENTES-PRINTZIOS, D., DITTRICH, V., HAMETNER, B., VEERASINGAM, D., ZIKIC,
13 4067 D. & MAROZAS, V. 2022. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular
14 4068 age: a review from VascAgeNet. *Am J Physiol Heart Circ Physiol*, 322, H493-H522.
- 15 4069 HASHIMOTO, J., WESTERHOF, B. E. & ITO, S. 2018. Carotid Flow Augmentation, Arterial Aging, and Cerebral
16 4070 White Matter Hyperintensities. *Arterioscler Thromb Vasc Biol*, 38, 2843-2853.
- 17 4071 NICHOLS, W. W. 2005. Clinical measurement of arterial stiffness obtained from noninvasive pressure
18 4072 waveforms. *Am J Hypertens*, 18, 3S-10S.
- 19 4073 VAN DE VELDE, L., EEFTINCK SCHATTENKERK, D. W., VENEMA, P., BEST, H. J., VAN DEN BOGAARD, B., STOK, W.
20 4074 J., WESTERHOF, B. E. & VAN DEN BORN, B. J. H. 2018. Myocardial preload alters central pressure augmentation
21 4075 through changes in the forward wave. *J Hypertens*, 36, 544-551.
- 22 4076 WESTERHOF, B. E., VAN DEN WIJNGAARD, J. P., MURGO, J. P. & WESTERHOF, N. 2008. Location of a reflection
23 4077 site is elusive: consequences for the calculation of aortic pulse wave velocity. *Hypertension*, 52, 478-83.
- 24 4078 WESTERHOF, B. E. & WESTERHOF, N. 2012. Magnitude and return time of the reflected wave: the effects of
25 4079 large artery stiffness and aortic geometry. *J Hypertens*, 30, 932-9.
- 26 4080 WESTERHOF, B. E. & WESTERHOF, N. 2018. Uniform tube models with single reflection site do not explain
27 4081 aortic wave travel and pressure wave shape. *Physiol Meas*, 39, 124006.
- 28
29
30
31
32
33
34 4082
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

24. Using multiple sensing modalities to assess vascular age

4084

4085 Author(s): Panicos A Kyriacou and Parmis Karimpour

4086 Institution(s): Research Centre for Biomedical Engineering, City, University of London, UK

4087 ORCID(s): 0000-0002-2868-485X

4088

4089 Status

4090 It is estimated that 7.6 million people are living with cardiovascular diseases in the UK, and the annual
4091 healthcare costs are over £9 billion^{1,2}. Blood vessels begin to deteriorate with age, a phenomenon
4092 known as vascular ageing. Vascular ageing can cause changes to the structure and function of the
4093 blood vessels, increasing the likelihood of an individual developing a cardiovascular disease (CVD).
4094 Regular monitoring of vascular health and cardiac function could reduce mortality, morbidity, and
4095 unplanned hospital admissions, in addition to improving exercise capacity, quality of life and
4096 psychological well-being. However, at present, there is no medical grade technology that can provide
4097 the precision, resolution, and patient comfort necessary to achieve regular, repeated, long-term
4098 monitoring of vascular health, particularly outside of a hospital environment.

4099 Researchers over the years have been working on the utilisation of non-invasive sensing modalities
4100 for the assessment of vascular disease^{3,4,5}. Despite the very encouraging research outcomes from
4101 many studies there is still no reliable and clinically acceptable non-invasive sensor modality that is
4102 used routinely for the rapid assessment/screening of vascular ageing and disease.

4103 Primarily the assessment of vascular ageing nowadays remains reliant on rather costly, impractical,
4104 and expert-dependent imaging modalities (Diagnostic Ultrasound, Magnetic Resonance Imaging
4105 (MRI)) or other more invasive and resource intensive interventions such as angiography which can
4106 only be implemented in a clinical setting. Even though such technologies are currently available, in the
4107 UK patients must be referred by their General Practitioner (GP) to undergo such investigational
4108 procedures in a hospital setting which can cause significant delays and added anxiety to patients.

4109 The development of reliable and accessible non-invasive sensor technologies that will allow for the
4110 early screening and diagnosis of vascular ageing at a GP level could bring about transformative
4111 solutions in the early assessment of cardiovascular disease.

4112

4113 Current and future challenges

4114 One of the most common techniques that clinicians use for the assessment of vascular disease is the
4115 ankle-brachial index (ABI) test. This technique is the preferred first test for symptomatic patients,
4116 which could provide information relating to the location and extent of peripheral arterial disease
4117 (PAD). This test requires a Doppler ultrasound probe to locate the artery, and pressure cuffs for blood
4118 pressure measurements in the upper and lower limbs. ABI is calculated by dividing the blood pressure
4119 measured in an artery of the ankle by the blood pressure measured in an artery of the arm. Normal
4120 calculated ABI values are between 0.9 and 1.4. An abnormal ABI below 0.9 could act as a strong
4121 indicator of cardiovascular risk.

4122 While the ABI technique is non-invasive and relatively inexpensive, it is not very practical, and it
4123 requires a degree of expertise especially when using the Doppler ultrasound probe and hence it could

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 4124 be operator depended. If further tests are required, clinicians can refer the patients for further
4 4125 diagnostic ultrasound tests, an angiogram, or other imaging modalities.

6 4126 Diagnostic ultrasound, an acoustical based imaging modality, is one of the main methods for assessing
7 4127 vascular age. It can provide arterial visualisation non-invasively, without radiation exposure.
8 4128 Measurements can be taken from deep tissue, asynchronously without the need for anaesthetics, and
9 4129 without interruption to blood flow circulation⁶. However, diagnostic ultrasound techniques can be
10 4130 costly and more importantly require experts to perform the measurement/scanning. Vascular health
11 4131 can also be monitored with perhaps a less costly technique using a laser Doppler flowmeter (LDF),
12 4132 however this technique has been proven unfavourable as it can suffer from motion artefact and signal
13 4133 processing limitations⁷.

16 4134 Angiography is also popular for investigating vascular ageing. It provides the anatomical and structural
17 4135 images of the vascular system. A contrast agent is injected into the vessel and the vessel is projected
18 4136 on a series of x-rays, allowing the inner vessel wall and flow in the lumen to be visualised⁸. Also,
19 4137 Computed Tomography Coronary Angiography (CTCA) is a non-invasive technique, which accurately
20 4138 evaluates luminal and outer vessel wall dimensions, and classifies high-risk plaques. However, it
21 4139 suffers from radiation exposure and has a limited imaging resolution, causing difficulties in accurately
22 4140 specify between lipid and fibrotic tissue components⁹. Also, other more advanced imaging modalities
23 4141 can be employed for the diagnosis of arterial disease, such as positron emission tomography (PET) and
24 4142 magnetic resonance imaging (MRI), however such modalities are very expensive, less practical, and
25 4143 patients can be impacted from radiation exposure⁴.

28 4144 While the above technologies used for the assessment of vascular ageing are well established, there
29 4145 is a gap in technologies which could be utilised for the early diagnosis on vascular health especially at
30 4146 a GP level. Such technologies could enable prompt detection of pathologies relating to vascular ageing
31 4147 and prompt early-stage interventions. This could be accomplished by innovation on non-invasive
32 4148 sensor technologies which are currently growing exponentially in the field of health and wellbeing
33 4149 applications.

34 4150

40 4151 **Advances in science and technology to meet challenges**

41 4152 Over the years many researchers have attempted to develop sensor technologies to assess peripheral
42 4153 arterial disease (PAD) and vascular ageing. These were primarily based on the optical technique of
43 4154 photoplethysmography (PPG)⁴. Photoplethysmography is a non-invasive optical technique widely
44 4155 used in the study and monitoring of the pulsations associated with changes in blood volume in a
45 4156 peripheral vascular bed. This technique is widely used in both medical devices, such as pulse oximetry
46 4157 where it is used for the non-invasive measurement of arterial blood oxygen saturation (SpO₂), and in
47 4158 the majority of wearable technologies (bracelets, wrist watches, etc) where it is used to monitor
48 4159 various physiological parameters, including pulse and respiratory rate, relating to health and fitness.

51 4160 The main driver of how PPG could be utilised for the assessment of vascular ageing is based on the
52 4161 hypothesis that PPG provides information relating to both changes in haemodynamics and vascular
53 4162 mechanics, both of which are directly related to vascular health. Such an approach seems very
54 4163 attractive for the non-invasive and rapid assessment of vascular ageing.

56 4164 PPG can be used to assess Pulse Wave Velocity (PWV) and Pulse Transit Time (PTT), both of which
57 4165 relate to vascular ageing. Such approaches utilise two PPG signals measured at different sites or one
58
59
60

1
2
3 4166 PPG and one ECG signal. More recently researchers have also developed pulse wave analysis (PWA)
4 4167 and Machine Learning (ML) models in an effort to identify features of PPG signals which are related to
5 4168 vascular health^{3,4}. Despite the high volume of publications in this field, where promising findings are
6 4169 presented, there is still no available and clinically routinely used technology based on PPG for the
7 4170 assessment of vascular ageing¹⁰.

8
9
10 4171 While there is robust evidence that the PPG relates to changes in vascular ageing, there are still many
11 4172 barriers that limit the utilisation of PPG-based technologies to reach a commercial clinical device used
12 4173 for the routine assessment of vascular ageing.

13
14 4174 These could be related to:

- 15 4175
- 16 4176 ● Lack of standardisation of the PPG technology (optical-front-end (OFE)). This included the
17 4177 selection of optical wavelengths used, optical component topology, and site(s) of application.
 - 18 4177 ● Lack of standardisation of the PPG technology, analogue-front-end (AFE). This includes the
19 4178 electronics needed for the optimal acquisition of PPG signals.
 - 20 4178 ● Lack of standardisation of the PPG signals processing and analysis. This could include:
 - 21 4179 ○ PPG signal processing (pre-processing, motion artefact removal, signal quality
22 4180 assessment, calculating derivatives, decomposition)
 - 23 4181 ○ Methods for feature-based PPG signals analysis (Fiducial point detection, Feature
24 4182 extraction)
 - 25 4182 ○ Methods for PPG Time and Frequency Domain Analysis
 - 26 4183 ○ Optimal and relevant PPG Machine learning models used for vascular ageing
27 4184 assessment.
 - 28 4184 ● Lack of standardisation of signal acquisition protocols used for the assessment of vascular
29 4185 ageing. Authors have engaged in diverse studies in an effort to unravel the relation of PPG and
30 4186 vascular ageing. These include in vivo studies on healthy volunteers, small groups of patients,
31 4187 utilisation of simulated PPGs, utilisation of diverse existing databases, including in vitro studies
32 4188 utilising PPG phantom technologies. Such approaches have failed to secure the correct
33 4189 protocol or approach needed for such an assessment.
34 4190
35 4191
36 4192

37 4193 All of the above challenges have resulted in diverse and sometimes inconclusive results. There is
38 4194 clearly a need for a more systematic approach of how best we can use PPG for the assessment of
39 4195 vascular ageing.

40
41 4196 Another potential approach of sensors technologies used for the assessment of vascular ageing which
42 4197 has not be considered, at least in detail, is a multi-sensor approach. While we know that PPG has clear
43 4198 relations with vascular ageing, using PPG alone might not be the only or the best solution. The addition
44 4199 of other sensors in combination with PPG might be a more attractive option. A multimodal approach
45 4200 could perhaps mitigate some of the challenges of PPG and yield a more robust sensor technology used
46 4201 for vascular ageing.

47
48 4202 An additional sensor technology that could be used in such multimodal applications is acoustical
49 4203 sensing.

50
51 4204 The human body and organs generate acoustic signals, including sounds and vibrations, that
52 4205 propagate through the surrounding tissues and reach the body surface. These signals can be measured
53 4206 and monitored transcutaneously by acoustic sensors such as microphones, accelerometers, and
54 4207 gyroscopes. These signals provide information about the mechanical aspects of cardiovascular activity,

1
2
3 4208 and thus may contain diagnostic information. With the employment of advanced computational
4 4209 techniques (feature extraction, machine learning, wavelet transform, power spectral density, etc)
5 4210 these signals representing cardiovascular sounds can help into the classification of healthy and
6 4211 diseased groups. Also, acoustic pressure fluctuations have been recognized as the primary flow-
7 4212 induced source of the sound through arteries. These pressure fluctuations, and their correlation with
8 4213 highly turbulent shear stresses and vibration on the internal arterial wall can be further excited by
9 4214 blood flow turbulence due to medical conditions such as stenosis, vascular disease, and aneurysms¹¹.
12 4215 These signals may also provide complementary information to other monitoring methods. For
13 4216 example, while an ECG test, assesses the electrical activity of the heart, acoustic signals such as sounds
14 4217 and vibrations can provide a more in-depth understanding of the mechanical activity of the
15 4218 cardiovascular system. This complementary information can lead to the detection of early signs of
16 4219 CVDs.

19 4220 In addition to the above, the emergence of ultrasound based photoacoustical (PA) sensors can provide
20 4221 an alternative means of developing the next generation cardiovascular monitoring technology¹². An
21 4222 ultrasound based PA imaging sensor delivers diffused light through tissue, where the photons are
22 4223 absorbed by dominant chromophores and converted to sound waves for acoustic imaging. Also, there
23 4224 has been strong evidence that PA can provide more accurate measurement of blood oxygenation
24 4225 levels compare to pure optical methods (such as widely used clinical pulse oximeter) which can be
25 4226 significantly affected by the skin tone¹³. Such sensors not only will work in a complementary fashion
26 4227 with optical sensors but they will also contribute toward the real time imaging of vessels and
27 4228 circulation which will be an invaluable tool in the assessment of vascular disease.

31 4229 Of course, the sky is the limit of what other sensors can be incorporate in this multimodal approach
32 4230 used for obtaining additional physiological information which can contribute further and more
33 4231 holistically in the assessment of vascular disease. These could include dry electrodes (designed and
34 4232 fabricated using flexible light-weight nano materials (e.g. carbon nanotube and/or graphene aerogel
35 4233 fibre electrodes)) for ECG measurements and temperature sensors, etc.

38 4234

40 4235 **Concluding Remarks**

41 4236 In the current market, established diagnostic techniques have been widely used for the diagnosis and
42 4237 evaluation of vascular ageing. However, their limitations such as their high costs, bulky sizes, usability
43 4238 for early screening at GP level, and patient discomfort inhibit their application to certain patient
44 4239 groups and prevents their use outside of a hospital environment.

47 4240 Advancements in wearables and sensing technology, coupled with the developments in computing,
48 4241 signal processing, and machine learning methods have enabled the long-term, real-time measurement
49 4242 and analysis of these signals even outside of healthcare facilities, which may result in the earlier
50 4243 diagnosis of diseases and the timely referral of the patients to their caregivers. Many of these devices
51 4244 are both practical and affordable, and enable monitoring of vulnerable populations from the comfort
52 4245 of their homes, while at the same time providing critical alerts for events requiring prompt medical
53 4246 attention or hospitalization.

56 4247 The research community needs to grasp the opportunities provided by non-invasive sensor
57 4248 technologies and collectively focus their efforts, using a systematic approach, to innovate multimodal
58 4249 non-invasive sensor technologies for the early assessment of vascular ageing. Such transformative
59
60

1
2
3 4250 sensor solutions will enable the early diagnosis of vascular disease and prompt the timely treatments
4 4251 to both symptomatic and asymptomatic patients.
5

6 4252
7

8 4253 **References**
9

- 10 4254 1. NHS England Long Term Plan: Cardiovascular Disease. (2019).
11 4255 2. British Heart Foundation UK Factsheet. (2018).
12
13 4256 3. Charlton, P.H., Paliakaitė, B., Pilt, K., Bachler, M., Zanelli, S., Kulin, D., Allen, J., Hallab, M., Bianchini, E.,
14 4257 Mayer, C.C., Terentes-Printzios, D., Dittrich, V., Hametner, B., Veerasingam, D., Žikić, D., Marozas, V.,
15 4258 2022. Assessing hemodynamics from the photoplethysmogram to gain insights into vascular age: a
16 4259 review from VascAgeNet. *Am. J. Physiol.-Heart Circ. Physiol.* 322, H493–H522.
17 4260 <https://doi.org/10.1152/ajpheart.00392.2021>
18
19 4261 4. *Photoplethysmography: Technology, Signal Analysis and Applications (1st Edition)*, Editors: Panicos A
20 4262 Kyriacou & John Allen, Academic Press, ISBN: 9780128233740.
21 4263 5. Kramer, C.M. (Ed.), 2020. *Imaging in Peripheral Arterial Disease: Clinical and Research Applications*.
22 4264 Springer International Publishing, Cham. <https://doi.org/10.1007/978-3-030-24596-2>
23
24 4265 6. Haschek, W.M., Rousseaux, C.G., Wallig, M.A., 2010. Chapter 12 - Cardiovascular and Skeletal Muscle
25 4266 Systems, in: Haschek, W.M., Rousseaux, C.G., Wallig, M.A. (Eds.), *Fundamentals of Toxicologic*
26 4267 *Pathology (Second Edition)*. Academic Press, San Diego, pp. 319–376. [https://doi.org/10.1016/B978-](https://doi.org/10.1016/B978-0-12-370469-6.00012-X)
27 4268 [0-12-370469-6.00012-X](https://doi.org/10.1016/B978-0-12-370469-6.00012-X)
28
29 4269 7. Obeid, A.N., Barnett, N.J., Dougherty, G., Ward, G., 1990. A critical review of laser Doppler flowmetry.
30 4270 *J. Med. Eng. Technol.* 14, 178–181. <https://doi.org/10.3109/03091909009009955>.
31 4271 8. Omeh, D.J., Shlofmitz, E., 2022. *Angiography*, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
32 4272 9. Mushenkova, N.V., Summerhill, V.I., Zhang, D., Romanenko, E.B., Grechko, A.V., Orekhov, A.N., 2020.
33 4273 *Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of*
34 4274 *Vulnerable Plaque*. *Int. J. Mol. Sci.* 21, 2992. <https://doi.org/10.3390/ijms21082992>
35
36 4275 10. Alnaeb, M., Alobaid, N., Seifalian, A., Mikhailidis, D., Hamilton, G., 2007. Optical Techniques in the
37 4276 Assessment of Peripheral Arterial Disease. *Curr. Vasc. Pharmacol.* 5, 53–9.
38 4277 <https://doi.org/10.2174/157016107779317242>
39
40 4278 11. J Cook, M Umar, F Khalili and A Taebi. *Body Acoustics for the Non-Invasive Diagnosis of Medical*
41 4279 *Conditions*. *Bioengineering* 2022, 9, 149. <https://doi.org/10.3390/bioengineering9040149>
42 4280 12. Zhao, T., Zhang, M., Ourselin, S. & Xia, W. Wavefront Shaping-Assisted Forward-Viewing
43 4281 Photoacoustic Endomicroscopy Based on a Transparent Ultrasound Sensor. *Applied Sciences* vol. 12 at
44 4282 <https://doi.org/10.3390/app122412619> (2022).
45
46 4283 13. Mantri, Y. & Jokerst, J. V. Impact of skin tone on photoacoustic oximetry and tools to minimize bias.
47 4284 *Biomed. Opt. Express* 13, 875–887 (2022).
48 4285

49
50
51
52
53
54
55
56
57
58
59
60
Accepted Manuscript